@NP	Tissue sparing	1
@NP	behavioral recovery	17
@NP	supraspinal axonal sparing/regeneration	38
@NP	sub-acute glial transplantation	88
@NP	a model	123
@NP	spinal cord contusion Helen R Barbour2	134
@NP	Christine D Plant1	174
@NP	Alan R Harvey3	194
@NP	Giles W Plant1 ,2	213
@NP	Abstract Background	232
@NP	It	253
@NP	olfactory ensheathing glia -LRB- OEG -RRB-	276
@NP	olfactory ensheathing glia	276
@NP	OEG	304
@NP	Schwann cell -LRB- SCs -RRB- transplantation	313
@NP	Schwann cell -LRB- SCs -RRB-	313
@NP	Schwann cell	313
@NP	SCs	327
@NP	cellular treatments for spinal cord injury -LRB- SCI -RRB-	366
@NP	cellular treatments	366
@NP	spinal cord injury -LRB- SCI -RRB-	390
@NP	spinal cord injury	390
@NP	SCI	410
@NP	acute and sub-acute time points	427
@NP	this study	463
@NP	we	475
@NP	DsRED	491
@NP	adult OEG and SCs sub-acutely	508
@NP	adult OEG and SCs	508
@NP	adult OEG	508
@NP	SCs	522
@NP	14 days	539
@NP	a T10 moderate spinal cord contusion injury in the rat	558
@NP	a T10 moderate spinal cord contusion injury	558
@NP	T10	560
@NP	the rat	605
@NP	Behaviour	614
@NP	open field -LRB- BBB -RRB-	640
@NP	open field	640
@NP	BBB	652
@NP	horizontal ladder walking tests to ascertain improvements in locomotor function	661
@NP	horizontal ladder	661
@NP	tests	687
@NP	improvements	706
@NP	locomotor function	722
@NP	Fluorogold staining	742
@NP	the distal spinal cord	780
@NP	the extent of supraspinal and propriospinal axonal sparing/regeneration	816
@NP	the extent	816
@NP	supraspinal and propriospinal axonal sparing/regeneration	830
@NP	4 months post injection time point	891
@NP	4 months	891
@NP	post injection time point	900
@NP	The purpose of this study	927
@NP	The purpose	927
@NP	this study	942
@NP	OEG and SCs cells	975
@NP	sub acutely -LRB- 14 days after injury -RRB-	1002
@NP	sub acutely	1002
@NP	14 days after injury	1015
@NP	14 days	1015
@NP	injury	1029
@NP	i	1045
@NP	behavioral outcomes , -LRB- ii -RRB-	1056
@NP	behavioral outcomes	1056
@NP	ii	1078
@NP	sparing/regeneration of propriospinal and supraspinal projections ,	1089
@NP	sparing/regeneration of propriospinal	1089
@NP	sparing/regeneration	1089
@NP	propriospinal	1113
@NP	supraspinal projections	1131
@NP	iii	1161
@NP	tissue loss	1173
@NP	Results	1186
@NP	OEG and SCs	1195
@NP	transplanted rats	1207
@NP	significant increased locomotion	1232
@NP	injury	1290
@NP	the open field tests -LRB- BBB -RRB-	1305
@NP	the open field tests	1305
@NP	BBB	1327
@NP	the ladder walk test	1342
@NP	statistically significant differences between treatment and control groups	1376
@NP	statistically significant differences	1376
@NP	treatment and control groups	1422
@NP	a statistically significant increase	1489
@NP	the number of supraspinal nuclei	1529
@NP	the number	1529
@NP	supraspinal nuclei	1543
@NP	the distal spinal cord in both OEG and SCs	1578
@NP	the distal spinal cord	1578
@NP	both OEG and SCs	1604
@NP	OEG	1609
@NP	SCs	1617
@NP	transplanted rats	1621
@NP	These	1640
@NP	the raphe , reticular and vestibular systems	1655
@NP	the raphe	1655
@NP	reticular and vestibular systems	1666
@NP	Further pairwise multiple comparison tests	1700
@NP	a statistically significant increase	1755
@NP	raphe	1795
@NP	neurons in OEG transplanted rats	1812
@NP	neurons	1812
@NP	OEG transplanted rats	1823
@NP	SCs	1862
@NP	transplanted animals	1866
@NP	Immunohistochemistry	1888
@NP	spinal cord sections short term -LRB- 2 weeks -RRB-	1912
@NP	spinal cord sections	1912
@NP	short term -LRB- 2 weeks -RRB-	1933
@NP	short term	1933
@NP	2 weeks	1945
@NP	long term -LRB- 4 months -RRB-	1958
@NP	long term	1958
@NP	4 months	1969
@NP	differences	1986
@NP	host glial activity	2001
@NP	migration and proteoglycan deposits between the two cell types	2022
@NP	migration and proteoglycan deposits	2022
@NP	the two cell types	2066
@NP	Histochemical staining	2086
@NP	the volume of tissue remaining at the lesion site	2123
@NP	the volume	2123
@NP	tissue remaining at the lesion site	2137
@NP	tissue remaining	2137
@NP	the lesion site	2157
@NP	all OEG and SCs treated groups	2190
@NP	all OEG and SCs	2190
@NP	groups	2214
@NP	Significant tissue sparing	2222
@NP	both time points following glial SCs transplantation	2265
@NP	both time points	2265
@NP	glial SCs transplantation	2292
@NP	addition	2322
@NP	OEG transplants	2332
@NP	decreased chondroitin proteoglycan synthesis in the lesion site	2369
@NP	decreased chondroitin proteoglycan synthesis	2369
@NP	the lesion site	2417
@NP	a more CNS tolerant graft	2445
@NP	CNS	2452
@NP	Conclusions	2472
@NP	These results	2485
@NP	transplantation of OEG and SCs in a sub-acute phase	2509
@NP	transplantation	2509
@NP	OEG and SCs	2528
@NP	a sub-acute phase	2543
@NP	anatomical outcomes	2573
@NP	a contusion injury	2599
@NP	the spinal cord	2621
@NP	the number of spared/regenerated supraspinal fibers	2652
@NP	the number	2652
@NP	spared/regenerated supraspinal fibers	2666
@NP	cavitation	2714
@NP	tissue integrity	2739
@NP	This	2757
@NP	important information	2771
@NP	the time window of glial transplantation for the repair of the spinal cord	2796
@NP	the time window	2796
@NP	glial transplantation for the repair of the spinal cord	2815
@NP	glial transplantation	2815
@NP	the repair of the spinal cord	2841
@NP	the repair	2841
@NP	the spinal cord	2855
@NP	Background	2873
@NP	models of spinal cord injury -LRB- SCI -RRB-	2887
@NP	models	2887
@NP	spinal cord injury -LRB- SCI -RRB-	2897
@NP	spinal cord injury	2897
@NP	SCI	2917
@NP	transplantation of growth-permissive tissues and cells	2923
@NP	transplantation	2923
@NP	growth-permissive tissues and cells	2942
@NP	trophic support	3008
@NP	damaged neurons	3028
@NP	the inhibitory milieu of the lesion site	3061
@NP	the inhibitory milieu	3061
@NP	the lesion site	3086
@NP	this	3103
@NP	axons	3115
@NP	the otherwise impenetrable glial scar or cystic cavity	3137
@NP	the otherwise impenetrable glial scar	3137
@NP	cystic cavity	3178
@NP	Olfactory ensheathing glia -LRB- OEG -RRB-	3193
@NP	Olfactory ensheathing glia	3193
@NP	OEG	3221
@NP	the growth	3237
@NP	newly-generated olfactory sensory axons	3251
@NP	the olfactory bulb in normal adults -LSB- 1-4 -RSB-	3296
@NP	the olfactory bulb	3296
@NP	normal adults -LSB- 1-4 -RSB-	3318
@NP	normal adults	3318
@NP	1-4 -RSB-	3333
@NP	olfactory nerve section -LSB- 5,6 -RSB-	3348
@NP	olfactory nerve section	3348
@NP	5,6 -RSB-	3373
@NP	These cells	3379
@NP	the potential to facilitate repair after injury	3396
@NP	repair	3424
@NP	injury	3437
@NP	their potential to enhance tissue repair	3449
@NP	experimental SCI models -LSB- 7-14 -RSB-	3521
@NP	experimental SCI models	3521
@NP	7-14 -RSB-	3546
@NP	Schwann cell -LRB- SCs -RRB- grafts	3553
@NP	Schwann cell	3553
@NP	SCs	3567
@NP	the ability	3589
@NP	axonal regeneration following peripheral and CNS injuries -LSB- 14-18 -RSB-	3612
@NP	axonal regeneration	3612
@NP	peripheral and CNS injuries -LSB- 14-18 -RSB-	3642
@NP	peripheral and CNS injuries	3642
@NP	14-18 -RSB-	3671
@NP	such	3686
@NP	this study	3704
@NP	the outcomes achieved using OEG in sub-acute spinal cord injury model	3726
@NP	the outcomes	3726
@NP	OEG	3754
@NP	sub-acute spinal cord injury model	3761
@NP	Standard methods for isolating adult rat and human SCs	3797
@NP	Standard methods	3797
@NP	adult rat and human SCs	3828
@NP	adult rat	3828
@NP	human SCs	3842
@NP	a homogenous population of cells	3889
@NP	a homogenous population	3889
@NP	cells	3916
@NP	stable characteristics -LSB- 19-22 -RSB-	3927
@NP	stable characteristics	3927
@NP	19-22 -RSB-	3951
@NP	methods to both	3968
@NP	methods	3968
@NP	both	3979
@NP	the OEG and transplant	3992
@NP	the OEG	4015
@NP	the experimental results	4048
@NP	considerable morphological plasticity	4086
@NP	changing phenotype within hours after changes in culture conditions	4134
@NP	changing phenotype	4134
@NP	hours after changes in culture conditions	4160
@NP	hours	4160
@NP	changes in culture conditions	4172
@NP	changes	4172
@NP	culture conditions	4183
@NP	23-26 -RSB-	4203
@NP	this	4219
@NP	consistent functional and anatomical improvements	4225
@NP	olfactory bulb-derived p75-purified OEG	4300
@NP	adult inbred rats -LSB- 8-11,13,27 -RSB-	4345
@NP	adult inbred rats	4345
@NP	8-11,13,27 -RSB-	4364
@NP	results with lamina	4377
@NP	results	4377
@NP	lamina	4390
@NP	OEG	4412
@NP	28-30 -RSB-	4437
@NP	OEG and SCs	4480
@NP	immunohistochemistry	4493
@NP	an antibody	4520
@NP	low affinity nerve growth factor receptor -LRB- p75 -RRB-	4535
@NP	low affinity nerve growth factor receptor	4535
@NP	p75	4578
@NP	this approach	4601
@NP	it	4639
@NP	transplanted OEG and SCs	4683
@NP	endogenous SCs	4713
@NP	the spinal cord via dorsal root entry zones	4745
@NP	the spinal cord	4745
@NP	dorsal root entry zones	4765
@NP	blood vessels -LSB- 21,31-33 -RSB-	4792
@NP	blood vessels	4792
@NP	21,31-33 -RSB-	4807
@NP	Detection of p75	4818
@NP	Detection	4818
@NP	p75	4831
@NP	its ligand-binding domain	4867
@NP	vivo	4911
@NP	endogenous proteases -LSB- 34,35 -RSB-	4932
@NP	endogenous proteases	4932
@NP	34,35 -RSB-	4954
@NP	this reason	4966
@NP	lentiviral ex-vivo prelabeling -LSB- 12,26,36 -RSB- of OEG and SCs with DSRED-2	4979
@NP	lentiviral ex-vivo prelabeling	4979
@NP	12,26,36 -RSB- of OEG and SCs	5011
@NP	12,26,36 -RSB-	5011
@NP	OEG and SCs	5024
@NP	DSRED-2	5041
@NP	this study	5066
@NP	This	5078
@NP	the quantification	5091
@NP	surviving	5113
@NP	cells	5131
@NP	the analysis	5138
@NP	their distribution and influence on endogenous spinal cord cells and axons	5154
@NP	their distribution and influence	5154
@NP	endogenous spinal cord cells and axons	5190
@NP	assessment of their impact	5234
@NP	assessment	5234
@NP	their impact	5248
@NP	matrix deposition and the host repair process	5264
@NP	matrix deposition	5264
@NP	the host repair process	5286
@NP	We	5311
@NP	transplants of adult OEG or SCs	5332
@NP	transplants	5332
@NP	adult OEG or SCs	5347
@NP	their ability to promote axonal sparing / regeneration -LSB- 4,37 -RSB-	5378
@NP	regeneration -LSB- 4,37 -RSB-	5419
@NP	regeneration	5419
@NP	4,37 -RSB-	5433
@NP	a delayed transplant at 14 days post injury	5448
@NP	a delayed transplant	5448
@NP	14 days post injury	5472
@NP	14 days	5472
@NP	anatomical and functional outcomes following a spinal cord contusion	5506
@NP	anatomical and functional outcomes	5506
@NP	a spinal cord contusion	5551
@NP	This experimental study	5576
@NP	numerous years of research	5612
@NP	numerous years	5612
@NP	research	5630
@NP	glial types	5649
@NP	CNS injuries	5664
@NP	the spinal cord	5688
@NP	This time point	5705
@NP	it	5745
@NP	a realistic time window	5759
@NP	this type of cellular therapy in a clinical trial	5791
@NP	this type	5791
@NP	cellular therapy in a clinical trial	5804
@NP	cellular therapy	5804
@NP	a clinical trial	5824
@NP	This time period	5842
@NP	consideration	5870
@NP	time	5888
@NP	sufficient autologous OEGs for transplantation	5923
@NP	sufficient autologous OEGs	5923
@NP	transplantation	5954
@NP	injured patients	5975
@NP	stabilization surgery	5993
@NP	an optimal time window for best outcomes -LSB- 38 -RSB- ,	6019
@NP	an optimal time window	6019
@NP	best outcomes -LSB- 38 -RSB- ,	6046
@NP	best outcomes	6046
@NP	38 -RSB-	6061
@NP	ii	6067
@NP	experimental data	6071
@NP	previous animal studies	6094
@NP	delayed transplantation	6132
@NP	cell survival , integration	6183
@NP	cell survival	6183
@NP	integration	6198
@NP	immune mediated rejection	6222
@NP	8,14,20,38-41 -RSB-	6249
@NP	15 days in vivo a significant scar forms that may inhibit cell integration	6281
@NP	15 days	6281
@NP	a significant scar forms that may inhibit cell integration	6297
@NP	a significant scar forms	6297
@NP	cell integration	6339
@NP	axonal regeneration -LSB- 38	6360
@NP	axonal regeneration	6360
@NP	38	6381
@NP	support of this time point	6389
@NP	support	6389
@NP	this time point	6400
@NP	14 days	6417
@NP	the time point	6429
@NP	the recent oligodendrocyte precursor and activated macrophage clinical trials	6455
@NP	It	6534
@NP	the term `` sparing/regeneration ''	6563
@NP	relation	6612
@NP	the analysis of axonal growth	6624
@NP	the analysis	6624
@NP	axonal growth	6640
@NP	this manuscript	6661
@NP	this	6678
@NP	a contusion model study -LSB- 8	6721
@NP	a contusion model study	6721
@NP	8	6746
@NP	fluorogold	6755
@NP	we	6767
@NP	spared and regenerated axons	6803
@NP	Methods Animals Adult -LRB- 180-200 g -RRB- female Fischer 344 rats	6834
@NP	Methods Animals Adult -LRB- 180-200 g -RRB-	6834
@NP	Methods Animals	6834
@NP	Adult -LRB- 180-200 g -RRB-	6850
@NP	Adult	6850
@NP	180-200 g	6857
@NP	female Fischer 344 rats	6868
@NP	female Fischer	6868
@NP	344 rats	6883
@NP	Animal Resource Centre	6893
@NP	Murdoch	6917
@NP	Western Australia	6926
@NP	groups of three	6960
@NP	groups	6960
@NP	three	6970
@NP	controlled conditions of temperature and humidity	6982
@NP	controlled conditions	6982
@NP	temperature and humidity	7007
@NP	free access to food and water	7038
@NP	free access	7038
@NP	food and water	7053
@NP	All procedures	7069
@NP	the Animal Ethics Committee	7101
@NP	The University of Western Australia -LRB- approval number 99/008/E42 -RRB-	7132
@NP	The University	7132
@NP	Western Australia -LRB- approval number 99/008/E42 -RRB-	7150
@NP	Western Australia	7150
@NP	approval number 99/008/E42	7169
@NP	approval number	7169
@NP	99/008/E42	7185
@NP	Six additional rats	7612
@NP	2 weeks	7646
@NP	contusion	7660
@NP	a transplant	7678
@NP	the lesion milieu	7703
@NP	transplanted cells	7732
@NP	Total rats	7779
@NP	n = 74	7795
@NP	n	7795
@NP	74	7797
@NP	All rats	7801
@NP	a transplant	7820
@NP	medium were perfused at 2 weeks or 4 months after transplantation	7840
@NP	medium	7840
@NP	2 weeks or 4 months	7864
@NP	2 weeks	7864
@NP	4 months	7875
@NP	transplantation	7890
@NP	The numbers of animals	7907
@NP	The numbers	7907
@NP	animals	7922
@NP	final numbers analyzed	7935
@NP	final numbers	7935
@NP	the long term groups	7962
@NP	3 animals	7983
@NP	the short term groups 6 rats	8005
@NP	the short term groups	8005
@NP	6 rats	8027
@NP	Olfactory ensheathing glia and Schwann cell culture and purification OEG	8035
@NP	Olfactory ensheathing glia	8035
@NP	Schwann cell culture and purification OEG	8066
@NP	the olfactory bulbs of adult female Fischer 344 rats -LSB- 8,13,33 -RSB-	8127
@NP	the olfactory bulbs	8127
@NP	adult female Fischer 344 rats -LSB- 8,13,33 -RSB-	8150
@NP	adult female Fischer 344 rats	8150
@NP	8,13,33 -RSB-	8181
@NP	brief	8194
@NP	the bulbs	8201
@NP	the olfactory nerve layer	8231
@NP	Tissue	8268
@NP	trypsin	8321
@NP	0.5 % w/v -LRB- Worthington Biochemical Corporation , Lakewood , NJ -RRB-	8329
@NP	0.5 % w/v	8329
@NP	Worthington	8339
@NP	Biochemical Corporation , Lakewood , NJ	8351
@NP	Biochemical Corporation	8351
@NP	Lakewood , NJ	8376
@NP	Hank 's Balanced Saline Solution -LRB- Sigma -RRB-	8393
@NP	Hank 's Balanced Saline Solution	8393
@NP	Hank 's	8393
@NP	Sigma	8426
@NP	60 minutes at 37 °C in a CO2-free incubator	8437
@NP	60 minutes	8437
@NP	37 °C in a CO2-free incubator	8451
@NP	37 °C	8451
@NP	a CO2-free incubator	8459
@NP	Tissue	8481
@NP	centrifugation	8504
@NP	1500 rpm	8522
@NP	5 minutes	8535
@NP	DF10S medium	8561
@NP	1:1 DMEM	8575
@NP	F-12 - Sigma	8585
@NP	F-12	8585
@NP	Sigma	8591
@NP	10 % -LRB- v/v -RRB- fetal calf serum - Hunter Antisera -RRB-	8599
@NP	10 % -LRB- v/v -RRB- fetal calf serum	8599
@NP	10 %	8599
@NP	v/v	8604
@NP	fetal calf serum	8609
@NP	Hunter Antisera	8628
@NP	Hunter	8628
@NP	Antisera	8635
@NP	bovine pituitary extract -LRB- 20 μg/mL Gibco -RRB-	8663
@NP	bovine pituitary extract	8663
@NP	20 μg/mL Gibco	8689
@NP	forskolin -LRB- 2 μM Sigma -RRB- , then plated on poly	8709
@NP	forskolin -LRB- 2 μM Sigma -RRB-	8709
@NP	forskolin	8709
@NP	2 μM Sigma	8720
@NP	poly	8748
@NP	L-lysine-coated culture dishes -LRB- Corning , Acton , MA -RRB- for one week	8754
@NP	L-lysine-coated culture dishes -LRB- Corning , Acton , MA -RRB-	8754
@NP	L-lysine-coated culture dishes	8754
@NP	Corning	8786
@NP	Acton	8795
@NP	MA	8802
@NP	one week	8810
@NP	OEG	8820
@NP	immunoaffinity	8841
@NP	an antibody	8859
@NP	the p75 receptor -LRB- 192-IgG -RRB- -LSB- 13,33 -RSB-	8874
@NP	the p75 receptor -LRB- 192-IgG -RRB-	8874
@NP	the p75 receptor	8874
@NP	192-IgG	8892
@NP	13,33 -RSB-	8902
@NP	SCs	8910
@NP	adult female Fischer 344 rats -LSB- 19,33 -RSB-	8933
@NP	adult female Fischer 344 rats	8933
@NP	19,33 -RSB-	8964
@NP	the sciatic nerves	8981
@NP	35 mm uncoated tissue culture dishes	9026
@NP	D10S medium	9066
@NP	DMEM -LRB- Sigma St Louis , MO -RRB- with 10 % fetal calf serum	9092
@NP	DMEM -LRB- Sigma St Louis , MO -RRB-	9092
@NP	DMEM	9092
@NP	Sigma St Louis	9098
@NP	MO	9114
@NP	10 % fetal calf serum	9123
@NP	Hunter Antisera Jesmond , NSW , Australia	9145
@NP	Hunter Antisera Jesmond	9145
@NP	NSW	9170
@NP	Australia	9175
@NP	1-2 mm3 pieces	9199
@NP	Each week	9215
@NP	nerve segments	9226
@NP	a new culture dish	9261
@NP	fibroblasts that had migrated out of the explants	9296
@NP	fibroblasts	9296
@NP	the explants	9333
@NP	three weeks of fibroblast depletion	9353
@NP	three weeks	9353
@NP	fibroblast depletion	9368
@NP	explants	9390
@NP	new dishes	9466
@NP	culture	9481
@NP	the presence	9492
@NP	20 μg/mL Gibco , Carlsbad , CA	9534
@NP	20 μg/mL Gibco	9534
@NP	Carlsbad , CA	9550
@NP	2 μM Sigma	9579
@NP	2 μM	9579
@NP	Sigma	9584
@NP	22 -RSB-	9592
@NP	Lentiviral labelling of glia Lentiviral vectors encoding the gene for DSRED-2	9597
@NP	Lentiviral labelling	9597
@NP	glia Lentiviral vectors encoding the gene for DSRED-2	9621
@NP	glia Lentiviral vectors	9621
@NP	the gene for DSRED-2	9654
@NP	the gene	9654
@NP	DSRED-2	9667
@NP	methods described by -LSB- 104 -RSB-	9698
@NP	methods	9698
@NP	-LSB- 104 -RSB-	9719
@NP	Cultured OEG or SCs	9726
@NP	Cultured OEG	9726
@NP	SCs	9742
@NP	the vector	9769
@NP	a multiplicity of infection of 100 -LSB- 12	9787
@NP	a multiplicity	9787
@NP	infection of 100 -LSB- 12	9805
@NP	infection	9805
@NP	100 -LSB- 12	9818
@NP	the culture medium	9830
@NP	16 hours , followed by 2 washes in culture medium and fresh media for growth	9853
@NP	16 hours	9853
@NP	2 washes in culture medium and fresh media for growth	9875
@NP	2 washes in culture medium	9875
@NP	2 washes	9875
@NP	culture medium	9887
@NP	fresh media for growth	9906
@NP	fresh media	9906
@NP	growth	9922
@NP	Spinal cord injury and post-operative care	9930
@NP	Anesthesia	9973
@NP	5 % -LRB- v/v -RRB- halothane -LRB- in 60:40 O2 : N2O -RRB-	10001
@NP	5 % -LRB- v/v -RRB- halothane	10001
@NP	5 % -LRB- v/v -RRB-	10001
@NP	5 %	10001
@NP	v/v	10005
@NP	60:40 O2 : N2O	10024
@NP	60:40 O2	10024
@NP	N2O	10033
@NP	2-3 %	10057
@NP	The skin and muscle layers	10063
@NP	the vertebral column	10125
@NP	a T10 laminectomy	10151
@NP	-LSB- 8 -RSB-	10179
@NP	an New York University -LRB- NYU -RRB- impactor	10189
@NP	New York University -LRB- NYU -RRB-	10192
@NP	New York University	10192
@NP	NYU	10213
@NP	a moderate contusion injury	10228
@NP	a 10 g weight	10280
@NP	a 12.5 mm height -LSB- 99,105 -RSB- Gel-Foam	10299
@NP	a 12.5 mm height	10299
@NP	99,105 -RSB- Gel-Foam	10317
@NP	99,105	10317
@NP	Gel-Foam	10325
@NP	Pharmacia & Upjohn	10335
@NP	Kalamazoo	10355
@NP	MI	10366
@NP	some animals	10399
@NP	Animals	10413
@NP	clamps	10451
@NP	the dorsal processes of T8 and T11/12	10461
@NP	the dorsal processes	10461
@NP	T8 and T11/12	10485
@NP	diaphragm-induced dorso-ventral movement of the spinal column	10514
@NP	diaphragm-induced dorso-ventral movement	10514
@NP	the spinal column	10558
@NP	the injury	10595
@NP	the animal	10607
@NP	the clamps	10635
@NP	the muscles	10650
@NP	layers with Vicryl -LRB- Johnson & Johnson , New Brunswick , NJ -RRB-	10673
@NP	layers	10673
@NP	Vicryl -LRB- Johnson & Johnson , New Brunswick , NJ -RRB-	10685
@NP	Vicryl	10685
@NP	Johnson & Johnson	10693
@NP	New Brunswick	10712
@NP	NJ	10727
@NP	Skin	10732
@NP	Michel suture clips	10753
@NP	Fine Science Tools Inc. , North Vancouver , BC , Canada	10774
@NP	Fine Science Tools Inc.	10774
@NP	North Vancouver	10799
@NP	BC	10816
@NP	Canada	10820
@NP	surgery	10847
@NP	each animal	10856
@NP	penicillin -LRB- Benacillin intramuscular -RRB-	10886
@NP	penicillin	10886
@NP	Benacillin	10898
@NP	analgesic -LRB- Temgesic buprenorphine sub-cutaneous 0.1 mg/kg -RRB-	10925
@NP	analgesic	10925
@NP	Temgesic buprenorphine sub-cutaneous 0.1 mg/kg	10936
@NP	Temgesic buprenorphine sub-cutaneous	10936
@NP	0.1 mg/kg	10973
@NP	2-4 mL 0.9 % saline -LRB- sub-cutaneous -RRB-	10988
@NP	2-4 mL	10988
@NP	0.9 % saline -LRB- sub-cutaneous -RRB-	10995
@NP	0.9 % saline	10995
@NP	Animal cages	11024
@NP	a heating pad for 24 hours	11064
@NP	a heating pad	11064
@NP	24 hours	11082
@NP	maintenance of body temperature	11107
@NP	maintenance	11107
@NP	body temperature	11122
@NP	Antibiotics	11140
@NP	alternate days	11170
@NP	analgesic twice daily and saline once daily for one	11191
@NP	analgesic twice daily	11191
@NP	saline once daily for one	11217
@NP	saline	11217
@NP	one	11239
@NP	week	11243
@NP	Manual bladder expression	11249
@NP	two	11305
@NP	three weeks , by which time all animals had recovered bladder tone	11312
@NP	three weeks	11312
@NP	all animals	11339
@NP	bladder tone	11365
@NP	Cell transplantation Cells	11379
@NP	no more than 2 weeks in vitro -LSB- 8 -RSB-	11430
@NP	no more than 2 weeks	11430
@NP	-LSB- 8 -RSB-	11460
@NP	Fourteen days	11465
@NP	adult female rats	11495
@NP	anesthetized and the spinal cord exposed as described above	11518
@NP	anesthetized and the spinal cord	11518
@NP	5 μL	11586
@NP	a cell suspension	11594
@NP	5 × 105 OEG	11623
@NP	5 ×	11623
@NP	105 OEG	11627
@NP	SCs in culture medium , or medium alone , -LRB- 1:1 DMEM/F -12 Sigma -RRB-	11638
@NP	SCs	11638
@NP	culture medium , or medium alone , -LRB- 1:1 DMEM/F -12 Sigma -RRB-	11645
@NP	culture medium , or medium alone ,	11645
@NP	culture medium	11645
@NP	medium alone	11664
@NP	1:1 DMEM/F -12 Sigma	11679
@NP	1:1	11679
@NP	DMEM/F -12 Sigma	11683
@NP	the center of the lesion	11718
@NP	the center	11718
@NP	the lesion	11732
@NP	a period	11748
@NP	3 minutes	11760
@NP	a 5 μL syringe -LRB- Hamilton , Reno , NV -RRB- mounted in a stereotaxic frame	11776
@NP	a 5 μL syringe	11776
@NP	Hamilton	11792
@NP	Reno	11802
@NP	NV	11808
@NP	a stereotaxic frame	11823
@NP	The needle	11844
@NP	3 minutes later	11869
@NP	cell integration	11898
@NP	the injection site	11920
@NP	Wounds	11940
@NP	post-operative care	11964
@NP	Behavioral testing All testing of the BBB and ladder walk	12021
@NP	Behavioral testing All testing of the BBB	12021
@NP	Behavioral testing	12021
@NP	All testing of the BBB	12040
@NP	All testing	12040
@NP	the BBB	12055
@NP	ladder walk	12067
@NP	observers blinded to the treatments	12099
@NP	observers	12099
@NP	the treatments	12120
@NP	BBB testing -LSB- 99 -RSB-	12136
@NP	BBB testing	12136
@NP	99 -RSB-	12149
@NP	each animal	12170
@NP	the day following contusion	12185
@NP	the successful lesion -LRB- a score of 0 -RRB-	12225
@NP	the successful lesion	12225
@NP	a score of 0	12248
@NP	a score	12248
@NP	0	12259
@NP	The BBB test	12263
@NP	day 3 , day 7 and day 14	12292
@NP	day 3	12292
@NP	day 7	12299
@NP	day 14	12309
@NP	contusion thereafter every week after cell transplantation	12322
@NP	contusion	12322
@NP	every week	12343
@NP	cell transplantation	12360
@NP	3 weeks	12382
@NP	animals	12403
@NP	BBB results of 10 -- 11	12437
@NP	BBB results of 10	12437
@NP	BBB results	12437
@NP	10	12452
@NP	11	12455
@NP	A ladder rung walking test modified from -LSB- 106 -RSB-	12459
@NP	A ladder	12459
@NP	test modified from -LSB- 106 -RSB-	12481
@NP	test	12481
@NP	-LSB- 106 -RSB-	12500
@NP	1 week	12521
@NP	injury	12534
@NP	every week	12554
@NP	4 months	12569
@NP	The ladder rung walking test	12579
@NP	The ladder	12579
@NP	test	12603
@NP	6 points -LRB- Table 2 -RRB-	12617
@NP	6 points	12617
@NP	Table 2	12627
@NP	scoring	12640
@NP	a greater level of sensitivity	12663
@NP	a greater level	12663
@NP	sensitivity	12682
@NP	the two BBB points	12699
@NP	they	12727
@NP	The ladder	12748
@NP	test	12772
@NP	106 -RSB- apparatus	12778
@NP	1.5 m in length	12797
@NP	1.5 m	12797
@NP	length	12806
@NP	two clear Perspex sidewalls and a floor	12830
@NP	two clear Perspex sidewalls	12830
@NP	a floor	12862
@NP	removable metal rungs	12875
@NP	1 cm	12904
@NP	surgery	12925
@NP	rats	12934
@NP	the ladder to reach their home cage	12966
@NP	their home cage	12986
@NP	1	13008
@NP	week	13010
@NP	injury	13021
@NP	trials	13029
@NP	weekly and video recorded	13051
@NP	weekly	13051
@NP	video recorded	13062
@NP	video	13062
@NP	The animals	13078
@NP	3 runs per day	13094
@NP	3 runs	13094
@NP	day	13105
@NP	The video camera	13122
@NP	the central portion	13165
@NP	the ladder , approximately 30 cm in length ,	13188
@NP	the ladder	13188
@NP	approximately 30 cm in length	13200
@NP	approximately 30 cm	13200
@NP	length	13223
@NP	analysis of approximately 8 steps of each hind limb	13240
@NP	analysis	13240
@NP	approximately 8 steps of each hind limb	13252
@NP	approximately 8 steps	13252
@NP	each hind limb	13277
@NP	Each hind limb step in each trial	13293
@NP	Each hind limb step	13293
@NP	each trial	13316
@NP	Table	13345
@NP	the scores	13354
@NP	a single value , per rat , per trial	13387
@NP	a single value , per rat ,	13387
@NP	a single value	13387
@NP	rat	13407
@NP	trial	13416
@NP	Fluorogold labeling	13423
@NP	Ten days	13443
@NP	perfusion -LRB- 4 months post-transplantation of cells -RRB-	13461
@NP	perfusion	13461
@NP	4 months post-transplantation of cells	13472
@NP	4 months post-transplantation	13472
@NP	cells	13505
@NP	11 rats from each of the long term	13513
@NP	11 rats	13513
@NP	each of the long term	13526
@NP	each	13526
@NP	the long term	13534
@NP	4 month	13549
@NP	groups	13558
@NP	a T12 laminectomy	13609
@NP	a stereotaxic frame	13642
@NP	Fluorogold -LRB- 1 μL Fluorochrome Inc. , Denver , CO -RRB-	13663
@NP	Fluorogold	13663
@NP	1 μL Fluorochrome Inc. , Denver , CO	13675
@NP	1 μL	13675
@NP	Fluorochrome Inc.	13680
@NP	Denver , CO	13699
@NP	the spinal cord	13729
@NP	4 points	13748
@NP	0.25 μL each	13758
@NP	0.25 μL	13758
@NP	each	13766
@NP	2 segments	13773
@NP	8 mm	13792
@NP	the contusion site	13801
@NP	All injections	13821
@NP	the same individual	13854
@NP	comparability	13887
@NP	animals	13909
@NP	this individual	13917
@NP	groups	13962
@NP	OEG , SCs or control cells	14003
@NP	OEG	14003
@NP	SCs	14008
@NP	control cells	14015
@NP	Muscles	14030
@NP	layers and the skin	14054
@NP	layers	14054
@NP	the skin	14065
@NP	Michel	14086
@NP	suture clips -LRB- Fine Science Tools Inc. , North Vancouver , BC , Canada -RRB-	14093
@NP	suture clips	14093
@NP	Fine Science Tools Inc. , North Vancouver , BC , Canada	14107
@NP	Fine Science Tools Inc.	14107
@NP	North Vancouver	14132
@NP	BC	14149
@NP	Canada	14153
@NP	Animals	14162
@NP	the post-operative care regime detailed above	14188
@NP	the post-operative care regime	14188
@NP	Tissue processing	14235
@NP	2 weeks or 4 months	14256
@NP	2 weeks	14256
@NP	4 months	14267
@NP	Schwann cell or OEG transplantation	14282
@NP	Schwann cell	14282
@NP	OEG transplantation	14298
@NP	rats	14319
@NP	Nembutal	14358
@NP	intraperitoneal sodium pentobarbital Merial Australia	14368
@NP	Parramatta	14423
@NP	NSW	14435
@NP	Australia	14440
@NP	approximately 150 mL	14484
@NP	heparinized phosphate-buffered saline	14508
@NP	Heparin 1 U/mL David Bull Laboratories , Melbourne , VIC , Australia	14547
@NP	Heparin 1 U/mL	14547
@NP	David Bull Laboratories	14562
@NP	Melbourne , VIC , Australia	14587
@NP	approximately 150 mL 4 % buffered paraformaldehyde solution	14626
@NP	approximately 150 mL	14626
@NP	paraformaldehyde solution	14659
@NP	The spinal cord and brain	14686
@NP	The spinal cord	14686
@NP	brain	14706
@NP	buffered paraformaldehyde overnight at 4 °C	14755
@NP	buffered paraformaldehyde overnight	14755
@NP	4 °C	14794
@NP	The following day	14799
@NP	paraformaldehyde	14818
@NP	0.1 M phosphate buffer	14853
@NP	tissue sectioning	14886
@NP	each spinal cord or brain	14905
@NP	each spinal cord	14905
@NP	brain	14925
@NP	sucrose -LRB- 30 % w/v in phosphate buffer -RRB- overnight and embedded	14947
@NP	sucrose -LRB- 30 % w/v in phosphate buffer -RRB-	14947
@NP	sucrose	14947
@NP	30 % w/v in phosphate buffer	14956
@NP	30 % w/v	14956
@NP	phosphate buffer	14967
@NP	gelatin -LRB- 10 % w/v in phosphate buffer Difco , Franklin Lakes , NJ -RRB-	15011
@NP	gelatin	15011
@NP	10 % w/v in phosphate buffer Difco	15020
@NP	10 % w/v	15020
@NP	phosphate buffer Difco	15031
@NP	Franklin Lakes , NJ	15055
@NP	Franklin Lakes	15055
@NP	NJ	15071
@NP	The gelatin block	15076
@NP	immersion	15107
@NP	paraformaldehyde for 2 hours	15129
@NP	paraformaldehyde	15129
@NP	2 hours	15150
@NP	buffered sucrose solution overnight	15174
@NP	buffered sucrose solution	15174
@NP	Tissue	15211
@NP	spinal cord	15233
@NP	40 μm brain at 50 μm	15248
@NP	40 μm brain	15248
@NP	50 μm	15263
@NP	a freezing sledge microtome	15276
@NP	phosphate buffer	15320
@NP	0.05 %	15348
@NP	w/v sodium azide	15354
@NP	Tissue analysis	15372
@NP	Quantification Numbers of animals per group	15390
@NP	Quantification Numbers	15390
@NP	animals per group	15416
@NP	animals	15416
@NP	group	15428
@NP	8 -- 12 and based on :	15439
@NP	8	15439
@NP	12 and based on	15441
@NP	12	15441
@NP	-LRB- i -RRB- a prior power analysis	15458
@NP	experimental numbers	15504
@NP	animal models of spinal cord injuries	15528
@NP	animal models	15528
@NP	spinal cord injuries	15545
@NP	statistical differences	15600
@NP	-LRB- ii -RRB- previous publications from the laboratory	15629
@NP	previous publications	15634
@NP	the laboratory	15661
@NP	All rats	15677
@NP	BBB , gridwalk , fluorogold traced , immunohistochemistry , and tissue analysis	15703
@NP	BBB , gridwalk , fluorogold traced	15703
@NP	BBB	15703
@NP	gridwalk	15708
@NP	fluorogold traced	15718
@NP	fluorogold	15718
@NP	immunohistochemistry	15737
@NP	tissue analysis	15763
@NP	These	15780
@NP	the groups	15813
@NP	the knowledge of the surgeon or behaviorist	15832
@NP	the knowledge	15832
@NP	the surgeon or behaviorist	15849
@NP	Animals	15877
@NP	the naïve cages	15901
@NP	post-surgery cages	15936
@NP	This number	15969
@NP	an independent person	16002
@NP	the treatment	16036
@NP	every level	16054
@NP	the person	16066
@NP	the treatment	16092
@NP	The perfusions	16107
@NP	the same day for all groups	16140
@NP	the same day	16140
@NP	all groups	16157
@NP	the same fixative batch	16173
@NP	The immunohistochemistry	16198
@NP	each of the groups	16252
@NP	each	16252
@NP	the groups	16260
@NP	differences	16280
@NP	staining between days and groups	16295
@NP	staining	16295
@NP	days and groups	16312
@NP	The analysis	16329
@NP	a trained viewer who was blinded to the groups	16359
@NP	a trained viewer	16359
@NP	the groups	16395
@NP	Tissue volume estimation One in six sections from each spinal cord	16407
@NP	Tissue volume	16407
@NP	One	16432
@NP	six sections	16439
@NP	each spinal cord	16457
@NP	gelatin-coated microscope slides	16491
@NP	gold chloride solution	16541
@NP	myelin followed by cresyl violet for Nissl substance -LSB- 107 -RSB-	16568
@NP	myelin	16568
@NP	cresyl violet for Nissl substance	16587
@NP	cresyl violet	16587
@NP	Nissl substance	16605
@NP	107 -RSB-	16622
@NP	Slides	16628
@NP	an ethanol/toluene series	16659
@NP	DPX -LRB- Chem Supply , Gillman , Australia -RRB-	16700
@NP	DPX	16700
@NP	Chem Supply	16705
@NP	Gillman	16718
@NP	Australia	16727
@NP	Sections	16739
@NP	a Leica DM RBE microscope	16770
@NP	Image Pro Plus -LRB- Media Cybernetics , Silver Spring , MD -RRB-	16824
@NP	Image Pro Plus	16824
@NP	Image	16824
@NP	Pro Plus	16830
@NP	Pro	16830
@NP	Plus	16834
@NP	Media Cybernetics	16840
@NP	Silver Spring	16859
@NP	MD	16874
@NP	the tissue area of a 4.5 mm section of spinal cord	16898
@NP	the tissue area	16898
@NP	a 4.5 mm section of spinal cord	16917
@NP	a 4.5 mm section	16917
@NP	spinal cord	16937
@NP	the lesion center	16954
@NP	its midpoint	16975
@NP	Tissue cavitation	16989
@NP	all animals	17023
@NP	an estimate	17043
@NP	the effect	17058
@NP	the transplanted cells upon the preservation of tissue at the lesion site	17072
@NP	the transplanted cells	17072
@NP	the preservation of tissue at the lesion site	17100
@NP	the preservation	17100
@NP	tissue at the lesion site	17120
@NP	tissue	17120
@NP	the lesion site	17130
@NP	the volume of tissue remaining at the injury site	17146
@NP	the volume	17146
@NP	tissue remaining at the injury site	17160
@NP	tissue remaining	17160
@NP	the injury site	17180
@NP	a similar manner	17212
@NP	that described previously -LSB- 8,14,108	17232
@NP	that	17232
@NP	8,14,108	17259
@NP	The combined area of any cysts	17269
@NP	The combined area	17269
@NP	any cysts	17290
@NP	the total tissue area of the section	17335
@NP	the total tissue area	17335
@NP	the section	17360
@NP	a value	17381
@NP	the total tissue remaining	17393
@NP	the total tissue	17393
@NP	Areas showing signs of degeneration	17421
@NP	Areas	17421
@NP	signs of degeneration	17435
@NP	signs	17435
@NP	degeneration	17444
@NP	microcysts and loss of neuronal profiles	17466
@NP	microcysts and loss	17466
@NP	neuronal profiles	17489
@NP	the values for total tissue remaining to obtain a measure of intact tissue	17529
@NP	the values	17529
@NP	total tissue remaining to obtain a measure of intact tissue	17544
@NP	total tissue	17544
@NP	a measure of intact tissue	17577
@NP	a measure	17577
@NP	intact tissue	17590
@NP	The values for the centre four sections of each spinal cord	17605
@NP	The values	17605
@NP	the centre four sections of each spinal cord	17620
@NP	the centre four sections	17620
@NP	each spinal cord	17648
@NP	a single semi-quantitative value of remaining tissue volume value for each rat	17687
@NP	a single semi-quantitative value	17687
@NP	remaining tissue volume value for each rat	17723
@NP	remaining tissue volume value	17723
@NP	each rat	17757
@NP	Values from four equivalent sections of an uninjured spinal cord	17767
@NP	Values	17767
@NP	four equivalent sections of an uninjured spinal cord	17779
@NP	four equivalent sections	17779
@NP	an uninjured spinal cord	17807
@NP	the tissue remaining as a proportion of uninjured spinal cord	17853
@NP	the tissue	17853
@NP	a proportion of uninjured spinal cord	17877
@NP	a proportion	17877
@NP	uninjured spinal cord	17893
@NP	Immunohistochemistry Series of one in six tissue sections	17916
@NP	Immunohistochemistry Series	17916
@NP	one	17947
@NP	six tissue sections	17954
@NP	2 week or 4 month time points	17978
@NP	2 week	17978
@NP	4 month time points	17988
@NP	mouse monoclonal or rabbit polyclonal antibodies	18047
@NP	mouse monoclonal	18047
@NP	rabbit polyclonal antibodies	18067
@NP	Sections	18097
@NP	4 °C	18134
@NP	primary antibody diluted in phosphate buffer containing 10 % normal goat serum	18141
@NP	primary antibody	18141
@NP	phosphate buffer	18169
@NP	10 % normal goat serum	18197
@NP	0.2 % -LRB- v/v -RRB- Triton X-100	18223
@NP	0.2 %	18223
@NP	v/v	18229
@NP	Triton X-100	18234
@NP	Mouse monoclonal antibodies used	18248
@NP	Mouse monoclonal antibodies	18248
@NP	anti-chondroitin sulfate proteoglycans -LRB- CS-56 1:50 Sigma -RRB-	18290
@NP	anti-chondroitin sulfate proteoglycans	18290
@NP	CS-56 1:50 Sigma	18330
@NP	proteoglycan deposition	18360
@NP	the lesion site	18387
@NP	low affinity nerve growth factor receptor p75	18408
@NP	supernatant 192-IgG	18455
@NP	OEG and Schwann cells -LRB- both transplanted and endogenous -RRB-	18489
@NP	OEG and Schwann cells	18489
@NP	transplanted and endogenous	18517
@NP	transplanted	18517
@NP	endogenous	18534
@NP	high neurofilaments RT-97	18568
@NP	supernatant Developmental Hybridoma Bank	18595
@NP	supernatant Developmental Hybridoma	18595
@NP	Bank	18631
@NP	spared and regenerated axons	18650
@NP	Rabbit polyclonal antibodies were used for	18680
@NP	Rabbit	18680
@NP	polyclonal antibodies	18687
@NP	p75 -LRB- 1:200 Promega , Madison , WI -RRB-	18727
@NP	p75	18727
@NP	1:200 Promega , Madison , WI	18732
@NP	1:200 Promega , Madison	18732
@NP	WI	18756
@NP	Glial fibrillary acidic protein -LRB- GFAP -RRB-	18761
@NP	Glial fibrillary acidic protein	18761
@NP	GFAP	18794
@NP	1:500 DakoCytomation	18801
@NP	Denmark	18823
@NP	astrocytes , unmyelinated Schwann cells and olfactory glia , ii -RRB-	18845
@NP	astrocytes , unmyelinated Schwann cells and olfactory glia	18845
@NP	astrocytes	18845
@NP	unmyelinated Schwann cells	18857
@NP	olfactory glia	18888
@NP	ii	18904
@NP	IV	18922
@NP	1:200 Rockland Inc. , Gilbertsville , PA	18926
@NP	1:200 Rockland Inc.	18926
@NP	Gilbertsville	18947
@NP	PA	18962
@NP	the distribution	18979
@NP	basal lamina and blood vessels and iii -RRB- anti-laminin-1	18999
@NP	1:200 Sigma	19055
@NP	1:200	19055
@NP	Sigma	19061
@NP	basal lamina and blood vessels	19072
@NP	The following day	19104
@NP	sections	19123
@NP	three times	19144
@NP	phosphate buffer	19161
@NP	the same solution	19228
@NP	primary antibodies	19253
@NP	30 minutes at room temperature	19277
@NP	30 minutes	19277
@NP	room temperature	19291
@NP	Sections	19309
@NP	three times	19330
@NP	phosphate buffer	19347
@NP	gelatin-coated glass	19378
@NP	microscope slides	19399
@NP	air dried and then coverslipped in a glycerol-based mounting medium	19418
@NP	air	19418
@NP	a glycerol-based mounting medium	19453
@NP	Semi-quantitative analysis	19487
@NP	proteoglycan , matrix and cell survival	19517
@NP	One	19564
@NP	6 series of sections at 4 months post transplantation -LRB- and controls -RRB-	19571
@NP	6 series	19571
@NP	sections at 4 months post transplantation -LRB- and controls -RRB-	19583
@NP	sections	19583
@NP	4 months post transplantation	19595
@NP	Low magnification photomicrographs -LRB- 10 × objective -RRB-	19655
@NP	Low magnification photomicrographs	19655
@NP	10 × objective	19691
@NP	10	19691
@NP	× objective	19693
@NP	an IX70 Olympus microscope	19723
@NP	Pixel fluorescence of immunostaining for CS-56 , laminin and collagen IV	19751
@NP	Pixel fluorescence	19751
@NP	immunostaining for CS-56 , laminin and collagen IV	19773
@NP	immunostaining	19773
@NP	CS-56 , laminin and collagen IV	19792
@NP	CS-56	19792
@NP	laminin	19799
@NP	collagen IV	19811
@NP	rostral	19839
@NP	middle and caudal locations	19848
@NP	the contusion	19879
@NP	injury sites and the average pixel fluorescence	19894
@NP	injury sites	19894
@NP	the average pixel fluorescence	19911
@NP	background readings of the three areas compared between medium control and OEG	19948
@NP	background readings	19948
@NP	the three areas compared between medium control and OEG	19971
@NP	the three areas	19971
@NP	medium control and OEG	20004
@NP	SCs groups -LSB- 37,57	20030
@NP	SCs groups	20030
@NP	37,57	20042
@NP	addition	20053
@NP	one in 4 series of sections	20063
@NP	one	20063
@NP	4 series of sections	20070
@NP	4 series	20070
@NP	sections	20082
@NP	the presence of DSRED-2 labeled cells in the 2 week and 4 month survival groups	20109
@NP	the presence	20109
@NP	DSRED-2 labeled cells in the 2 week and 4 month survival groups	20125
@NP	DSRED-2	20125
@NP	cells	20141
@NP	the 2 week and 4 month survival groups	20150
@NP	the 2 week	20150
@NP	4 month survival groups	20165
@NP	Pixel fluorescence	20190
@NP	the 2 survival points	20235
@NP	survival of OEG and SCs	20269
@NP	survival	20269
@NP	OEG and SCs	20281
@NP	4 months expressed as a percentage of those present at 2 weeks	20296
@NP	4 months	20296
@NP	a percentage of those present at 2 weeks	20318
@NP	a percentage	20318
@NP	those present at 2 weeks	20334
@NP	Fluorogold	20360
@NP	A 1 in 6 series of brain sections	20394
@NP	A 1	20394
@NP	6 series of brain sections	20401
@NP	6 series	20401
@NP	brain sections	20413
@NP	gelatin-coated glass microscope slides	20446
@NP	a glycerol-based mounting medium	20511
@NP	Sections	20545
@NP	a Hitachi HV-C20M digital camera	20577
@NP	a large tiled image	20613
@NP	a fluorescence microscope -LRB- Leica DM RBE -RRB-	20639
@NP	a fluorescence microscope	20639
@NP	Leica DM RBE	20666
@NP	a motorized stage controlled with Image Pro	20685
@NP	a motorized stage	20685
@NP	Image Pro	20719
@NP	Image	20719
@NP	Pro	20725
@NP	5.1	20735
@NP	software -LRB- Media Cybernetics -RRB-	20740
@NP	software	20740
@NP	Media Cybernetics	20750
@NP	The optical dissector method	20770
@NP	photograph and count fluorogold-labeled neurons	20811
@NP	photograph	20811
@NP	count fluorogold-labeled neurons	20826
@NP	inaccuracies	20878
@NP	double counting	20898
@NP	109 -RSB- Photographs	20915
@NP	the centre of the z-axis of each section	20946
@NP	the centre	20946
@NP	the z-axis of each section	20960
@NP	the z-axis	20960
@NP	each section	20974
@NP	Those cell bodies in focus	20988
@NP	Those cell bodies	20988
@NP	focus	21009
@NP	then	21032
@NP	Image Pro	21062
@NP	Image	21062
@NP	Pro	21068
@NP	Plus	21072
@NP	Seven areas were analyzed	21078
@NP	Seven areas	21078
@NP	the reticular formation	21105
@NP	vestibular nucleus	21130
@NP	trigeminal and dorsal column nuclei	21150
@NP	raphe nucleus	21187
@NP	red nucleus	21202
@NP	hypothalamus	21215
@NP	motor cortex	21232
@NP	sparing/regeneration of descending propriospinal neurons	21258
@NP	sparing/regeneration	21258
@NP	descending propriospinal neurons	21282
@NP	the labeled cell bodies	21316
@NP	an identical method in the spinal cord region	21359
@NP	an identical method	21359
@NP	the spinal cord region	21382
@NP	the lesion site	21416
@NP	Six spinal cord sections -LRB- 1 cm in length -RRB- from each animal	21433
@NP	Six spinal cord sections -LRB- 1 cm in length -RRB-	21433
@NP	Six spinal cord sections	21433
@NP	1 cm in length	21459
@NP	1 cm	21459
@NP	length	21467
@NP	each animal	21480
@NP	Statistical analysis	21507
@NP	The methods of statistical analysis	21528
@NP	The methods	21528
@NP	statistical analysis	21543
@NP	the animal numbers	21591
@NP	this study	21618
@NP	Fluorogold labeling of supraspinal projecting nuclei in the brain	21634
@NP	Fluorogold labeling	21634
@NP	nuclei	21680
@NP	the brain	21690
@NP	experimental groups	21701
@NP	a one-way analysis	21741
@NP	variance	21763
@NP	ANOVA	21773
@NP	the Dunnetts methods of multiple comparisons	21792
@NP	the Dunnetts methods	21792
@NP	multiple comparisons	21816
@NP	a single control group -LRB- injury only -RRB-	21844
@NP	a single control group	21844
@NP	injury only	21868
@NP	the Tukey test	21890
@NP	multiple comparison procedures between all experimental and control groups	21909
@NP	multiple comparison procedures	21909
@NP	all experimental and control groups	21948
@NP	Fluorogold analysis of propriospinal projections into the distal spinal cord	21985
@NP	Fluorogold analysis	21985
@NP	propriospinal projections into the distal spinal cord	22008
@NP	propriospinal projections	22008
@NP	the distal spinal cord	22039
@NP	a one way analysis of variance -LRB- ANOVA -RRB-	22082
@NP	a one way analysis	22082
@NP	variance -LRB- ANOVA -RRB-	22104
@NP	variance	22104
@NP	ANOVA	22114
@NP	This	22122
@NP	the case for the tissue sparing and proteoglycan and cell survival analysis	22136
@NP	the case	22136
@NP	the tissue sparing and proteoglycan and cell survival analysis	22149
@NP	the tissue sparing	22149
@NP	proteoglycan and cell survival analysis	22172
@NP	the analysis of the BBB scores	22216
@NP	the analysis	22216
@NP	the BBB scores	22232
@NP	groups	22248
@NP	the non parametric Kruskal Wallace ANOVA	22275
@NP	ranks	22319
@NP	This	22326
@NP	Dunnetts method of multiple comparisons versus a single control group	22347
@NP	Dunnetts method	22347
@NP	multiple comparisons versus a single control group	22366
@NP	multiple comparisons	22366
@NP	a single control group	22394
@NP	Results	22419
@NP	Table 1 Retrogradely Fluorogold-Labeled Neurons	22427
@NP	Control , OEG Transplanted and SC	22478
@NP	groups	22524
@NP	2 Scoring scale	22538
@NP	the ladder	22568
@NP	test	22592
@NP	Metz and Whishaw	22613
@NP	-LSB- 63 -RSB-	22631
@NP	Figure 1 Graphic describing the amount of total tissue remaining	22638
@NP	Figure 1 Graphic	22638
@NP	the amount of total tissue remaining	22666
@NP	the amount	22666
@NP	total tissue remaining	22680
@NP	intact tissue	22707
@NP	the site	22724
@NP	the spinal cord contusion injury at day of transplant 2 weeks and 4 months	22736
@NP	the spinal cord contusion injury at day of transplant 2 weeks	22736
@NP	the spinal cord contusion injury	22736
@NP	day of transplant 2 weeks	22772
@NP	day	22772
@NP	transplant	22779
@NP	2 weeks	22790
@NP	4 months	22802
@NP	Quantification of gold chloride and Nissl	22812
@NP	Quantification	22812
@NP	gold chloride and Nissl	22830
@NP	sagittal sections	22862
@NP	the amount of intact tissue and total tissue remaining	22891
@NP	the amount	22891
@NP	intact tissue and total tissue remaining	22905
@NP	intact tissue	22905
@NP	total tissue remaining	22923
@NP	each of the experimental groups	22953
@NP	each	22953
@NP	the experimental groups	22961
@NP	Image	22991
@NP	Pro	22997
@NP	-LRB- A -RRB-	23002
@NP	Total tissue remaining 2 weeks and 4 months after cell transplantation	23007
@NP	Total tissue	23007
@NP	2 weeks and 4 months	23030
@NP	2 weeks	23030
@NP	4 months	23042
@NP	cell transplantation	23057
@NP	-LRB- B -RRB-	23079
@NP	Intact tissue remaining 2 weeks and 4 months after cell transplantation	23084
@NP	Intact tissue	23084
@NP	2 weeks and 4 months	23108
@NP	2 weeks	23108
@NP	4 months	23120
@NP	cell transplantation	23135
@NP	There	23157
@NP	a significant increase	23167
@NP	p <	23193
@NP	p	23193
@NP	<	23194
@NP	0.05	23195
@NP	intact tissue	23204
@NP	the OEG and Schwann cell treated groups	23227
@NP	medium controls	23284
@NP	C , G	23302
@NP	C	23302
@NP	G	23305
@NP	: Appearance of spinal cord lesion site 2 weeks	23307
@NP	: Appearance of spinal cord lesion site	23307
@NP	Appearance	23309
@NP	spinal cord lesion site	23323
@NP	2 weeks	23347
@NP	injury -LRB- i.e. day of cell transplantation -RRB- -LRB- D -RRB-	23361
@NP	injury	23361
@NP	i.e. day of cell transplantation	23369
@NP	i.e.	23369
@NP	day of cell transplantation	23374
@NP	day	23374
@NP	cell transplantation	23381
@NP	D	23404
@NP	remaining	23420
@NP	at 2 weeks	23430
@NP	at 2	23430
@NP	weeks	23435
@NP	medium injection	23447
@NP	-LRB- E -RRB-	23465
@NP	Appearance	23469
@NP	spinal cord lesion site	23483
@NP	2 weeks	23507
@NP	OEG transplantation -LRB- 4 weeks after injury -RRB-	23521
@NP	OEG transplantation	23521
@NP	4 weeks after injury	23542
@NP	4 weeks	23542
@NP	injury	23556
@NP	-LRB- F -RRB-	23565
@NP	Appearance	23569
@NP	the spinal cord lesion epicenter	23583
@NP	2 weeks	23616
@NP	Schwann cell transplantation -LRB- 4 weeks after initial injury -RRB-	23630
@NP	Schwann cell transplantation	23630
@NP	4 weeks after initial injury	23660
@NP	4 weeks	23660
@NP	initial injury	23674
@NP	-LRB- H -RRB-	23691
@NP	Appearance of spinal cord lesion site 4 months after medium injection	23696
@NP	Appearance	23696
@NP	spinal cord lesion site 4 months after medium injection	23710
@NP	spinal cord lesion site	23710
@NP	4 months	23734
@NP	medium injection	23749
@NP	-LRB- I -RRB-	23767
@NP	the spinal cord tissue	23784
@NP	4 months	23807
@NP	OEG transplantation	23822
@NP	the considerable increased retention of intact tissue	23848
@NP	the considerable increased retention	23848
@NP	intact tissue	23888
@NP	a reduction in cystic volume	23906
@NP	a reduction	23906
@NP	cystic volume	23921
@NP	image -LRB- H -RRB-	23952
@NP	image	23952
@NP	H	23959
@NP	-LRB- J -RRB-	23963
@NP	spinal cord at 4 months	23976
@NP	spinal cord	23976
@NP	4 months	23991
@NP	Schwann cells	24026
@NP	the 14 day treatment time point	24043
@NP	the presence	24081
@NP	small microcysts	24097
@NP	black arrow	24119
@NP	the spinal cord parenchyma	24139
@NP	the Schwann cells	24182
@NP	Scale bar : 200 μm .	24213
@NP	Scale bar	24213
@NP	200 μm	24224
@NP	Figure 2 Photomicrographs representing lentiviral	24233
@NP	Figure 2 Photomicrographs	24233
@NP	Figure	24233
@NP	2 Photomicrographs	24240
@NP	OEG and Schwann cells	24311
@NP	A : OEG in vitro labeled with lentiviral DsRed2 .	24334
@NP	A : OEG in vitro labeled with lentiviral DsRed2	24334
@NP	A : OEG in vitro	24334
@NP	OEG in vitro	24337
@NP	OEG	24337
@NP	vitro	24344
@NP	lentiviral DsRed2	24363
@NP	B : Schwann cells in vitro labeled with lentiviral DsRed2 .	24382
@NP	B	24382
@NP	Schwann cells in vitro labeled with lentiviral DsRed2	24385
@NP	Schwann cells	24385
@NP	lentiviral DsRed2	24421
@NP	Scale bar -LRB- A B -RRB- : 50 μm .	24440
@NP	Scale bar -LRB- A B -RRB-	24440
@NP	Scale bar	24440
@NP	A B	24451
@NP	50 μm	24457
@NP	C D	24464
@NP	Localization	24469
@NP	transplanted OEG -LRB- C -RRB-	24485
@NP	transplanted OEG	24485
@NP	C	24503
@NP	Schwann cells -LRB- D -RRB-	24510
@NP	Schwann cells	24510
@NP	D	24525
@NP	the spinal cord lesion site 2 weeks after transplantation	24535
@NP	the spinal cord lesion site	24535
@NP	2 weeks	24563
@NP	transplantation	24577
@NP	Schwann cells	24594
@NP	greater numbers than the OEG	24635
@NP	greater numbers	24635
@NP	the OEG	24656
@NP	OEG	24674
@NP	the spinal cord tissue	24705
@NP	Schwann cells	24734
@NP	a dense aggregate	24758
@NP	Scale bar -LRB- C D -RRB- : 100 μm .	24777
@NP	Scale bar -LRB- C D -RRB-	24777
@NP	Scale bar	24777
@NP	C D	24788
@NP	100 μm	24794
@NP	Figure 3 Glial scar formation at the lesion site	24803
@NP	Figure 3 Glial scar formation	24803
@NP	Figure 3	24803
@NP	Glial scar formation	24812
@NP	the lesion site	24836
@NP	GFAP and CSPG immunoreactivity	24865
@NP	A-D : GFAP in green DsRed2-labeled transplanted cells in red .	24897
@NP	A-D	24897
@NP	GFAP in green DsRed2-labeled transplanted cells in red	24902
@NP	GFAP	24902
@NP	green DsRed2-labeled transplanted cells in red	24910
@NP	green DsRed2-labeled transplanted cells	24910
@NP	red	24953
@NP	A-B : Lesion site 2 weeks after transplantation of OEG .	24958
@NP	A-B	24958
@NP	Lesion site 2 weeks after transplantation of OEG	24963
@NP	Lesion site	24963
@NP	2 weeks	24975
@NP	transplantation of OEG	24989
@NP	transplantation	24989
@NP	OEG	25008
@NP	C-D : Lesion site 2 weeks after transplantation of Schwann cells .	25013
@NP	C-D	25013
@NP	Lesion site 2 weeks after transplantation of Schwann cells	25018
@NP	Lesion site	25018
@NP	2 weeks	25030
@NP	transplantation of Schwann cells	25044
@NP	transplantation	25044
@NP	Schwann cells	25063
@NP	Dispersal of transplanted cells	25078
@NP	Dispersal	25078
@NP	transplanted cells	25091
@NP	OEG	25125
@NP	Schwann cells	25138
@NP	Schwann cells	25153
@NP	a dense aggregate at the lesion site surrounded by strong GFAP immunoreactivity	25177
@NP	a dense aggregate	25177
@NP	the lesion site surrounded by strong GFAP immunoreactivity	25198
@NP	the lesion site	25198
@NP	strong GFAP immunoreactivity	25228
@NP	E	25258
@NP	Schwann cells	25261
@NP	dense proteoglycan network CSPG -LRB- green -RRB-	25293
@NP	dense proteoglycan network CSPG	25293
@NP	DsRed2-labeled transplanted cells -LRB- red -RRB-	25334
@NP	DsRed2-labeled transplanted cells	25334
@NP	red	25369
@NP	Scale bars : A-D	25375
@NP	Scale bars	25375
@NP	A-D	25387
@NP	100 μm , E : 200 μm	25392
@NP	100 μm	25392
@NP	E	25400
@NP	200 μm	25403
@NP	F	25411
@NP	Graph	25414
@NP	the quantitative fluorescence	25428
@NP	mean pixels	25471
@NP	GFAP and CSPG	25487
@NP	the distal interface of the transplant zone	25504
@NP	the distal interface	25504
@NP	the transplant zone	25528
@NP	n = 10 for each group	25549
@NP	n = 10	25549
@NP	n	25549
@NP	10	25551
@NP	each group	25558
@NP	OEG	25571
@NP	significantly less -LRB- p < 0.05 -RRB- CSPG expression	25579
@NP	p < 0.05	25599
@NP	p	25599
@NP	< 0.05	25600
@NP	<	25600
@NP	0.05	25601
@NP	Schwann cells	25640
@NP	Schwann cells	25663
@NP	significantly greater -LRB- p < 0.05 -RRB- CSPG expression	25681
@NP	p < 0.05	25704
@NP	p	25704
@NP	< 0.05	25705
@NP	<	25705
@NP	0.05	25707
@NP	medium	25746
@NP	controls -LRB- see # -RRB-	25762
@NP	controls	25762
@NP	Figure 4 Schwann cell , OEG and medium treated spinal cords at 4 months .	25781
@NP	Figure 4 Schwann cell	25781
@NP	Figure	25781
@NP	4 Schwann cell	25788
@NP	OEG and medium treated spinal cords at 4 months	25804
@NP	OEG and medium	25804
@NP	spinal cords	25827
@NP	4 months	25843
@NP	Photomicrographs	25853
@NP	the distribution and immunoreactivity	25880
@NP	laminin-1 -LRB- A , B , D-K -RRB- and collagen IV -LRB- C , L-S -RRB-	25922
@NP	laminin-1	25922
@NP	A , B , D-K	25933
@NP	collagen IV	25948
@NP	C , L-S	25961
@NP	C	25961
@NP	L-S	25964
@NP	the site of spinal cord contusion lesion	25972
@NP	the site	25972
@NP	spinal cord contusion lesion	25984
@NP	the transplantation of SCs and OEG	26029
@NP	the transplantation	26029
@NP	SCs and OEG	26052
@NP	Areas of strong immunoreactivity for laminin	26065
@NP	Areas	26065
@NP	strong immunoreactivity for laminin	26074
@NP	strong immunoreactivity	26074
@NP	laminin	26102
@NP	the areas	26134
@NP	the transplanted cells -LRB- see arrow in D depicting DsRed-2 OEG -RRB-	26147
@NP	the transplanted cells	26147
@NP	arrow in D depicting DsRed-2 OEG	26175
@NP	arrow	26175
@NP	D depicting DsRed-2 OEG	26184
@NP	D	26184
@NP	DsRed-2 OEG	26196
@NP	Laminin immunostaining	26210
@NP	the surface of the OEG cells -LRB- see arrows in G -RRB-	26271
@NP	the surface	26271
@NP	the OEG cells	26286
@NP	arrows	26305
@NP	G	26315
@NP	Laminin	26319
@NP	surrounding Schwann cell transplants -LRB- see H -RRB-	26341
@NP	surrounding Schwann cell transplants	26341
@NP	H	26383
@NP	Arrow	26387
@NP	the central core of the transplant	26401
@NP	the central core	26401
@NP	the transplant	26421
@NP	Laminin	26437
@NP	the region of the Schwann cells	26463
@NP	the region	26463
@NP	the Schwann cells	26477
@NP	I-J	26500
@NP	the host spinal cord below the dashed line	26510
@NP	the host spinal cord	26510
@NP	the dashed line	26537
@NP	intensity of staining	26565
@NP	intensity	26565
@NP	staining	26578
@NP	Collagen IV immunostaining	26588
@NP	Collagen	26588
@NP	a central core of staining close	26623
@NP	a central core	26623
@NP	staining close	26641
@NP	the lesion site surrounding any surviving OEG	26659
@NP	the lesion site	26659
@NP	any surviving OEG	26687
@NP	L	26710
@NP	cells -LRB- see arrows in O -RRB-	26725
@NP	cells	26725
@NP	arrows	26736
@NP	O	26746
@NP	collagen IV	26772
@NP	Collagen IV immunostaining	26785
@NP	Schwann cell transplanted spinal cords show intense staining surrounding	26815
@NP	Schwann cell	26815
@NP	transplanted spinal cords	26828
@NP	intense staining surrounding	26859
@NP	intense staining	26859
@NP	the DsRed-2 SC transplant area -LRB- see arrow -RRB-	26899
@NP	the DsRed-2 SC transplant area	26899
@NP	arrow	26935
@NP	higher power	26946
@NP	the staining	26959
@NP	dashed line	27006
@NP	some areas	27023
@NP	Scale bars : 100 μm .	27043
@NP	Scale bars	27043
@NP	100 μm	27055
@NP	Scale	27063
@NP	A	27076
@NP	C , D , H , L and P.	27090
@NP	C	27090
@NP	D	27093
@NP	H	27096
@NP	L	27099
@NP	P.	27105
@NP	Scale	27108
@NP	B	27121
@NP	E , F , I , J , M , N , Q and R.	27135
@NP	E	27135
@NP	F	27138
@NP	I	27141
@NP	J	27144
@NP	M	27147
@NP	N	27150
@NP	Q	27153
@NP	R.	27159
@NP	Figure	27163
@NP	5 Axonal staining at the lesion site of Schwann cell , OEG and medium groups	27170
@NP	5 Axonal staining	27170
@NP	the lesion site of Schwann cell , OEG and medium groups	27191
@NP	the lesion site	27191
@NP	Schwann cell , OEG and medium groups	27210
@NP	Immunoreactivity	27247
@NP	RT-97	27268
@NP	the site	27277
@NP	spinal cord contusion 4 months after medium -LRB- A -RRB- OEG -LRB- B-C -RRB-	27289
@NP	spinal cord contusion	27289
@NP	4 months	27311
@NP	medium -LRB- A -RRB- OEG -LRB- B-C -RRB-	27326
@NP	medium -LRB- A -RRB- OEG	27326
@NP	A	27334
@NP	B-C	27342
@NP	Schwann cells -LRB- D-E -RRB- transplantation	27351
@NP	Schwann cells	27351
@NP	D-E	27366
@NP	transplantation	27371
@NP	RT97 positive axons	27388
@NP	the lesion site in all groups	27428
@NP	the lesion site	27428
@NP	all groups	27447
@NP	number and distribution	27462
@NP	Axons in the OEG group -LRB- B -RRB-	27494
@NP	Axons in the OEG group	27494
@NP	Axons	27494
@NP	the OEG group	27503
@NP	B	27518
@NP	fascicular bundles	27538
@NP	rostral	27574
@NP	caudal orientation	27585
@NP	axons beneath the graft area	27611
@NP	axons	27611
@NP	the graft area	27625
@NP	the ventral white matter	27657
@NP	-LRB- C -RRB- for higher power image of -LRB- B -RRB- .	27687
@NP	-LRB- C -RRB-	27687
@NP	higher power image of -LRB- B -RRB- .	27695
@NP	higher power image	27695
@NP	B	27718
@NP	RT97 staining after Schwann cell transplantation -LRB- see D -RRB- .	27722
@NP	RT97 staining	27722
@NP	Schwann cell transplantation -LRB- see D -RRB-	27742
@NP	Schwann cell transplantation	27742
@NP	D	27776
@NP	These axons	27780
@NP	a close association	27799
@NP	DsRed-2 positive cells	27824
@NP	a non linear path	27860
@NP	Arrows in -LRB- E -RRB-	27879
@NP	Arrows in	27879
@NP	Arrows	27879
@NP	E	27890
@NP	DsRed-2	27900
@NP	Schwann cells	27916
@NP	the transplants	27942
@NP	microcysts -LRB- * -RRB-	27970
@NP	microcysts	27970
@NP	Scale bars : 100 μm .	27986
@NP	Scale bars	27986
@NP	100 μm	27998
@NP	Scale	28006
@NP	D	28019
@NP	A and B scale bar in E	28033
@NP	A and B scale bar	28033
@NP	E	28054
@NP	C.	28068
@NP	Figure 6 Photomicrographs	28072
@NP	p75 immunoreactivity of spinal cord sections in the lesion site	28108
@NP	p75 immunoreactivity	28108
@NP	spinal cord sections in the lesion site	28132
@NP	spinal cord sections	28132
@NP	the lesion site	28156
@NP	SCI	28178
@NP	Endogenous p75 positive cells Schwann cells	28183
@NP	Endogenous p75 positive cells	28183
@NP	Schwann cells	28213
@NP	the lesion site 2 weeks -LRB- A -RRB- and 4 months post injury -LRB- B -RRB-	28246
@NP	the lesion site 2 weeks -LRB- A -RRB-	28246
@NP	the lesion site	28246
@NP	2 weeks -LRB- A -RRB-	28262
@NP	A	28271
@NP	4 months post injury -LRB- B -RRB-	28278
@NP	4 months post injury	28278
@NP	4 months	28278
@NP	B	28300
@NP	p75 positive profiles	28304
@NP	numbers in OEG -LRB- C-D -RRB- and Schwann cell -LRB- E-F -RRB-	28347
@NP	numbers	28347
@NP	OEG -LRB- C-D -RRB- and Schwann cell -LRB- E-F -RRB-	28358
@NP	OEG	28358
@NP	C-D	28363
@NP	Schwann cell	28372
@NP	E-F	28386
@NP	The arrows in C and D	28412
@NP	The arrows	28412
@NP	C and D	28426
@NP	DsRED-2	28444
@NP	positive transplanted OEG within the lesion site	28452
@NP	positive transplanted OEG	28452
@NP	the lesion site	28485
@NP	host p75 positive Schwann cells	28516
@NP	the Schwann cell transplanted group the p75	28552
@NP	the Schwann cell transplanted group	28552
@NP	the p75	28588
@NP	positive endogenous Schwann cells -LRB- see arrows -RRB-	28596
@NP	positive endogenous Schwann cells	28596
@NP	arrows	28635
@NP	the transplanted DsRed-2	28657
@NP	The Schwann cell transplants	28697
@NP	the dispersed OEG	28755
@NP	C-D	28778
@NP	Scale	28784
@NP	C -LRB- 100 μm -RRB-	28797
@NP	C	28797
@NP	100 μm	28800
@NP	A and B.	28820
@NP	A	28820
@NP	B.	28826
@NP	Figure 7 Number	28830
@NP	neurons in brain/brainstem nuclei retrogradely labeled with Fluorogold	28849
@NP	neurons	28849
@NP	brain/brainstem nuclei retrogradely labeled with Fluorogold	28860
@NP	brain/brainstem nuclei	28860
@NP	Fluorogold	28909
@NP	8 mm caudal	28929
@NP	the thoracic spinal cord lesion site	28944
@NP	OEG transplantation into the contused spinal cord 14 days after injury	28982
@NP	OEG transplantation	28982
@NP	the contused spinal cord 14 days after injury	29007
@NP	the	29007
@NP	spinal cord	29020
@NP	14 days	29032
@NP	injury	29046
@NP	significant axonal sparing/regeneration of Raphe -	29062
@NP	significant axonal sparing/regeneration	29062
@NP	Raphe	29105
@NP	Vestibular	29113
@NP	Reticulo-spinal axons	29129
@NP	Graphs	29152
@NP	the mean numbers	29166
@NP	total FG-labeled neurons	29186
@NP	the brains and brainstems of the four groups -LRB- A -RRB-	29214
@NP	the brains and brainstems	29214
@NP	the four groups -LRB- A -RRB-	29243
@NP	the four groups	29243
@NP	A	29260
@NP	Mean neuron numbers	29264
@NP	the Raphe -LRB- B -RRB-	29287
@NP	the Raphe	29287
@NP	B	29298
@NP	Rubrospinal -LRB- C -RRB-	29302
@NP	Hypothalamic -LRB- D -RRB-	29319
@NP	Reticular -LRB- E -RRB-	29337
@NP	Trigeminal/DC -LRB- F -RRB-	29352
@NP	Trigeminal/DC	29352
@NP	F	29367
@NP	Cortical layer V -LRB- G -RRB-	29371
@NP	Cortical layer V	29371
@NP	G	29389
@NP	Vestibular -LRB- H -RRB-	29396
@NP	Vestibular	29396
@NP	H	29408
@NP	Experimental groups	29412
@NP	a one-way analysis	29452
@NP	variance -LRB- ANOVA -RRB-	29474
@NP	variance	29474
@NP	ANOVA	29484
@NP	the Dunnett 's method	29504
@NP	the Dunnett 's	29504
@NP	multiple comparisons versus a single control group -LRB- injury only -RRB-	29528
@NP	multiple comparisons versus a single control group	29528
@NP	multiple comparisons	29528
@NP	a single control group	29556
@NP	injury only	29580
@NP	the Tukey test	29602
@NP	multiple comparison procedures between all experimental and control groups	29621
@NP	multiple comparison procedures	29621
@NP	all experimental and control groups	29660
@NP	Figure 8	29698
@NP	Propriospinal neurons rostral to the lesion site	29707
@NP	Propriospinal neurons rostral	29707
@NP	the lesion site	29740
@NP	Fluorogold	29787
@NP	caudal -LRB- 8 mm -RRB-	29807
@NP	caudal	29807
@NP	8 mm	29815
@NP	the lesion site -LRB- A -RRB-	29824
@NP	the lesion site	29824
@NP	A	29841
@NP	Significantly higher numbers of propriospinal neurons	29845
@NP	Significantly higher numbers	29845
@NP	propriospinal neurons	29877
@NP	n = 10 , p < 0.05	29900
@NP	n = 10 , p <	29900
@NP	n	29900
@NP	10 , p <	29902
@NP	10	29902
@NP	0.05	29908
@NP	the Schwann cell-transplanted group	29931
@NP	#	29968
@NP	OEG-transplanted groups	29975
@NP	the medium-injected group -LRB- B -RRB-	30015
@NP	the medium-injected group	30015
@NP	B	30042
@NP	Figure 9 Mean BBB scores	30047
@NP	4 months	30077
@NP	injection of medium	30092
@NP	injection	30092
@NP	medium	30105
@NP	Schwann cells and OEG	30113
@NP	Schwann cells	30113
@NP	OEG	30131
@NP	contusion injury	30151
@NP	The red dotted line	30174
@NP	the transplant day	30202
@NP	A statistically significant increase in BBB scores	30222
@NP	A statistically significant increase	30222
@NP	BBB scores	30262
@NP	the Schwann cell group when compared to contusion only -LRB- # , p < 0.05 -RRB-	30285
@NP	the Schwann cell group	30285
@NP	# , p < 0.05	30341
@NP	# , p <	30341
@NP	# , p	30341
@NP	<	30345
@NP	0.05	30346
@NP	A significant increase in BBB scores	30353
@NP	A significant increase	30353
@NP	BBB scores	30379
@NP	the OEG group	30407
@NP	injury only -LRB- * , p < 0.05 -RRB-	30446
@NP	injury only	30446
@NP	* , p < 0.05	30459
@NP	* , p <	30459
@NP	*	30459
@NP	0.05	30464
@NP	Figure 10 Ladder walking behavioral testing .	30472
@NP	Figure 10 Ladder	30472
@NP	behavioral testing	30497
@NP	A : representative photo of a rat traversing the horizontal ladder .	30517
@NP	: representative photo of a rat traversing the horizontal ladder .	30518
@NP	representative photo	30520
@NP	a rat traversing the horizontal ladder .	30544
@NP	a rat	30544
@NP	the horizontal ladder	30561
@NP	B	30584
@NP	ladder scores	30587
@NP	treatment groups	30604
@NP	horizontal ladder walking test 6 weeks after cell transplantation date	30624
@NP	horizontal ladder walking test	30624
@NP	6 weeks	30655
@NP	cell transplantation date	30669
@NP	C : as for B at 4 months after cell transplantation date .	30696
@NP	C	30696
@NP	as for B at 4 months after cell transplantation date	30699
@NP	B at 4 months	30706
@NP	B	30706
@NP	4 months	30711
@NP	cell transplantation	30726
@NP	no stage	30756
@NP	statistical differences between groups observed on the horizontal ladder test	30770
@NP	statistical differences	30770
@NP	groups observed on the horizontal ladder test	30802
@NP	groups	30802
@NP	the horizontal ladder test	30821
@NP	Cell transplantation	30850
@NP	improved retention of tissue at the lesion site	30890
@NP	improved retention	30890
@NP	tissue at the lesion site	30912
@NP	tissue	30912
@NP	the lesion site	30922
@NP	All experimental groups	30938
@NP	loss of tissue	30972
@NP	loss	30972
@NP	tissue	30980
@NP	the lesion site following the initial contusion injury -LRB- Figure 1 -RRB-	30990
@NP	the lesion site	30990
@NP	the initial contusion injury -LRB- Figure 1 -RRB-	31016
@NP	the initial contusion injury	31016
@NP	Figure 1	31046
@NP	Morphological analysis	31057
@NP	the total amount of residual tissue	31099
@NP	the total amount	31099
@NP	residual tissue	31119
@NP	this	31136
@NP	intact tissue	31150
@NP	the remaining graft and other degenerate/regenerate tissue	31176
@NP	the remaining graft	31176
@NP	other degenerate/regenerate tissue	31200
@NP	white or grey matter	31267
@NP	The total tissue remaining	31289
@NP	degenerate/regenerate tissue	31325
@NP	the cellular trabeculae between cysts , lesion site	31358
@NP	the cellular trabeculae	31358
@NP	cysts , lesion site	31390
@NP	cysts	31390
@NP	lesion site	31397
@NP	cells	31421
@NP	Tissue integrity classification	31428
@NP	Nissl gold myelin staining	31478
@NP	distinction between intact and non-intact tissue containing macrophages	31519
@NP	distinction	31519
@NP	intact and non-intact tissue containing macrophages	31539
@NP	intact and non-intact tissue	31539
@NP	macrophages	31579
@NP	The extent of the injury/transplant zone	31592
@NP	The extent	31592
@NP	the injury/transplant zone	31606
@NP	the use	31656
@NP	GFAP immunostaining	31667
@NP	the area of intact spinal cord versus the cyst areas	31701
@NP	the area	31701
@NP	intact spinal cord versus the cyst areas	31713
@NP	intact spinal cord	31713
@NP	the cyst areas	31739
@NP	the day of transplantation -LRB- i.e. 2 weeks post initial SCI -RRB-	31772
@NP	the day	31772
@NP	transplantation -LRB- i.e. 2 weeks post initial SCI -RRB-	31783
@NP	transplantation	31783
@NP	i.e. 2 weeks post	31800
@NP	i.e.	31800
@NP	2 weeks	31805
@NP	initial SCI	31818
@NP	the total spinal cord tissue remaining	31832
@NP	the total spinal cord tissue	31832
@NP	88.4 ±	31875
@NP	8.0 % of uninjured spinal cord and the amount of remaining intact tissue	31880
@NP	8.0 %	31880
@NP	uninjured spinal cord and the amount of remaining intact tissue	31888
@NP	uninjured spinal cord	31888
@NP	the amount of remaining intact tissue	31914
@NP	the amount	31914
@NP	remaining intact tissue	31928
@NP	55.4 ± 12.8 % -LRB- mean ± s.e.m -RRB-	31956
@NP	55.4 ± 12.8 %	31956
@NP	55.4 ±	31956
@NP	12.8 %	31961
@NP	mean ± s.e.m	31968
@NP	mean	31968
@NP	± s.e.m	31972
@NP	Two weeks following cell SCs transplantation	31981
@NP	Two weeks	31981
@NP	cell SCs transplantation	32001
@NP	OEG or SCs	32027
@NP	there	32040
@NP	no significant differences between groups in the amount of total tissue	32051
@NP	no significant differences	32051
@NP	groups in the amount of total tissue	32086
@NP	groups	32086
@NP	the amount of total tissue	32096
@NP	the amount	32096
@NP	total tissue	32110
@NP	p	32124
@NP	0.27	32126
@NP	72.4 ± 3.7 % > -LRB- n = 6 -RRB- of normal in the medium-injected group	32138
@NP	72.4 ±	32138
@NP	3.7 %	32143
@NP	n = 6	32151
@NP	n	32151
@NP	= 6	32152
@NP	normal in the medium-injected group	32159
@NP	normal	32159
@NP	the medium-injected group	32169
@NP	74.6 ± 9.2 % -LRB- n = 6 -RRB- in the OEG-transplanted group	32196
@NP	74.6	32196
@NP	± 9.2 % -LRB- n = 6 -RRB- in the OEG-transplanted group	32200
@NP	± 9.2 % -LRB- n = 6 -RRB-	32200
@NP	± 9.2 %	32200
@NP	n	32207
@NP	6	32209
@NP	the OEG-transplanted group	32215
@NP	85.1 ± 2.9 %	32246
@NP	85.1	32246
@NP	± 2.9 %	32250
@NP	n	32257
@NP	6	32259
@NP	the SCs-transplanted group	32265
@NP	there	32304
@NP	no significant differences	32315
@NP	p	32343
@NP	0.25	32345
@NP	groups	32359
@NP	intact tissue remaining	32370
@NP	29.5 ± 4.6 % -LRB- n = 6 -RRB- of normal in the medium-injected group	32405
@NP	29.5 ±	32405
@NP	n = 6	32416
@NP	n	32416
@NP	= 6	32417
@NP	normal in the medium-injected group	32424
@NP	normal	32424
@NP	the medium-injected group	32434
@NP	38.9 ± 7.7 % -LRB- n = 6 -RRB- in the OEG-transplanted group	32461
@NP	38.9 ±	32461
@NP	n = 6	32472
@NP	n	32472
@NP	= 6	32473
@NP	the OEG-transplanted group	32480
@NP	41.6 ± 2.3 % -LRB- n = 6 -RRB-	32511
@NP	41.6	32511
@NP	± 2.3 % -LRB- n = 6 -RRB-	32515
@NP	± 2.3 %	32515
@NP	n	32522
@NP	6	32524
@NP	the SCs-transplanted group	32530
@NP	It	32558
@NP	the 4 month time point	32575
@NP	tissue in the transplanted groups	32609
@NP	tissue	32609
@NP	the transplanted groups	32619
@NP	controls	32686
@NP	p = 0.028	32696
@NP	p	32696
@NP	= 0.028	32697
@NP	Total tissue	32706
@NP	46.5 ± 6.2 % -LRB- n = 11 -RRB-	32723
@NP	46.5 ± 6.2 %	32723
@NP	46.5 ±	32723
@NP	6.2 %	32728
@NP	n	32734
@NP	11	32736
@NP	uninjured spinal cord tissue in the medium-injected group	32743
@NP	uninjured spinal cord tissue	32743
@NP	the medium-injected group	32775
@NP	63.1 ± 3.7 % -LRB- n = 11 -RRB- in the OEGtransplanted group	32802
@NP	63.1 ± 3.7 % -LRB- n = 11 -RRB-	32802
@NP	63.1 ± 3.7 %	32802
@NP	63.1 ±	32802
@NP	3.7 %	32807
@NP	n	32813
@NP	11	32815
@NP	the OEGtransplanted group	32822
@NP	64.1 ± 5.7 %	32852
@NP	64.1 ±	32852
@NP	5.7 %	32857
@NP	n	32863
@NP	11	32865
@NP	the SCstransplanted group	32872
@NP	A significant difference -LRB- p = 0.028 -RRB-	32899
@NP	A significant difference	32899
@NP	p	32925
@NP	0.028	32927
@NP	groups	32956
@NP	4 months	32966
@NP	the amount	32978
@NP	intact tissue remaining	32992
@NP	26.0 ± 3.9 % -LRB- n = 11 -RRB- of normal in the medium-injected group	33027
@NP	26.0 ±	33027
@NP	n = 11	33038
@NP	n	33038
@NP	= 11	33039
@NP	normal in the medium-injected group	33047
@NP	normal	33047
@NP	the medium-injected group	33057
@NP	39.5 ± 4.1 % -LRB- n = 11 -RRB- in the OEG-transplanted group	33084
@NP	39.5 ±	33084
@NP	n = 11	33095
@NP	n	33095
@NP	= 11	33096
@NP	the OEG-transplanted group	33104
@NP	35.1 ± 6.4 %	33136
@NP	35.1 ±	33136
@NP	the SCs-transplanted group -LRB- Figure 1A , B -RRB-	33149
@NP	the SCs-transplanted group	33149
@NP	Figure 1A , B	33177
@NP	Figure 1A	33177
@NP	B	33188
@NP	Nissl staining/gold chloride staining	33192
@NP	Spinal cord sections	33230
@NP	Nissl staining	33267
@NP	good preservation of spinal tissue	33289
@NP	good preservation	33289
@NP	spinal tissue	33310
@NP	Cysts that were present	33325
@NP	Cysts	33325
@NP	Figure 1D , E and F	33376
@NP	Figure 1D	33376
@NP	E	33386
@NP	F	33392
@NP	number	33411
@NP	no difference in tissue survival	33439
@NP	no difference	33439
@NP	tissue survival	33456
@NP	any of the control or transplanted groups -LRB- OEG or SCs -RRB-	33485
@NP	any	33485
@NP	the control or transplanted groups -LRB- OEG or SCs -RRB-	33492
@NP	the control	33492
@NP	transplanted groups -LRB- OEG or SCs -RRB-	33507
@NP	transplanted groups	33507
@NP	OEG or SCs	33528
@NP	Nissl gold myelin staining at 4 months	33541
@NP	Nissl gold myelin staining	33541
@NP	4 months	33571
@NP	a reduction	33587
@NP	tissue loss , particularly the reduction	33602
@NP	tissue loss	33602
@NP	the reduction	33628
@NP	cyst volume and sparing of white and grey matter within the lesion zone	33645
@NP	cyst volume and sparing	33645
@NP	white and grey matter within the lesion zone	33672
@NP	white and grey matter	33672
@NP	the lesion zone	33701
@NP	Figure 1H , I and J	33722
@NP	Figure 1H	33722
@NP	I	33732
@NP	J	33738
@NP	The presence of round microcysts	33742
@NP	The presence	33742
@NP	round microcysts	33758
@NP	the spinal cords of SCs treated rats , and were present in 2	33793
@NP	the spinal cords	33793
@NP	SCs treated rats , and were present in 2	33813
@NP	SCs	33813
@NP	rats	33825
@NP	2	33851
@NP	week	33853
@NP	4 month spinal cords	33862
@NP	4 month	33862
@NP	spinal cords	33870
@NP	OEG transplanted rats or control -LRB- medium injected -RRB-	33892
@NP	OEG	33892
@NP	transplanted rats or control -LRB- medium injected -RRB-	33896
@NP	transplanted rats or control	33896
@NP	medium injected	33926
@NP	medium	33926
@NP	rats	33943
@NP	these cysts	33955
@NP	Transgene expression	33968
@NP	cell dispersal and survival	33990
@NP	transplanted Schwann cells	34021
@NP	OEG	34052
@NP	Approximately 92 % of OEG and 99 % of SCs	34056
@NP	Approximately 92 % of OEG	34056
@NP	Approximately 92 %	34056
@NP	OEG	34077
@NP	99 % of SCs	34085
@NP	99 %	34085
@NP	SCs	34092
@NP	a total of all Hoechst 33342 labeled cells	34122
@NP	a total	34122
@NP	all Hoechst 33342 labeled cells	34133
@NP	all Hoechst 33342	34133
@NP	cells	34159
@NP	Figure 2A and B	34167
@NP	OEG or SCs	34185
@NP	self	34232
@NP	lentiviral-DSRED-2 vectors	34250
@NP	This vector	34278
@NP	non-toxic -LRB- data not shown -RRB-	34306
@NP	non-toxic	34306
@NP	data not shown	34317
@NP	data	34317
@NP	visualization of cytoplasmic spread	34345
@NP	visualization	34345
@NP	cytoplasmic spread	34362
@NP	cellular morphology for up to 4 months post-transplantation into the CNS	34385
@NP	cellular morphology	34385
@NP	up to 4 months post-transplantation into the CNS	34409
@NP	up to 4 months	34409
@NP	the CNS	34450
@NP	DSRED-2 's stability and capacity to track cells	34459
@NP	DSRED-2 's stability and capacity	34459
@NP	DSRED-2 's	34459
@NP	track cells	34495
@NP	GFP -LSB- 12,26,36,42 -RSB-	34565
@NP	GFP	34565
@NP	12,26,36,42 -RSB-	34570
@NP	DSRED-2 labeled	34584
@NP	DSRED-2	34584
@NP	no additional immunological response	34607
@NP	the GFP transgene which may occur with LacZ	34669
@NP	the GFP transgene	34669
@NP	LacZ	34708
@NP	43 -RSB- or human placental alkaline phosphatase	34714
@NP	43 -RSB-	34714
@NP	human placental alkaline phosphatase	34721
@NP	44 -RSB-	34759
@NP	Figures 2C and D	34764
@NP	Figures 2C	34764
@NP	D	34779
@NP	representative spinal cord	34786
@NP	sagittal sections with OEG and SCs	34813
@NP	sagittal sections	34813
@NP	OEG and SCs	34836
@NP	2 weeks following cell transplantation	34855
@NP	2 weeks	34855
@NP	cell transplantation	34873
@NP	Lentiviral-DSRED-2 labeled OEG	34895
@NP	Lentiviral-DSRED-2	34895
@NP	OEG	34922
@NP	all but one of the animals	34942
@NP	all	34942
@NP	one of the animals	34950
@NP	one	34950
@NP	the animals	34957
@NP	lentiviral-DSRED-2 labeled SCs	34977
@NP	lentiviral-DSRED-2	34977
@NP	SCs	35004
@NP	all animals	35024
@NP	2 weeks after transplantation to the injured spinal cord	35040
@NP	2 weeks	35040
@NP	transplantation to the injured spinal cord	35054
@NP	transplantation	35054
@NP	the injured spinal cord	35073
@NP	DSRED-2 fluorescence pixel intensity for surviving transplanted OEG	35098
@NP	DSRED-2 fluorescence pixel intensity	35098
@NP	transplanted OEG	35149
@NP	70 ± 29	35170
@NP	the rostral aspects of the transplant/lesion zone	35179
@NP	the rostral aspects	35179
@NP	the transplant/lesion zone	35202
@NP	91 ±	35237
@NP	37	35240
@NP	SCs	35247
@NP	the center of the lesion 86 ±	35255
@NP	the center	35255
@NP	the lesion 86 ±	35269
@NP	35 for OEG	35283
@NP	35	35283
@NP	OEG	35290
@NP	100 ± 41 for SCs	35298
@NP	100 ± 41	35298
@NP	SCs	35309
@NP	the DSRED-2 fluorescence pixel intensity	35321
@NP	the caudal edge of the transplant/lesion	35365
@NP	the caudal edge	35365
@NP	the transplant/lesion	35384
@NP	83 ± 34	35410
@NP	OEG and 79 ± 32 for SCs	35420
@NP	OEG	35420
@NP	79 ± 32 for SCs	35428
@NP	79 ± 32	35428
@NP	SCs	35438
@NP	rats at 2 weeks -LRB- n = 6 per group -RRB- analyzed	35446
@NP	rats	35446
@NP	2 weeks -LRB- n = 6 per group -RRB- analyzed	35454
@NP	2 weeks -LRB- n = 6 per group -RRB-	35454
@NP	n = 6 per group	35463
@NP	n = 6	35463
@NP	n	35463
@NP	6	35465
@NP	group	35471
@NP	transplanted OEG	35499
@NP	some cases	35523
@NP	5 mm	35550
@NP	the center of the injection site , the furthest distance measured	35560
@NP	the center	35560
@NP	the injection site , the furthest distance measured	35574
@NP	the injection site	35574
@NP	the furthest distance measured	35594
@NP	the furthest distance	35594
@NP	contrast , DSRED-2	35629
@NP	contrast	35629
@NP	DSRED-2	35639
@NP	positive transplanted SCs	35647
@NP	the site of injection	35698
@NP	the site	35698
@NP	injection	35710
@NP	more than 0.6 mm	35735
@NP	the injection site	35757
@NP	2 weeks post transplantation	35780
@NP	2 weeks	35780
@NP	the surviving OEG	35809
@NP	the lesion site and adjacent spinal cord tissue	35853
@NP	the lesion site	35853
@NP	adjacent spinal cord tissue	35873
@NP	the rostrocaudal axis of the spinal cord	35925
@NP	the rostrocaudal axis	35925
@NP	the spinal cord	35950
@NP	SCs	35967
@NP	an alignment	35997
@NP	the graft area	36041
@NP	the intact host CNS tissue surrounding the lesion site	36082
@NP	the intact host CNS tissue	36082
@NP	the lesion site	36121
@NP	Four months	36138
@NP	OEG transplantation	36156
@NP	DSRED-2 positive OEG	36177
@NP	7	36215
@NP	11 animals -LRB- 64 % -RRB-	36224
@NP	11 animals	36224
@NP	64 %	36236
@NP	DSRED-2 positive SCs	36249
@NP	11	36287
@NP	11 animals -LRB- 100 % -RRB-	36297
@NP	11 animals	36297
@NP	100 %	36309
@NP	Measurements of DSRED	36316
@NP	Measurements	36316
@NP	DSRED	36332
@NP	2 fluorescence pixel intensity	36339
@NP	OEG	36377
@NP	the rostral part of the lesion	36384
@NP	the rostral part	36384
@NP	the lesion	36404
@NP	22 ± 9 and SCs 34 ± 14	36418
@NP	22 ± 9	36418
@NP	22 ±	36418
@NP	9	36421
@NP	SCs 34 ± 14	36427
@NP	SCs 34	36427
@NP	± 14	36433
@NP	the center of the lesion the values were 21 ± 9 for OEG and 29 ± 12 for SCs	36441
@NP	the center	36441
@NP	the lesion the values were 21 ± 9 for OEG and 29 ± 12 for SCs	36455
@NP	the lesion	36455
@NP	the values	36466
@NP	21 ± 9	36482
@NP	OEG and 29 ± 12 for SCs	36491
@NP	OEG	36491
@NP	29 ± 12 for SCs	36499
@NP	29 ± 12	36499
@NP	SCs	36509
@NP	DSRED-2 pixel fluorescence	36514
@NP	19 ± 8	36557
@NP	OEG at the caudal part of the lesion and 28 ± 12 for SCs	36566
@NP	OEG	36566
@NP	the caudal part of the lesion and 28 ± 12 for SCs	36573
@NP	the caudal part of the lesion	36573
@NP	the caudal part	36573
@NP	the lesion	36592
@NP	28 ± 12 for SCs	36607
@NP	28 ± 12	36607
@NP	SCs	36617
@NP	the DSRED-2 fluorescence	36640
@NP	the levels of OEG present within the spinal cord	36666
@NP	the levels	36666
@NP	OEG present within the spinal cord	36680
@NP	OEG	36680
@NP	the spinal cord	36699
@NP	the rostral-caudal axis of the lesion	36740
@NP	the rostral-caudal axis	36740
@NP	the lesion	36767
@NP	74 % at 4 months from the value seen at 2 weeks post transplantation	36781
@NP	74 %	36781
@NP	4 months from the value seen at 2 weeks post transplantation	36788
@NP	4 months	36788
@NP	the value seen at 2 weeks post transplantation	36802
@NP	the value	36802
@NP	2 weeks post transplantation	36820
@NP	2 weeks	36820
@NP	the same time DSRED-2 fluorescence pixel values	36853
@NP	SCs reduced from 2 weeks and 4 months	36905
@NP	SCs	36905
@NP	2 weeks and 4 months	36922
@NP	2 weeks	36922
@NP	4 months	36934
@NP	fluorescence levels	36952
@NP	OEG levels -LRB- p < 0.05 -RRB-	37003
@NP	OEG levels	37003
@NP	p < 0.05	37015
@NP	p	37015
@NP	< 0.05	37016
@NP	<	37016
@NP	0.05	37017
@NP	Additional file 1 : Table S1	37028
@NP	file 1	37039
@NP	Table S1	37047
@NP	Table	37047
@NP	S1	37053
@NP	Scar formation	37058
@NP	CS56 synthesis and gliosis Deposition	37074
@NP	proteoglycan	37115
@NP	transplanted OEG	37170
@NP	SCs	37188
@NP	control medium	37197
@NP	spinal cords	37221
@NP	immunofluorescence section staining with antibodies to GFAP and CS56	37237
@NP	immunofluorescence section staining	37237
@NP	antibodies to GFAP and CS56	37278
@NP	antibodies	37278
@NP	GFAP and CS56	37292
@NP	chondroitin sulphate proteoglycans	37311
@NP	The extent of staining	37348
@NP	The extent	37348
@NP	staining	37362
@NP	the lesion site in a rostro-caudal direction	37391
@NP	the lesion site	37391
@NP	a rostro-caudal direction	37410
@NP	2 weeks post transplantation	37443
@NP	2 weeks	37443
@NP	OEG spinal cords	37473
@NP	a moderate change	37497
@NP	GFAP staining	37518
@NP	SCs and medium treated spinal cords -LRB- n = 6 -LRB- Figure 3A , C -RRB-	37549
@NP	SCs and medium	37549
@NP	spinal cords -LRB- n = 6 -LRB- Figure 3A , C -RRB-	37572
@NP	spinal cords -LRB- n = 6	37572
@NP	spinal cords	37572
@NP	n = 6	37586
@NP	n	37586
@NP	6	37588
@NP	Figure 3A , C	37591
@NP	Figure 3A	37591
@NP	C	37601
@NP	this	37620
@NP	the caudal aspect of the transplant zone -LRB- Figure 3B , D -RRB-	37638
@NP	the caudal aspect	37638
@NP	the transplant zone -LRB- Figure 3B , D -RRB-	37659
@NP	the transplant zone	37659
@NP	Figure 3B , D	37680
@NP	Figure 3B	37680
@NP	D	37690
@NP	4 months following OEG , SCs and medium injections	37697
@NP	4 months	37697
@NP	OEG , SCs and medium injections	37716
@NP	OEG	37716
@NP	SCs	37721
@NP	medium injections	37729
@NP	GFAP immunofluorescence staining -LRB- analyzed by pixel intensity -RRB-	37748
@NP	GFAP immunofluorescence staining	37748
@NP	pixel intensity	37794
@NP	a trend	37820
@NP	a lower degree of GFAP immunofluorescence	37836
@NP	a lower degree	37836
@NP	GFAP immunofluorescence	37854
@NP	the injury zone	37881
@NP	The OEG	37898
@NP	transplanted group	37906
@NP	a reduction of 27 % in GFAP immunofluorescence	37932
@NP	a reduction	37932
@NP	27 % in GFAP immunofluorescence	37947
@NP	27 %	37947
@NP	GFAP immunofluorescence	37954
@NP	the SCs	37995
@NP	transplanted group and a 23 % reduction	38003
@NP	transplanted group	38003
@NP	a 23 % reduction	38026
@NP	GFAP immunofluorescence when	38045
@NP	GFAP immunofluorescence	38045
@NP	the medium-injected group	38086
@NP	this difference	38122
@NP	p < 0.05	38173
@NP	p	38173
@NP	< 0.05	38174
@NP	<	38174
@NP	0.05	38175
@NP	Integration of transplanted cells with host astrocytes	38182
@NP	Integration	38182
@NP	transplanted cells with host astrocytes	38197
@NP	transplanted cells	38197
@NP	host astrocytes	38221
@NP	the OEG transplant groups but infrequent for the SCs transplant animals	38254
@NP	OEG transplant groups	38258
@NP	OEG	38258
@NP	transplant groups	38262
@NP	the SCs	38299
@NP	CS56 proteoglycan staining	38327
@NP	the OEG , SCs and medium groups in the 4 month post transplant spinal cords	38374
@NP	the OEG , SCs and medium groups in the 4 month post transplant	38374
@NP	the OEG	38374
@NP	SCs	38383
@NP	medium groups in the 4 month post transplant	38391
@NP	medium groups	38391
@NP	the 4 month post transplant	38408
@NP	n	38450
@NP	11	38452
@NP	Immunofluorescence staining	38457
@NP	CS56	38489
@NP	the SCs	38497
@NP	transplanted group -LRB- Figure 3E -RRB-	38505
@NP	transplanted group	38505
@NP	Figure 3E	38525
@NP	medium	38567
@NP	control sections -LRB- p < 0.001 -RRB- -LRB- Figure 3F -RRB-	38583
@NP	control sections -LRB- p < 0.001 -RRB-	38583
@NP	control sections	38583
@NP	p < 0.001	38601
@NP	p	38601
@NP	< 0.001	38602
@NP	<	38602
@NP	0.001	38603
@NP	Figure 3F	38611
@NP	the CS56 immunofluorescence	38626
@NP	the SCs group	38669
@NP	the OEG transplanted group -LRB- p < 0.01 -RRB- -LRB- Figure 3F -RRB-	38695
@NP	the OEG transplanted group -LRB- p < 0.01 -RRB-	38695
@NP	the OEG transplanted group	38695
@NP	p < 0.01	38723
@NP	p	38723
@NP	< 0.01	38724
@NP	<	38724
@NP	0.01	38725
@NP	Figure 3F	38732
@NP	CS56 immunofluorescence in the OEG group	38744
@NP	CS56 immunofluorescence	38744
@NP	the OEG group	38771
@NP	the levels seen in the medium injected controls	38822
@NP	the levels	38822
@NP	the medium injected controls	38841
@NP	the medium	38841
@NP	controls	38861
@NP	Extracellular matrix deposition within the lesion site	38871
@NP	Extracellular matrix deposition	38871
@NP	the lesion site	38910
@NP	4 months post injury	38929
@NP	4 months	38929
@NP	the grey and white matter bordering the lesion site	38951
@NP	the grey and white matter	38951
@NP	the lesion site	38987
@NP	numerous blood vessels	39013
@NP	the walls	39037
@NP	laminin-1 staining -LRB- Figure 4A,B,D-K -RRB-	39076
@NP	laminin-1 staining	39076
@NP	Figure 4A,B,D-K	39096
@NP	The dura mater	39114
@NP	laminin-1	39161
@NP	all analyzed spinal cords	39174
@NP	all	39174
@NP	spinal cords	39187
@NP	addition to the meningeal and vascular-associated laminin-1	39204
@NP	addition	39204
@NP	the meningeal and vascular-associated laminin-1	39216
@NP	the meningeal	39216
@NP	vascular-associated laminin-1	39234
@NP	the graft sites of OEG and SCs grafts	39265
@NP	the graft sites	39265
@NP	OEG and SCs grafts	39284
@NP	laminin-1	39318
@NP	the medium injected control group	39341
@NP	the medium	39341
@NP	control group	39361
@NP	the laminin-1-stained area	39376
@NP	both the OEG and SCs	39430
@NP	the OEG	39435
@NP	SCs	39447
@NP	transplanted groups	39451
@NP	these differences	39476
@NP	p = 0.15	39530
@NP	p	39530
@NP	= 0.15	39531
@NP	higher magnification	39542
@NP	it	39564
@NP	areas strongly immunoreactive for laminin-1	39585
@NP	areas	39585
@NP	laminin-1	39619
@NP	the DSRED-2	39645
@NP	positive cells	39657
@NP	the SCs transplanted group -LRB- see Figure 4I , J , K vs.	39680
@NP	the SCs	39680
@NP	group	39701
@NP	Figure	39712
@NP	4I , J , K	39719
@NP	4I	39719
@NP	J , K	39722
@NP	vs.	39726
@NP	E , F , G -RRB- .	39730
@NP	E , F , G -RRB-	39730
@NP	E	39730
@NP	F , G -RRB-	39732
@NP	F	39732
@NP	the areas of strong laminin-1 immunoreactivity in OEG	39750
@NP	the areas	39750
@NP	strong laminin-1 immunoreactivity in OEG	39763
@NP	strong laminin-1 immunoreactivity	39763
@NP	OEG	39800
@NP	spinal cords	39812
@NP	the location of surviving DSRED-2 positive transplanted cells	39850
@NP	the location	39850
@NP	surviving DSRED-2 positive transplanted cells	39866
@NP	another source or cell type such as endothelial cells for the laminin-1	39924
@NP	another source or cell type	39924
@NP	endothelial cells for the laminin-1	39960
@NP	endothelial cells	39960
@NP	the laminin-1	39982
@NP	Laminin-1-positive structures around bundles of axons in both the OEG and SCs	39997
@NP	Laminin-1-positive structures	39997
@NP	bundles of axons in both the OEG and SCs	40034
@NP	bundles	40034
@NP	axons in both the OEG and SCs	40045
@NP	axons	40045
@NP	both the OEG and SCs	40054
@NP	the OEG	40059
@NP	SCs	40071
@NP	transplanted groups	40075
@NP	The profile of immunoreactivity for collagen IV -LRB- Figure 4C and L-S -RRB-	40110
@NP	The profile of immunoreactivity for collagen IV	40110
@NP	The profile	40110
@NP	immunoreactivity for collagen IV	40125
@NP	immunoreactivity	40125
@NP	collagen IV	40146
@NP	Figure 4C and L-S	40159
@NP	Figure 4C	40159
@NP	L-S	40173
@NP	that observed for laminin-1	40193
@NP	that	40193
@NP	laminin-1	40211
@NP	Structures resembling blood vessels	40222
@NP	Structures	40222
@NP	blood vessels	40244
@NP	the site	40278
@NP	the spinal cord lesion in the OEG transplanted group -LRB- Figure 4L -RRB-	40290
@NP	the spinal cord lesion	40290
@NP	the OEG transplanted group -LRB- Figure 4L -RRB-	40316
@NP	the OEG transplanted group	40316
@NP	Figure 4L	40344
@NP	the graft site of the OEG transplanted group	40362
@NP	the graft site	40362
@NP	the OEG transplanted group	40380
@NP	the OEG	40380
@NP	group	40401
@NP	more collagen IV immunofluorescence	40417
@NP	that of the other groups -LRB- Figure 4L and P vs.	40458
@NP	that	40458
@NP	the other groups -LRB- Figure 4L and P vs.	40466
@NP	other groups -LRB- Figure 4L and P	40470
@NP	other groups	40470
@NP	Figure 4L and P	40484
@NP	Figure 4L	40484
@NP	P	40498
@NP	C -RRB- , measurement using pixel intensity	40504
@NP	C -RRB- , measurement using pixel	40504
@NP	measurement using pixel	40508
@NP	measurement	40508
@NP	pixel	40526
@NP	intensity	40532
@NP	the collagen IV immunofluorescence	40551
@NP	each group to be statistically similar -LRB- p = 0.10 -RRB-	40590
@NP	0.10	40632
@NP	laminin-1	40647
@NP	higher magnification	40661
@NP	collagen IV	40683
@NP	high quantities in regions of the SCs grafts	40712
@NP	high quantities	40712
@NP	regions of the SCs grafts	40731
@NP	regions	40731
@NP	the SCs grafts	40742
@NP	the OEG transplanted group high amounts of collagen IV	40769
@NP	the OEG	40769
@NP	transplanted group high amounts	40777
@NP	collagen IV	40812
@NP	DSRED-2 negative cells in the vicinity of the DSRED-2	40851
@NP	DSRED-2 negative cells	40851
@NP	the vicinity of the DSRED-2	40877
@NP	the vicinity	40877
@NP	the DSRED-2	40893
@NP	positive cells	40905
@NP	Figure 4O , S	40921
@NP	Figure 4O	40921
@NP	S	40931
@NP	endogenous SCs invading from the periphery or host endothelial cells	40962
@NP	endogenous SCs	40962
@NP	the periphery or host endothelial cells	40991
@NP	the periphery	40991
@NP	host endothelial cells	41008
@NP	Axonal profiles	41032
@NP	lesion site Immunohistochemistry with the neurofilament-specific antibody RT-97	41055
@NP	lesion site Immunohistochemistry	41055
@NP	the neurofilament-specific antibody RT-97	41093
@NP	the presence	41156
@NP	medium and high neurofilament-containing axons	41172
@NP	the lesion site of all transplanted groups and controls	41233
@NP	the lesion site	41233
@NP	all transplanted groups and controls	41252
@NP	Figure 5	41290
@NP	the lesion epicenter of all groups	41304
@NP	the lesion epicenter	41304
@NP	all groups	41328
@NP	continuous white matter tracts of spared axons	41340
@NP	continuous white matter tracts	41340
@NP	spared axons	41374
@NP	the ventral edges of each section -LRB- Figure 5A , B , and D -RRB-	41404
@NP	the ventral edges	41404
@NP	each section -LRB- Figure 5A , B , and D -RRB-	41425
@NP	each section	41425
@NP	Figure 5A , B , and D	41439
@NP	Figure 5A	41439
@NP	B	41449
@NP	D	41456
@NP	Dorsal white matter tracts	41460
@NP	an improved state of preservation	41495
@NP	an improved state	41495
@NP	preservation	41516
@NP	OEG and SCs transplants	41535
@NP	addition	41563
@NP	RT97 + axons	41573
@NP	RT97	41573
@NP	axons	41579
@NP	the lesion site in all transplanted	41601
@NP	the lesion site	41601
@NP	all transplanted	41620
@NP	control groups with RT97 + axons being co-extensive with DSRED-2 OEG and SCs	41641
@NP	control groups	41641
@NP	RT97 + axons being co-extensive with DSRED-2 OEG and SCs	41661
@NP	RT97 + axons	41661
@NP	DSRED-2 OEG and SCs	41697
@NP	Figure 5E	41718
@NP	Axons entering SCs graft areas or putative graft areas	41730
@NP	Axons	41730
@NP	SCs graft areas or putative graft areas	41745
@NP	SCs graft areas	41745
@NP	putative graft areas	41764
@NP	rostral-caudal directionality	41817
@NP	the random internal organization of the graft -LRB- Figure 5E -RRB-	41872
@NP	the random internal organization	41872
@NP	the graft -LRB- Figure 5E -RRB-	41908
@NP	the graft	41908
@NP	Figure 5E	41919
@NP	this nonlinear pathway for axons	41939
@NP	this nonlinear pathway	41939
@NP	axons	41966
@NP	the OEG	41988
@NP	transplanted spinal cords -LRB- Figure 5C -RRB-	41996
@NP	transplanted spinal cords	41996
@NP	Figure 5C	42023
@NP	Evidence for infiltration of endogenous Schwann cells	42035
@NP	Evidence	42035
@NP	infiltration	42048
@NP	endogenous Schwann cells	42064
@NP	the spinal cord	42094
@NP	several	42113
@NP	the OEG or SCs transplanted animals , the lesion site	42124
@NP	the OEG or SCs	42124
@NP	transplanted animals , the lesion site	42139
@NP	transplanted animals	42139
@NP	the lesion site	42161
@NP	numerous fascicles of cells	42187
@NP	numerous fascicles	42187
@NP	cells	42209
@NP	glial-like spindle-shaped morphology	42220
@NP	these cells	42258
@NP	p75	42288
@NP	DSRED-2	42309
@NP	Sections from the medium-injected group	42318
@NP	Sections	42318
@NP	the medium-injected group	42332
@NP	p75-positive cells	42373
@NP	2 weeks	42400
@NP	4 months	42412
@NP	transplant day	42427
@NP	Figure 6A , B	42443
@NP	Figure 6A	42443
@NP	B	42453
@NP	The p75-positive cells	42457
@NP	the OEG -LRB- Figure 6C and D -RRB-	42483
@NP	the OEG	42483
@NP	Figure 6C and D	42492
@NP	Figure 6C	42492
@NP	D	42506
@NP	SCs -LRB- Figure 6E , F -RRB- transplant groups	42513
@NP	SCs	42513
@NP	Figure 6E , F	42518
@NP	Figure 6E	42518
@NP	F	42528
@NP	transplant groups	42531
@NP	donor cells that were not expressing the DSRED-2 transgene	42563
@NP	donor cells	42563
@NP	the DSRED-2 transgene	42600
@NP	It	42623
@NP	SCs	42648
@NP	the spinal cord from blood vessels	42670
@NP	the spinal cord	42670
@NP	blood vessels	42691
@NP	the spinal cord	42712
@NP	the dorsal roots -LSB- 45 -RSB-	42735
@NP	the dorsal roots	42735
@NP	45 -RSB-	42753
@NP	The latter	42758
@NP	the method using lentiviral vectors encoding transgene such as GFP	42793
@NP	the method	42793
@NP	lentiviral vectors	42810
@NP	transgene such as GFP	42838
@NP	transgene	42838
@NP	GFP	42856
@NP	long term expression -LSB- 12	42898
@NP	long term expression	42898
@NP	12	42920
@NP	these p75-positive cells	42928
@NP	the medium-injected groups	42975
@NP	Numbers	43003
@NP	retrogradely	43014
@NP	descending axons	43035
@NP	glial transplantation Retrograde labeling with Fluorogold	43065
@NP	glial transplantation Retrograde	43065
@NP	Fluorogold	43112
@NP	extension	43144
@NP	spared/regenerated descending supraspinal axons	43157
@NP	8 mm	43214
@NP	the most caudal edge of the contusion site	43226
@NP	the most caudal edge	43226
@NP	the contusion site	43250
@NP	Mean ± standard errors of numbers of descending Fluorogold-labeled cells	43270
@NP	Mean	43270
@NP	± standard errors	43274
@NP	numbers of descending Fluorogold-labeled cells	43294
@NP	numbers	43294
@NP	descending Fluorogold-labeled cells	43305
@NP	There	43356
@NP	statistically significant differences	43367
@NP	p < 0.05	43406
@NP	p	43406
@NP	< 0.05	43407
@NP	<	43407
@NP	0.05	43408
@NP	the total brain counts	43422
@NP	the OEG transplanted group -LRB- 3019 ± 216 -RRB-	43448
@NP	the OEG transplanted group	43448
@NP	3019 ± 216	43476
@NP	3019 ±	43476
@NP	216	43481
@NP	also the SCs transplanted group -LRB- 2767 ± 411 -RRB-	43490
@NP	also the SCs	43490
@NP	transplanted group -LRB- 2767 ± 411 -RRB-	43503
@NP	transplanted group	43503
@NP	2767 ± 411	43523
@NP	2767 ±	43523
@NP	411	43528
@NP	the control injury	43550
@NP	only group -LRB- 1204 ± 331 -RRB-	43569
@NP	only group	43569
@NP	1204 ± 331	43581
@NP	1204 ±	43581
@NP	331	43586
@NP	Statistical differences -LRB- p < 0.05 -RRB-	43592
@NP	Statistical differences	43592
@NP	p < 0.05	43617
@NP	p	43617
@NP	< 0.05	43618
@NP	<	43618
@NP	0.05	43619
@NP	a number of separate brain regions projecting distally through the injury zone	43638
@NP	a number	43638
@NP	separate brain regions projecting distally through the injury zone	43650
@NP	separate brain regions	43650
@NP	the injury zone	43701
@NP	OEG	43718
@NP	transplanted rats	43722
@NP	statistically significant differences	43747
@NP	the Raphe	43788
@NP	neurons -LRB- 562 ± 43 -RRB- compared to controls	43809
@NP	neurons -LRB- 562 ± 43 -RRB-	43809
@NP	neurons	43809
@NP	562 ± 43	43818
@NP	562 ±	43818
@NP	43	43822
@NP	controls	43838
@NP	184	43848
@NP	± 62	43851
@NP	Numbers of Fluorogold neurons	43857
@NP	Numbers	43857
@NP	Fluorogold neurons	43868
@NP	the Raphe for SCs	43890
@NP	the Raphe	43890
@NP	SCs	43904
@NP	transplanted rats -LRB- 296 ± 50 -RRB-	43908
@NP	transplanted rats	43908
@NP	296 ± 50	43927
@NP	296	43927
@NP	± 50	43930
@NP	significant differences	43948
@NP	injuries	43997
@NP	Rubrospinal Fluorogold numbers in the OEG and SCs grafted groups	44012
@NP	Rubrospinal Fluorogold numbers	44012
@NP	the OEG and SCs grafted groups	44046
@NP	the OEG and SCs	44046
@NP	groups	44070
@NP	243 ± 34 and 244 ± 50 respectively	44091
@NP	243 ± 34	44091
@NP	243 ±	44091
@NP	34	44095
@NP	244 ± 50 respectively	44102
@NP	244 ± 50	44102
@NP	the control injury only group -LRB- 115 ± 42 -RRB-	44174
@NP	the control injury	44174
@NP	only group -LRB- 115 ± 42 -RRB-	44193
@NP	only group	44193
@NP	115 ± 42	44205
@NP	115 ±	44205
@NP	42	44209
@NP	The numbers of Fluorogold labeled neurons in the hypothalamus	44214
@NP	The numbers	44214
@NP	Fluorogold labeled neurons in the hypothalamus	44229
@NP	Fluorogold	44229
@NP	neurons in the hypothalamus	44248
@NP	neurons	44248
@NP	the hypothalamus	44259
@NP	both the OEG and SCs groups -LRB- 135 ± 16 and 116 ± 23 respectively -RRB-	44305
@NP	the OEG	44310
@NP	SCs groups -LRB- 135 ± 16 and 116 ± 23 respectively -RRB-	44322
@NP	SCs groups	44322
@NP	135 ± 16 and 116 ± 23	44334
@NP	135 ± 16	44334
@NP	116 ± 23	44345
@NP	controls -LRB- 60 ± 15 -RRB-	44383
@NP	controls	44383
@NP	60 ± 15	44393
@NP	60	44393
@NP	± 15	44395
@NP	Fluorogold	44401
@NP	neurons	44420
@NP	the reticular formation in control injury	44431
@NP	the reticular formation	44431
@NP	control injury	44458
@NP	rats	44478
@NP	632 ±	44492
@NP	165	44496
@NP	1590 ± 100	44516
@NP	OEG	44529
@NP	rats and 1635 ± 23	44541
@NP	rats	44541
@NP	1635 ± 23	44550
@NP	1635 ±	44550
@NP	23	44555
@NP	SCs grafted animals -LRB- Table 1 and Figure 7 -RRB-	44562
@NP	SCs	44562
@NP	animals -LRB- Table 1 and Figure 7 -RRB-	44574
@NP	animals	44574
@NP	Table 1 and Figure 7	44583
@NP	Table 1	44583
@NP	Figure 7	44595
@NP	Fluorogold numbers in the trigeminal/DC	44606
@NP	Fluorogold numbers	44606
@NP	the trigeminal/DC	44628
@NP	all groups -LRB- Table 1 and Figure 7 -RRB-	44696
@NP	all groups	44696
@NP	Table 1 and Figure 7	44708
@NP	Table 1	44708
@NP	Figure 7	44720
@NP	This	44731
@NP	the case	44745
@NP	corticospinal layer V neurons	44758
@NP	axons	44794
@NP	the distal spinal cord -LRB- 8 mm -RRB-	44828
@NP	the distal spinal cord	44828
@NP	8 mm	44852
@NP	fluorogold injection site -LRB- Figure 7 -RRB-	44858
@NP	fluorogold injection site	44858
@NP	Figure 7	44885
@NP	neurons labeled in the vestibular system	44905
@NP	neurons	44905
@NP	the vestibular system	44924
@NP	significantly increased	44951
@NP	the OEG and SCs transplanted rats -LRB- 373 ± 65 and 360 ± 51 respectively -RRB-	44978
@NP	the OEG	44978
@NP	SCs transplanted rats -LRB- 373 ± 65 and 360 ± 51 respectively -RRB-	44990
@NP	SCs	44990
@NP	transplanted rats -LRB- 373 ± 65 and 360 ± 51 respectively -RRB-	44994
@NP	transplanted rats	44994
@NP	373 ± 65 and 360 ± 51	45013
@NP	373 ± 65	45013
@NP	360 ± 51	45024
@NP	injury	45070
@NP	rats -LRB- 117 ± 27 -RRB-	45082
@NP	rats	45082
@NP	117 ± 27	45088
@NP	117	45088
@NP	± 27	45091
@NP	Schwann and OEG cell grafts	45097
@NP	Schwann	45097
@NP	OEG cell grafts	45109
@NP	the number	45134
@NP	spared/regenerated propriospinal neurons Fluorogold	45148
@NP	propriospinal neurons	45200
@NP	spinal cord segments rostral to the lesion/transplantation site	45240
@NP	spinal cord segments	45240
@NP	the lesion/transplantation site	45272
@NP	Figure 8A	45322
@NP	Propriospinal neurons that had reached the caudal injected Fluorogold	45334
@NP	Propriospinal neurons	45334
@NP	the caudal injected Fluorogold	45373
@NP	the caudal	45373
@NP	Fluorogold	45393
@NP	8 mm caudal from the caudal borders of the injury site	45405
@NP	8 mm caudal	45405
@NP	the caudal borders of the injury site	45422
@NP	the caudal borders	45422
@NP	the injury site	45444
@NP	6 ± 3	45470
@NP	the medium	45477
@NP	group 38	45497
@NP	± 26 in the OEG transplanted group and 131 ± 59 in the SCs transplanted group	45505
@NP	± 26	45505
@NP	the OEG transplanted group and 131 ± 59 in the SCs transplanted group	45512
@NP	the OEG transplanted group	45512
@NP	131 ± 59 in the SCs transplanted group	45543
@NP	59	45547
@NP	the SCs	45553
@NP	Figure 8B	45585
@NP	Figure 8	45608
@NP	there	45617
@NP	a significant difference between the medium injected and OEG transplanted groups	45627
@NP	a significant difference between the medium injected	45627
@NP	a significant difference	45627
@NP	the medium injected	45660
@NP	the medium	45660
@NP	OEG transplanted groups	45684
@NP	a significantly larger number of labeled propriospinal neurons	45713
@NP	a significantly larger number	45713
@NP	labeled propriospinal neurons	45746
@NP	the SCs group	45792
@NP	the medium injected group -LRB- p < 0.03 -RRB-	45821
@NP	the medium	45821
@NP	group -LRB- p < 0.03 -RRB-	45841
@NP	group	45841
@NP	p < 0.03	45848
@NP	p	45848
@NP	< 0.03	45849
@NP	<	45849
@NP	0.03	45850
@NP	There	45857
@NP	no statistically significant difference	45867
@NP	the OEG and SCs transplanted groups	45915
@NP	the OEG	45915
@NP	SCs	45927
@NP	Functional recovery	45952
@NP	open field behavioral testing -LRB- BBB -RRB- and Ladder	45973
@NP	open field behavioral testing -LRB- BBB -RRB-	45973
@NP	open field behavioral testing	45973
@NP	BBB	46004
@NP	Ladder	46013
@NP	testing	46025
@NP	two weeks after injury and again at two weeks after transplantation	46036
@NP	two weeks	46036
@NP	injury	46052
@NP	two weeks after transplantation	46072
@NP	two weeks	46072
@NP	transplantation	46088
@NP	rats in all groups	46105
@NP	rats	46105
@NP	all groups	46113
@NP	bladder function	46137
@NP	field	46160
@NP	behavioral scoring	46166
@NP	no statistically significant changes in the BBB scores	46195
@NP	no statistically significant changes	46195
@NP	the BBB scores	46235
@NP	all groups	46253
@NP	transplantation -LRB- Figure 9 -RRB-	46271
@NP	transplantation	46271
@NP	Figure 9	46288
@NP	One week following transplantation of OEG or SCs	46299
@NP	One week	46299
@NP	transplantation of OEG or SCs	46318
@NP	transplantation	46318
@NP	OEG or SCs	46337
@NP	i.e. 21 days post injury	46349
@NP	i.e. 21 days post	46349
@NP	i.e.	46349
@NP	21 days	46354
@NP	injury	46367
@NP	these scores	46375
@NP	control scores , with all groups	46411
@NP	control scores	46411
@NP	all groups	46432
@NP	scoring 10 -- 11	46443
@NP	10 -- 11	46451
@NP	2 weeks after treatment with cells or medium	46461
@NP	2 weeks	46461
@NP	treatment with cells or medium	46475
@NP	treatment	46475
@NP	cells or medium	46490
@NP	control injury	46507
@NP	rats	46527
@NP	a mean of 11	46539
@NP	a mean	46539
@NP	11	46549
@NP	medium injected	46553
@NP	medium	46553
@NP	10	46576
@NP	OEG	46580
@NP	12	46591
@NP	SCs	46598
@NP	11 -LRB- Figure 9 -RRB-	46609
@NP	11	46609
@NP	Figure 9	46613
@NP	Three weeks following injection of cells , the mean BBB scores for OEG	46624
@NP	Three weeks	46624
@NP	injection of cells , the mean BBB scores for OEG	46646
@NP	injection	46646
@NP	cells , the mean BBB scores for OEG	46659
@NP	cells	46659
@NP	the mean BBB scores for OEG	46666
@NP	the mean BBB scores	46666
@NP	OEG	46690
@NP	rats	46703
@NP	13	46713
@NP	SCs	46717
@NP	12	46728
@NP	medium injected	46732
@NP	medium	46732
@NP	10	46755
@NP	injury	46762
@NP	11	46781
@NP	Theses scores	46785
@NP	all the following time points until day 133 and 144	46819
@NP	all the following time points	46819
@NP	day 133 and 144	46855
@NP	OEG	46876
@NP	a mean of 14	46887
@NP	a mean	46887
@NP	14	46897
@NP	SCs	46901
@NP	13	46912
@NP	medium injected	46916
@NP	medium	46916
@NP	11 and 10	46939
@NP	injury	46954
@NP	11 and 11	46973
@NP	Figure 9	47001
@NP	one	47018
@NP	week of testing on the BBB	47022
@NP	week	47022
@NP	testing on the BBB	47030
@NP	testing	47030
@NP	the BBB	47041
@NP	the rats	47055
@NP	the ladder walk -LRB- see Figure 10A -RRB-	47083
@NP	the ladder walk	47083
@NP	Figure 10A	47104
@NP	6 weeks or 4 months after treatment	47120
@NP	6 weeks	47120
@NP	4 months after treatment	47131
@NP	4 months	47131
@NP	treatment	47146
@NP	most rats	47157
@NP	between 3.5 and 5.5	47174
@NP	Table 2 -RRB- out of 6 on the horizontal ladder walking test -LRB- Figure 10B-C	47199
@NP	Table 2 -RRB- out of 6 on the horizontal ladder walking	47199
@NP	Table 2 -RRB- out of 6	47199
@NP	Table	47199
@NP	2 -RRB- out of 6	47205
@NP	out	47208
@NP	6	47215
@NP	the horizontal ladder walking	47220
@NP	the horizontal ladder	47220
@NP	test -LRB- Figure 10B-C	47250
@NP	test	47250
@NP	Figure 10B-C	47256
@NP	Figure	47256
@NP	10B-C	47263
@NP	no significant differences observed between groups	47276
@NP	no significant differences	47276
@NP	groups	47320
@NP	Discussion We have shown the capacity of purified	47329
@NP	Discussion	47329
@NP	We	47340
@NP	the capacity of purified	47354
@NP	the capacity	47354
@NP	primary OEG and SCs	47380
@NP	primary OEG	47380
@NP	SCs	47396
@NP	behavioral recovery , increase numbers of supraspinal axons	47411
@NP	behavioral recovery	47411
@NP	increase numbers of supraspinal axons	47432
@NP	increase numbers	47432
@NP	supraspinal axons	47452
@NP	increase tissue	47475
@NP	two weeks	47517
@NP	a moderate spinal cord contusion injury	47533
@NP	A lentiviral vector encoding DSRED-2	47574
@NP	OEG and SCs	47633
@NP	this study	47650
@NP	it	47661
@NP	both cell types	47723
@NP	4 months	47745
@NP	transplantation	47772
@NP	Viable transplanted OEG and SCs	47789
@NP	Viable transplanted OEG	47789
@NP	SCs	47817
@NP	similar numbers	47835
@NP	2 weeks	47854
@NP	4 months	47873
@NP	the OEG numbers	47882
@NP	the number of SCs remaining	47913
@NP	the number	47913
@NP	SCs remaining	47927
@NP	SCs	47927
@NP	Histochemical tissue analysis	47942
@NP	a significant reduction	47979
@NP	tissue loss in both the OEG and SCs groups	48006
@NP	tissue loss	48006
@NP	both the OEG and SCs groups	48021
@NP	the OEG	48026
@NP	SCs groups	48038
@NP	4 months	48049
@NP	dorsal white matter tracts	48089
@NP	the transplant groups	48151
@NP	non-cellular transplanted controls -LRB- medium -RRB-	48181
@NP	non-cellular transplanted controls	48181
@NP	medium	48217
@NP	Analysis of DSRED-2 labeled glia in the spinal cords	48226
@NP	Analysis	48226
@NP	DSRED-2 labeled glia in the spinal cords	48238
@NP	DSRED-2	48238
@NP	glia in the spinal cords	48254
@NP	glia	48254
@NP	the spinal cords	48262
@NP	a migration/dispersal difference between the two cell types	48286
@NP	a migration/dispersal difference	48286
@NP	the two cell types	48327
@NP	OEG	48347
@NP	a rostro-caudal direction	48383
@NP	greater integration of OEG with host astrocytes	48414
@NP	greater integration	48414
@NP	OEG with host astrocytes	48437
@NP	OEG	48437
@NP	host astrocytes	48446
@NP	the tight interwoven grafts in the SCs transplanted rats	48491
@NP	interwoven grafts in the SCs	48501
@NP	interwoven grafts	48501
@NP	the SCs	48522
@NP	OEG transplanted rats	48549
@NP	significantly lower levels of CS56 immunofluorescence	48581
@NP	significantly lower levels	48581
@NP	CS56 immunofluorescence	48611
@NP	the lesion/transplant site when	48653
@NP	the lesion/transplant site	48653
@NP	the SCs group	48697
@NP	Matrix deposition	48712
@NP	OEG and SCs groups	48750
@NP	laminin and collagen IV immunofluorescence	48774
@NP	laminin	48774
@NP	collagen IV immunofluorescence	48786
@NP	a closer co-existence of these matrix molecules	48824
@NP	a closer co-existence	48824
@NP	these matrix molecules	48849
@NP	SCs	48875
@NP	OEG	48887
@NP	Axonal staining using neurofilament antibodies	48892
@NP	Axonal staining	48892
@NP	neurofilament antibodies	48914
@NP	tighter bundles of axons within the SCs transplant zone	48946
@NP	tighter bundles	48946
@NP	axons within the SCs transplant zone	48965
@NP	axons	48965
@NP	the SCs transplant zone	48978
@NP	OEG zones	49010
@NP	field behavioral testing -LRB- BBB -RRB-	49026
@NP	field behavioral testing	49026
@NP	BBB	49052
@NP	significant differences	49064
@NP	the transplanted groups and the controls up to 4 months	49096
@NP	the transplanted groups	49096
@NP	the controls up to 4 months	49124
@NP	the controls	49124
@NP	up to 4 months	49137
@NP	transplantation	49158
@NP	BBB scores	49175
@NP	the OEG group	49214
@NP	injury	49248
@NP	medium and SCs	49256
@NP	rats	49280
@NP	Additional behavioral testing using the ladder walk however	49286
@NP	Additional behavioral testing	49286
@NP	the ladder walk	49322
@NP	any significant differences between experimental and control groups	49360
@NP	any significant differences	49360
@NP	experimental and control groups	49396
@NP	8 mm	49459
@NP	the injury/transplantation site	49474
@NP	significant differences between control groups and OEG and SCs	49515
@NP	significant differences between control groups	49515
@NP	significant differences	49515
@NP	control groups	49547
@NP	OEG and SCs	49566
@NP	OEG	49566
@NP	SCs	49574
@NP	transplanted groups in supraspinal projecting axon populations	49578
@NP	transplanted groups	49578
@NP	supraspinal projecting axon populations	49601
@NP	supraspinal	49601
@NP	axon populations	49624
@NP	This	49642
@NP	strong evidence	49656
@NP	a sub-acute transplant of SCs or OEG	49677
@NP	a sub-acute transplant	49677
@NP	SCs or OEG	49703
@NP	an environment	49722
@NP	promotion	49746
@NP	sparing/regeneration of supraspinal axonal projections to the spinal cord	49759
@NP	sparing/regeneration	49759
@NP	supraspinal axonal projections to the spinal cord	49783
@NP	supraspinal axonal projections	49783
@NP	the spinal cord	49817
@NP	SCs and OEG	49848
@NP	their interaction with host spinal cord cells and matrix production	49870
@NP	their interaction with host spinal cord cells	49870
@NP	their interaction	49870
@NP	host spinal cord cells	49893
@NP	matrix production	49920
@NP	Evidence of statistically significant tissue-protective effects of OEG	49939
@NP	Evidence	49939
@NP	statistically significant tissue-protective effects of OEG	49951
@NP	statistically significant tissue-protective effects	49951
@NP	OEG	50006
@NP	4 months	50023
@NP	transplantation	50038
@NP	2 weeks	50058
@NP	tissue loss	50088
@NP	The tissue-protective effects of transplanted OEG or SCs	50121
@NP	The tissue-protective effects	50121
@NP	transplanted OEG or SCs	50154
@NP	the secretion	50189
@NP	factors	50206
@NP	BDNF , NGF , GDNF and NT4/5 -LSB- 13,46-48 -RSB- or matrix	50237
@NP	BDNF , NGF , GDNF and NT4/5	50237
@NP	13,46-48 -RSB-	50264
@NP	matrix	50277
@NP	laminin-1	50285
@NP	collagen IV	50296
@NP	N-Cadherin	50332
@NP	49-51 -RSB-	50355
@NP	These mechanisms	50363
@NP	protection combined with tissue-rebuilding or new cell birth -LSB- 52 -RSB- ,	50383
@NP	protection combined with tissue-rebuilding or new cell birth	50383
@NP	protection	50383
@NP	tissue-rebuilding or new cell birth	50408
@NP	tissue-rebuilding	50408
@NP	new cell birth	50429
@NP	anatomical functional outcomes	50493
@NP	Proliferation of donor OEG	50525
@NP	Proliferation	50525
@NP	donor OEG	50542
@NP	the labeling method employed in this study	50571
@NP	the labeling method	50571
@NP	this study	50603
@NP	all daughter cells	50630
@NP	the number of labeled cells at 4 months in the lesion site	50669
@NP	the number	50669
@NP	labeled cells at 4 months in the lesion site	50683
@NP	labeled cells	50683
@NP	4 months in the lesion site	50700
@NP	4 months	50700
@NP	the lesion site	50712
@NP	2 weeks	50760
@NP	The fewer numbers of detectable OEG	50769
@NP	The fewer numbers	50769
@NP	detectable OEG	50790
@NP	movement	50814
@NP	the site	50833
@NP	injury -LRB- measurement area -RRB-	50845
@NP	injury	50845
@NP	measurement area	50853
@NP	death -LRB- via apoptotic or anoikis mechanisms -RRB- -LSB- 42,44	50875
@NP	death -LRB- via apoptotic or anoikis mechanisms -RRB-	50875
@NP	death	50875
@NP	apoptotic or anoikis mechanisms	50886
@NP	42,44	50920
@NP	a small number of animals	50931
@NP	a small number	50931
@NP	animals	50949
@NP	OEG	50958
@NP	several millimeters	50976
@NP	the injection site	51001
@NP	earlier studies	51040
@NP	OEG migration	51071
@NP	distances of 9 mm	51088
@NP	distances	51088
@NP	9 mm	51101
@NP	the injection site -LSB- 9,53,54 -RSB-	51111
@NP	the injection site	51111
@NP	9,53,54 -RSB-	51131
@NP	contrast to the OEG	51144
@NP	contrast	51144
@NP	the OEG	51156
@NP	SCs	51165
@NP	the immediate lesion area	51201
@NP	a distance of 1.5 mm	51250
@NP	a distance	51250
@NP	1.5 mm	51264
@NP	A similar lack of dispersal	51272
@NP	A similar lack	51272
@NP	dispersal	51290
@NP	peripheral nerve grafts inserted into the adult CNS -LSB- 55,56 -RSB-	51325
@NP	peripheral nerve grafts	51325
@NP	the adult CNS -LSB- 55,56 -RSB-	51363
@NP	the adult CNS	51363
@NP	55,56 -RSB-	51378
@NP	This	51386
@NP	interactions with host astrocytes	51408
@NP	interactions	51408
@NP	host astrocytes	51426
@NP	other endogenous non-neuronal cells -LSB- 57 -RSB-	51446
@NP	other endogenous non-neuronal cells	51446
@NP	57 -RSB-	51483
@NP	The observed difference	51488
@NP	the amount of intact tissue between the OEG and SCs transplanted groups	51515
@NP	the amount	51515
@NP	intact tissue between the OEG and SCs transplanted groups	51529
@NP	tissue between the OEG and SCs	51536
@NP	tissue	51536
@NP	the OEG and SCs	51551
@NP	the OEG	51551
@NP	SCs	51563
@NP	chemotropic effects	51597
@NP	the OEG -LSB- 58 -RSB- ,	51620
@NP	the OEG	51620
@NP	58 -RSB-	51629
@NP	the chemotropic effects	51645
@NP	glia	51680
@NP	development -LSB- 59	51692
@NP	development	51692
@NP	59	51705
@NP	increased infiltration of various cells into the lesion site	51724
@NP	increased infiltration	51724
@NP	various cells into the lesion site	51750
@NP	various cells	51750
@NP	the lesion site	51769
@NP	OEG	51786
@NP	a different inflammatory response	51821
@NP	the secretion	51858
@NP	chemokines	51875
@NP	CX3CL1	51894
@NP	60 -RSB-	51902
@NP	a known ligand	51916
@NP	the receptor CX3CR1 found on microglia and dendritic cells -LSB- 60,61 -RSB-	51935
@NP	the receptor CX3CR1	51935
@NP	microglia and dendritic cells	51964
@NP	microglia	51964
@NP	dendritic cells	51978
@NP	60,61 -RSB-	51995
@NP	the amount of tissue preservation/removal	52014
@NP	the amount	52014
@NP	tissue preservation/removal	52028
@NP	OEG	52057
@NP	death and subsequent phagocytosis	52100
@NP	death	52100
@NP	subsequent phagocytosis	52110
@NP	macrophages than SCs	52137
@NP	macrophages	52137
@NP	SCs	52154
@NP	OEG	52159
@NP	different factors	52184
@NP	unique antigenic profiles	52211
@NP	the ones	52248
@NP	them	52284
@NP	immune attack -LSB- 62 -RSB-	52309
@NP	immune attack	52309
@NP	62 -RSB-	52324
@NP	OEG and SCs transplants	52329
@NP	the properties	52358
@NP	proliferation or differentiation	52395
@NP	spinal cord progenitor cells/stem cells -LSB- 52,63 -RSB-	52431
@NP	spinal cord progenitor cells/stem cells	52431
@NP	52,63 -RSB-	52472
@NP	Glial transplants	52480
@NP	these stem cells , like fibroblasts -LSB- 64 -RSB- ,	52534
@NP	these stem cells	52534
@NP	fibroblasts -LSB- 64 -RSB-	52557
@NP	fibroblasts	52557
@NP	64 -RSB-	52570
@NP	neurons or myelinating glia	52580
@NP	neurons	52580
@NP	myelinating glia	52591
@NP	64-67 -RSB-	52609
@NP	our study	52620
@NP	we	52630
@NP	the direct OEG or SCs myelination potential or host myelination	52649
@NP	the direct OEG	52649
@NP	SCs myelination potential or host myelination	52667
@NP	SCs	52667
@NP	myelination potential or host myelination	52671
@NP	the lesion site	52720
@NP	Both cell types	52737
@NP	the capacity	52758
@NP	their effectiveness and mechanisms involved -LSB- 75 , Plant et al. ,	52798
@NP	their effectiveness and mechanisms	52798
@NP	75 , Plant et al. ,	52843
@NP	75	52843
@NP	Plant et al.	52847
@NP	Plant	52847
@NP	et al.	52853
@NP	unpublished observations	52862
@NP	The proliferation of endogenous cells	52889
@NP	The proliferation	52889
@NP	endogenous cells	52910
@NP	SCI -LSB- 45 -RSB-	52941
@NP	SCI -LSB-	52941
@NP	These cells	52951
@NP	progenitor cells	52975
@NP	endothelial	52993
@NP	pericytes stimulated by factors such as epidermal growth factor	53009
@NP	pericytes	53009
@NP	factors such as epidermal growth factor	53033
@NP	factors	53033
@NP	epidermal growth factor	53049
@NP	fibroblast growth factor-2	53080
@NP	68-70 -RSB-	53108
@NP	Proliferation	53116
@NP	OEG and SCs	53169
@NP	similar levels of FGF-2	53202
@NP	similar levels	53202
@NP	FGF-2	53220
@NP	71 -RSB-	53227
@NP	Two recent findings	53232
@NP	new cells	53267
@NP	a role in SCI	53282
@NP	a role	53282
@NP	SCI	53292
@NP	New evidence from Goritz and colleagues -LSB- 72 -RSB-	53297
@NP	New evidence from Goritz	53297
@NP	New evidence	53297
@NP	Goritz	53315
@NP	colleagues -LSB- 72 -RSB-	53326
@NP	colleagues	53326
@NP	72 -RSB-	53338
@NP	pericytes	53361
@NP	a role	53376
@NP	the spinal cord injury response	53386
@NP	these cells	53427
@NP	sites of injury	53459
@NP	sites	53459
@NP	injury	53468
@NP	OEG and SCs in our model	53476
@NP	OEG and SCs	53476
@NP	our model	53491
@NP	the number of these cells in the lesion site	53528
@NP	the number	53528
@NP	these cells in the lesion site	53542
@NP	these cells	53542
@NP	the lesion site	53557
@NP	a reparative outcome	53589
@NP	addition	53614
@NP	evidence by Decimo and colleagues -LSB- 73 -RSB-	53624
@NP	evidence by Decimo	53624
@NP	evidence	53624
@NP	Decimo	53636
@NP	colleagues -LSB- 73 -RSB-	53647
@NP	colleagues	53647
@NP	73 -RSB-	53659
@NP	new adult stem cell	53669
@NP	precursor cells	53690
@NP	the meninges	53727
@NP	SCI	53749
@NP	the injury site	53766
@NP	a target	53798
@NP	glial cell differentiation or activation	53811
@NP	glial cell differentiation	53811
@NP	activation	53841
@NP	this study	53856
@NP	we	53867
@NP	evidence	53878
@NP	following spinal cord contusion injury	53892
@NP	endogenous repair processes	53932
@NP	SCs migration	53970
@NP	Proliferation	53998
@NP	ependymal cells	54015
@NP	the walls of the central canal	54034
@NP	the walls	54034
@NP	the central canal	54047
@NP	adjacent intact parts of spinal cord -LSB- 45,52,65,74,75 -RSB-	54074
@NP	adjacent intact parts	54074
@NP	spinal cord -LSB- 45,52,65,74,75 -RSB-	54099
@NP	spinal cord	54099
@NP	45,52,65,74,75 -RSB-	54112
@NP	one route	54131
@NP	Ependymal cells	54142
@NP	the lesion site	54192
@NP	new blood vessels , astrocytes and fibroblasts	54219
@NP	This	54266
@NP	the cellular trabeculae and scar tissue	54307
@NP	our lesion cysts	54359
@NP	45,75,76 -RSB-	54377
@NP	Host SCs from the dorsal roots or blood vessels	54388
@NP	Host SCs	54388
@NP	the dorsal roots or blood vessels	54402
@NP	the lesion site	54453
@NP	our model	54472
@NP	large numbers of p75-positive	54492
@NP	large numbers	54492
@NP	p75-positive	54509
@NP	DSRED-2 negative cells	54523
@NP	all groups , as has previously been observed in the rat -LSB- 14,45,55,77,78	54549
@NP	all groups	54549
@NP	the rat -LSB- 14,45,55,77,78	54596
@NP	the rat	54596
@NP	14,45,55,77,78	54605
@NP	human -LSB- 79 -RSB- with the majority from the dorsal roots -LSB- 32 -RSB-	54625
@NP	human -LSB- 79 -RSB-	54625
@NP	the majority	54641
@NP	the dorsal roots	54659
@NP	32 -RSB-	54677
@NP	a previous study from our laboratory -LSB- 57 -RSB-	54685
@NP	a previous study	54685
@NP	our laboratory -LSB- 57 -RSB-	54707
@NP	our laboratory	54707
@NP	57 -RSB-	54723
@NP	we	54728
@NP	molecules -LRB- including neurotrophins -RRB-	54746
@NP	molecules	54746
@NP	neurotrophins	54767
@NP	Schwann cells promote the reactivity of astrocytes	54794
@NP	Schwann cells	54794
@NP	the reactivity of astrocytes	54816
@NP	the reactivity	54816
@NP	astrocytes	54834
@NP	SCs	54859
@NP	astrocytes	54873
@NP	CS56 staining	54929
@NP	This	54944
@NP	a dense glial scar	54955
@NP	the lesion	54981
@NP	the entry of axons	55005
@NP	the entry	55005
@NP	axons	55018
@NP	other host non-neuronal cells -LSB- 57 -RSB-	55032
@NP	other host non-neuronal cells	55032
@NP	57 -RSB-	55063
@NP	this study	55071
@NP	we	55082
@NP	sub-acute 14 day glial transplants	55100
@NP	OEG	55136
@NP	significantly lower CS56 expression and slightly higher collagen	55161
@NP	significantly lower CS56 expression	55161
@NP	slightly higher collagen	55201
@NP	IV expression in the lesion and graft site compared to SCs	55226
@NP	IV expression	55226
@NP	the lesion and graft site compared to SCs	55243
@NP	the lesion and graft site	55243
@NP	SCs	55281
@NP	OEG	55292
@NP	astrocytes	55331
@NP	-LSB- 49,80 -RSB-	55351
@NP	their release of extracellular matrix and cell adhesion molecules	55360
@NP	their release	55360
@NP	extracellular matrix and cell adhesion molecules	55377
@NP	their modulation of these factors	55430
@NP	their modulation	55430
@NP	these factors	55450
@NP	the observed axonal infiltration into the glial scar -LSB- 81 -RSB-	55485
@NP	the observed axonal infiltration	55485
@NP	the glial scar -LSB- 81 -RSB-	55523
@NP	the glial scar	55523
@NP	81 -RSB-	55539
@NP	Molecules such as Fibulin-3 and its ability to bind TIMP-3	55544
@NP	Molecules	55544
@NP	Fibulin-3 and its ability to bind TIMP-3	55562
@NP	Fibulin-3	55562
@NP	its ability to bind TIMP-3	55576
@NP	TIMP-3	55596
@NP	a part in the different interaction	55617
@NP	a part	55617
@NP	the different interaction	55627
@NP	host glia -LSB- 26 -RSB-	55658
@NP	host glia	55658
@NP	26 -RSB-	55669
@NP	OEG isolated from the olfactory bulb	55674
@NP	OEG	55674
@NP	the olfactory bulb	55692
@NP	high levels of this protein when	55716
@NP	high levels	55716
@NP	this protein when	55731
@NP	this protein	55731
@NP	SCs -LSB- 26 -RSB-	55761
@NP	SCs	55761
@NP	26 -RSB-	55766
@NP	One recent report	55771
@NP	an important role of MMP 's	55808
@NP	an important role	55808
@NP	MMP 's	55829
@NP	cell migration and modulation of the ECM -LSB- 82 -RSB-	55838
@NP	cell migration and modulation	55838
@NP	the ECM -LSB- 82 -RSB-	55871
@NP	both OEG and SCs	55891
@NP	both OEG	55891
@NP	SCs	55904
@NP	a greater quantity of extracellular matrix molecules in the lesion site	55939
@NP	a greater quantity	55939
@NP	extracellular matrix molecules in the lesion site	55961
@NP	extracellular matrix molecules	55961
@NP	the lesion site	55995
@NP	the effect of medium injection	56023
@NP	the effect	56023
@NP	medium injection	56037
@NP	their profiles	56061
@NP	The laminin	56086
@NP	a complementary and nonoverlapping pattern to DSRED-2 labeled SCs and OEG	56113
@NP	a complementary and nonoverlapping pattern	56113
@NP	DSRED-2 labeled SCs and OEG	56159
@NP	DSRED-2	56159
@NP	SCs and OEG	56175
@NP	SCs	56188
@NP	basement membrane	56212
@NP	OEG	56237
@NP	these molecules	56266
@NP	the quantity seen in SCs grafted animals	56293
@NP	the quantity	56293
@NP	SCs grafted animals	56314
@NP	SCs	56314
@NP	animals	56326
@NP	they	56343
@NP	other cells	56365
@NP	extracellular matrix such as astrocytes or endothelial cells	56388
@NP	extracellular matrix	56388
@NP	astrocytes or endothelial cells	56417
@NP	astrocytes	56417
@NP	endothelial cells	56431
@NP	This	56450
@NP	the role	56479
@NP	the OEG play	56488
@NP	the olfactory system	56504
@NP	OEG form channels	56532
@NP	axonal degeneration in the olfactory bulb for axons	56580
@NP	axonal degeneration	56580
@NP	the olfactory bulb for axons	56603
@NP	the olfactory bulb	56603
@NP	axons	56626
@NP	areas of the olfactory bulb	56669
@NP	areas	56669
@NP	the olfactory bulb	56678
@NP	83,84 -RSB-	56698
@NP	One mechanism for OEG reparative outcomes in the CNS	56706
@NP	One mechanism	56706
@NP	OEG reparative outcomes in the CNS	56724
@NP	OEG reparative outcomes	56724
@NP	the CNS	56751
@NP	their close	56762
@NP	fibroblasts/meningeal cells	56794
@NP	48,81 -RSB- and ability	56827
@NP	48,81 -RSB-	56827
@NP	ability	56838
@NP	these cells -LSB- 9,85 -RSB-	56863
@NP	these cells	56863
@NP	9,85 -RSB-	56876
@NP	OEGs	56883
@NP	a very close relationship with fibroblasts in the olfactory system	56893
@NP	a very close relationship	56893
@NP	fibroblasts in the olfactory system	56924
@NP	fibroblasts	56924
@NP	the olfactory system	56939
@NP	SCs in the peripheral nerve	56967
@NP	SCs	56967
@NP	the peripheral nerve	56974
@NP	their role	57000
@NP	SCs	57033
@NP	myelinate axons	57056
@NP	fibroblasts and their associated matrix -LSB- 86 -RSB-	57075
@NP	fibroblasts	57075
@NP	their associated matrix -LSB- 86 -RSB-	57091
@NP	their associated matrix	57091
@NP	86 -RSB-	57116
@NP	OEG	57129
@NP	an axonal replacement/regenerating system	57145
@NP	myelination -LSB- 87 -RSB-	57195
@NP	myelination	57195
@NP	87 -RSB-	57208
@NP	addition	57216
@NP	they	57225
@NP	a role in fascicle-forming arrangements	57262
@NP	a role	57262
@NP	fascicle-forming arrangements	57272
@NP	fibroblasts -LSB- 88-90 -RSB-	57310
@NP	fibroblasts	57310
@NP	88-90 -RSB-	57323
@NP	Olfactory glia and Schwann cells	57331
@NP	regeneration	57389
@NP	sub	57405
@NP	treated SCI	57415
@NP	Our results	57427
@NP	transplantation of OEG or SCs	57449
@NP	transplantation	57449
@NP	OEG or SCs	57468
@NP	2 weeks	57482
@NP	contusion	57496
@NP	significant axonal sparing	57518
@NP	regeneration	57546
@NP	those	57573
@NP	transplants carried out 7 days after a contusion injury -LSB- 33 -RSB-	57587
@NP	transplants	57587
@NP	7 days	57611
@NP	a contusion injury -LSB- 33 -RSB-	57624
@NP	a contusion injury	57624
@NP	33 -RSB-	57644
@NP	Significant increases in regenerated propriospinal fibers	57649
@NP	Significant increases	57649
@NP	regenerated propriospinal fibers	57674
@NP	graft groups	57733
@NP	numbers in SCs treated animals	57751
@NP	numbers	57751
@NP	SCs treated animals	57762
@NP	SCs	57762
@NP	animals	57774
@NP	OEG transplantation	57819
@NP	This	57840
@NP	a more potent , local secretion of factors	57855
@NP	a more potent , local secretion	57855
@NP	factors	57889
@NP	SCs compared to OEG	57900
@NP	SCs	57900
@NP	OEG	57916
@NP	no study	57932
@NP	these differences	57966
@NP	this study	57988
@NP	an OEG or SCs transplantation following a contusion injury	58000
@NP	an OEG or SCs transplantation	58000
@NP	a contusion injury	58040
@NP	an increased amount of intact tissue at the lesion site	58079
@NP	an increased amount	58079
@NP	intact tissue at the lesion site	58102
@NP	intact tissue	58102
@NP	the lesion site	58119
@NP	Immunohistochemistry for neurofilament-positive axons	58136
@NP	Immunohistochemistry	58136
@NP	neurofilament-positive axons	58161
@NP	strongly immunoreactive profiles	58197
@NP	the lesion site	58233
@NP	both OEG and SCs	58253
@NP	both OEG	58253
@NP	SCs	58266
@NP	transplanted groups after a 14 day delay of transplantation	58270
@NP	transplanted groups	58270
@NP	a 14 day delay of transplantation	58296
@NP	a 14 day delay	58296
@NP	transplantation	58314
@NP	Neurofilament positive axons in the SCs group	58331
@NP	Neurofilament positive axons	58331
@NP	the SCs group	58363
@NP	those seen in the OEG group	58411
@NP	those	58411
@NP	the OEG group	58425
@NP	This	58440
@NP	the interaction with host astrocytes	58467
@NP	the interaction	58467
@NP	host astrocytes	58488
@NP	the even distribution of the cells	58521
@NP	the even distribution	58521
@NP	the cells	58546
@NP	the formation of a clear cellular boundary -LSB- 91 -RSB-	58560
@NP	the formation	58560
@NP	a clear cellular boundary -LSB- 91 -RSB-	58577
@NP	a clear cellular boundary	58577
@NP	91 -RSB-	58604
@NP	Retrograde tracing using Fluorogold	58609
@NP	Retrograde	58609
@NP	Fluorogold	58634
@NP	statistically significant increased numbers for supraspinal tracts	58654
@NP	statistically significant increased numbers	58654
@NP	supraspinal tracts	58702
@NP	OEG or SCs transplantation	58727
@NP	OEG	58727
@NP	SCs transplantation	58734
@NP	Supraspinal spinal tracts such as reticular , vestibular and hypothalamic	58755
@NP	Supraspinal spinal tracts	58755
@NP	reticular , vestibular and hypothalamic	58789
@NP	reticular	58789
@NP	transplant groups	58867
@NP	It	58886
@NP	these supraspinal fibers	58910
@NP	8 mm	58954
@NP	the injury site	58969
@NP	so possible differences	58990
@NP	fiber numbers between the transplanted cell groups at the lesion site	59017
@NP	fiber numbers	59017
@NP	the transplanted cell groups at the lesion site	59039
@NP	the transplanted cell groups	59039
@NP	the lesion site	59071
@NP	itself	59087
@NP	the other spinal tracts	59123
@NP	the raphe tract	59148
@NP	a far more robust fashion in the OEG group	59177
@NP	a far more robust fashion	59177
@NP	the OEG group	59206
@NP	This	59221
@NP	increased responsiveness	59237
@NP	BDNF from the OEG directly	59265
@NP	BDNF	59265
@NP	the OEG directly	59275
@NP	the OEG	59275
@NP	the interaction	59298
@NP	activated microglia	59319
@NP	BDNF	59366
@NP	ATP activation	59377
@NP	the P2X4 receptor -LSB- 92 -RSB-	59400
@NP	the P2X4 receptor	59400
@NP	92 -RSB-	59419
@NP	OEG	59424
@NP	SCs in their levels of fractalkine secretion	59438
@NP	SCs	59438
@NP	their levels of fractalkine secretion	59445
@NP	their levels	59445
@NP	fractalkine secretion	59461
@NP	this	59488
@NP	microglia	59506
@NP	different neurotrophic profiles	59550
@NP	that initiated by SCs that do not secrete this protein at the same level	59585
@NP	that	59585
@NP	SCs that do not secrete this protein at the same level	59603
@NP	SCs	59603
@NP	this protein	59627
@NP	the same level	59643
@NP	An important consideration	59659
@NP	the time of cell delivery	59718
@NP	the time	59718
@NP	cell delivery	59730
@NP	the stage	59748
@NP	cellular differentiation of transplanted glia after a period of time in vivo	59761
@NP	cellular differentiation	59761
@NP	transplanted glia after a period of time in vivo	59789
@NP	transplanted glia	59789
@NP	a period of time in vivo	59813
@NP	a period	59813
@NP	time in vivo	59825
@NP	time	59825
@NP	vivo	59833
@NP	SCs	59839
@NP	myelin	59867
@NP	cells	59882
@NP	their regenerative/autocrine secretory products	59916
@NP	93-95	59965
@NP	OEG stay	59980
@NP	an undifferentiated -LSB- p75-positive -RRB- non-myelin	59992
@NP	state for a longer periods -LRB- Plant -- unpublished observations -RRB-	60046
@NP	state	60046
@NP	a longer periods -LRB- Plant -- unpublished observations -RRB-	60056
@NP	a longer periods	60056
@NP	Plant -- unpublished observations	60074
@NP	Plant	60074
@NP	unpublished observations	60082
@NP	all -LSB- 33 -RSB-	60132
@NP	Functional recovery	60142
@NP	sub acute transplantation	60180
@NP	OEG and SCs	60209
@NP	Significant behavioral differences	60221
@NP	the control injury	60278
@NP	medium injected rats	60301
@NP	both OEG and SCs grafted groups	60327
@NP	both OEG and SCs	60327
@NP	groups	60352
@NP	Improvements	60360
@NP	studies similar to that undertaken here	60405
@NP	studies	60405
@NP	that undertaken here	60424
@NP	that	60424
@NP	compensatory effects	60462
@NP	reflex-based segmental cord systems -LSB- 96 -RSB-	60500
@NP	reflex-based segmental cord systems	60500
@NP	96 -RSB-	60537
@NP	OEG transplantation into a completely transected spinal cord	60542
@NP	OEG transplantation	60542
@NP	a completely transected spinal cord	60567
@NP	improved hindlimb function -LSB- 9,10,97	60616
@NP	improved hindlimb function	60616
@NP	9,10,97	60644
@NP	One possibility that could increase locomotion	60667
@NP	locomotion	60703
@NP	increased noradrenergic and serotonergic varicosities	60717
@NP	the motor associated cholinergic neurons -LSB- 98 -RSB-	60780
@NP	the motor	60780
@NP	cholinergic neurons -LSB- 98 -RSB-	60801
@NP	cholinergic neurons	60801
@NP	98 -RSB-	60822
@NP	OEG treated rats	60827
@NP	OEG	60827
@NP	rats	60839
@NP	significant numbers	60851
@NP	raphe projecting axons reaching at least 8 mm distal from the injury site	60874
@NP	raphe	60874
@NP	axons	60891
@NP	at least 8 mm distal from the injury site	60906
@NP	at least 8 mm	60906
@NP	the injury site	60932
@NP	these	60952
@NP	such a behavioral response	60974
@NP	This	61002
@NP	the SCs	61032
@NP	rats which may use an alternate but effective pathway of locomotion	61048
@NP	rats	61048
@NP	an alternate but effective pathway of locomotion	61067
@NP	an alternate but effective pathway	61067
@NP	locomotion	61105
@NP	SCs	61117
@NP	recovery	61129
@NP	a graft relay system	61170
@NP	regeneration of propriospinal axons regeneration	61209
@NP	regeneration	61209
@NP	propriospinal axons regeneration	61225
@NP	our results	61269
@NP	Only small numbers of spared fibers -LRB- < 5 % -RRB-	61287
@NP	Only small numbers	61287
@NP	spared fibers -LRB- < 5 % -RRB-	61309
@NP	spared fibers	61309
@NP	< 5 %	61324
@NP	<	61324
@NP	5 %	61325
@NP	compensatory return of function via segmental circuits -LSB- 99 -RSB-	61356
@NP	compensatory return	61356
@NP	function via segmental circuits -LSB- 99 -RSB-	61379
@NP	function	61379
@NP	segmental circuits -LSB- 99 -RSB-	61392
@NP	segmental circuits	61392
@NP	99 -RSB-	61412
@NP	Phasic behavioral recovery in the SCs group	61417
@NP	Phasic behavioral recovery	61417
@NP	the SCs group	61447
@NP	particular 49 days	61465
@NP	the end of the experiment	61490
@NP	the end	61490
@NP	the experiment	61501
@NP	phasic secretion	61531
@NP	neurotrophins	61551
@NP	the same level via the transplantation of OEG	61595
@NP	the same level	61595
@NP	the transplantation of OEG	61614
@NP	the transplantation	61614
@NP	OEG	61637
@NP	Conclusions Glial cells transplanted at 14 days post injury	61642
@NP	Conclusions Glial cells	61642
@NP	Conclusions	61642
@NP	Glial cells	61654
@NP	14 days post injury	61682
@NP	14 days	61682
@NP	a less accommodating lesion site	61717
@NP	1 week	61768
@NP	injury	61781
@NP	a reduced glial survival	61807
@NP	particular for OEG than seen in earlier transplant studies	61835
@NP	particular	61835
@NP	OEG than seen in earlier transplant studies	61850
@NP	OEG	61850
@NP	earlier transplant studies	61867
@NP	14 days post SCI	61898
@NP	14 days	61898
@NP	proteoglycan deposition at the lesion site	61915
@NP	proteoglycan deposition	61915
@NP	the lesion site	61942
@NP	-LSB- 100,101	61991
@NP	the OEG transplanted groups	62032
@NP	a positive milieu	62070
@NP	the sparing/regeneration	62092
@NP	supraspinal axons -LRB- serotonergic positive fibers -RRB-	62120
@NP	supraspinal axons	62120
@NP	serotonergic positive fibers	62139
@NP	This evidence	62170
@NP	our use	62206
@NP	fluorogold	62217
@NP	immunohistochemistry for 5-HT	62262
@NP	immunohistochemistry	62262
@NP	5-HT	62287
@NP	98 -RSB- -LRB- which labels serotonergic axons innervating the spinal cord -RRB-	62293
@NP	98 -RSB-	62293
@NP	serotonergic axons innervating the spinal cord	62311
@NP	serotonergic axons	62311
@NP	the spinal cord	62342
@NP	Supplementation of glial transplants with neurotrophins	62360
@NP	Supplementation	62360
@NP	glial transplants with neurotrophins	62379
@NP	glial transplants	62379
@NP	neurotrophins	62402
@NP	cell survivability	62428
@NP	13 -RSB-	62448
@NP	combination	62459
@NP	removal of the glial scar by the use of chondroitinase	62476
@NP	removal	62476
@NP	the glial scar by the use of chondroitinase	62487
@NP	the glial scar	62487
@NP	the use of chondroitinase	62505
@NP	the use	62505
@NP	chondroitinase	62516
@NP	axonal regeneration	62557
@NP	this 14 day delayed glial transplant model -LSB- 102,103 -RSB-	62580
@NP	this 14 day	62580
@NP	glial transplant model -LSB- 102,103 -RSB-	62600
@NP	glial transplant model	62600
@NP	102,103 -RSB-	62624
@NP	the delay between injury and treatment	62642
@NP	the delay	62642
@NP	injury and treatment	62660
@NP	a strong bearing	62690
@NP	the experimental outcome but also the success of the glial type	62710
@NP	the experimental outcome	62710
@NP	the success of the glial type	62744
@NP	the success	62744
@NP	the glial type	62759
@NP	tissue and behavioral outcomes	62785
@NP	the lesion site	62824
@NP	sparing/regeneration of axonal populations	62852
@NP	sparing/regeneration	62852
@NP	axonal populations	62876
@NP	the present study	62915
@NP	it	62933
@NP	a 14 day delay in glial transplantation	62954
@NP	a 14 day delay	62954
@NP	glial transplantation	62972
@NP	a contusive spinal cord injury	63062
@NP	the mechanisms of repair of the two glial types	63097
@NP	the mechanisms	63097
@NP	repair of the two glial types	63115
@NP	repair	63115
@NP	the two glial types	63125
@NP	We	63160
@NP	two time points -LRB- 2 weeks and 4 months -RRB-	63177
@NP	two time points	63177
@NP	2 weeks and 4 months	63194
@NP	2 weeks	63194
@NP	4 months	63206
@NP	multiple behavioral and anatomical analysis	63222
@NP	an indication of efficacy	63293
@NP	an indication	63293
@NP	efficacy	63310
@NP	Further physiological , behavioral and anatomical correlative studies	63320
@NP	these glial cells at 14 days post injury time point	63395
@NP	glial cells at 14 days	63401
@NP	glial cells	63401
@NP	14 days	63416
@NP	valuable evidence of cell potential and reproducibility	63461
@NP	valuable evidence	63461
@NP	cell potential and reproducibility	63482
@NP	future CNS repair applications	63521
@NP	Additional file Additional file 1 : Table S1 .	63554
@NP	Additional file Additional file 1	63554
@NP	Additional file Additional file	63554
@NP	1	63586
@NP	Table S1	63589
@NP	Table	63589
@NP	S1	63595
@NP	DSRED-2 Fluorescence	63599
@NP	OEG Transplanted and SC Transplanted groups	63630
@NP	OEG Transplanted and SC	63630
@NP	groups	63667
@NP	Abbreviations OEG	63675
@NP	Abbreviations	63675
@NP	OEG	63689
@NP	Olfactory ensheathing glia ; SCs	63694
@NP	Olfactory ensheathing glia	63694
@NP	SCs	63722
@NP	Schwann cells ; BBB	63727
@NP	Schwann cells	63727
@NP	BBB	63742
@NP	Basso , Beattie and Bresnahan ; ANOVA	63747
@NP	Basso , Beattie and Bresnahan	63747
@NP	ANOVA	63777
@NP	One way analysis	63784
@NP	variance	63804
@NP	SCI	63814
@NP	Spinal cord injury	63819
@NP	GFP	63839
@NP	Green fluorescent protein	63844
@NP	GFAP	63871
@NP	Glial fibrillary acidic protein	63877
@NP	BDNF	63910
@NP	Brain	63916
@NP	neurotrophic factor	63930
@NP	NGF : Nerve growth factor	63951
@NP	NGF	63951
@NP	Nerve growth factor	63956
@NP	GDNF	63977
@NP	Glial	63983
@NP	neurotrophic factor ; NT4/5 : Neurotrophin 4/5	63997
@NP	neurotrophic factor	63997
@NP	NT4/5 : Neurotrophin 4/5	64018
@NP	NT4/5	64018
@NP	Neurotrophin 4/5	64025
@NP	DMEM	64043
@NP	Dulbecco 's	64049
@NP	eagle 's medium	64069
@NP	eagle 's	64069
@NP	NYU : New York University	64085
@NP	NYU	64085
@NP	New York University	64090
@NP	Competing interests	64111
@NP	The authors	64131
@NP	they	64156
@NP	no competing interests	64166
@NP	Authors ' contributions HB	64190
@NP	Authors '	64190
@NP	the acquisition of data , analysis and interpretation	64231
@NP	the acquisition	64231
@NP	data , analysis and interpretation	64250
@NP	CDP	64285
@NP	the analysis of data	64304
@NP	the analysis	64304
@NP	data	64320
@NP	manuscript	64338
@NP	intellectual content	64366
@NP	ARH	64388
@NP	the analysis of data	64407
@NP	the analysis	64407
@NP	data	64423
@NP	manuscript and intellectual content	64441
@NP	manuscript	64441
@NP	intellectual content	64456
@NP	GWP	64478
@NP	the study and design , acquisition of data , analysis	64495
@NP	the study and design	64495
@NP	acquisition of data , analysis	64517
@NP	acquisition	64517
@NP	data , analysis	64532
@NP	data	64532
@NP	analysis	64538
@NP	the manuscript	64559
@NP	All authors	64575
@NP	the manuscript	64610
@NP	Acknowledgements	64626
@NP	We	64643
@NP	Seok Voon Lee	64672
@NP	technical contributions	64690
@VP	walking tests to ascertain improvements in locomotor function	679
@VP	to ascertain improvements in locomotor function	693
@VP	ascertain improvements in locomotor function	696
@VP	injected sub acutely -LRB- 14 days after injury -RRB- could	993
@VP	could	1037
@VP	induce sparing/regeneration of propriospinal and supraspinal projections ,	1082
@VP	reduce tissue loss	1166
@VP	compared to control injury only in the open field tests -LRB- BBB -RRB-	1270
@VP	to control injury only in the open field tests -LRB- BBB -RRB-	1279
@VP	control injury only in the open field tests -LRB- BBB -RRB-	1282
@VP	show statistically significant differences between treatment and control groups	1371
@VP	tracing	1474
@VP	showed	1482
@VP	projecting into the distal spinal cord in both OEG and SCs transplanted rats	1562
@VP	included the raphe , reticular and vestibular systems	1646
@VP	compared to SCs transplanted animals	1850
@VP	had increased in all OEG and SCs treated groups	2173
@VP	increased in all OEG and SCs treated groups	2177
@VP	treated groups	2206
@VP	was observed at both time points following glial SCs transplantation	2249
@VP	observed at both time points following glial SCs transplantation	2253
@VP	suggesting a more CNS tolerant graft	2434
@VP	increasing the number of spared/regenerated supraspinal fibers	2641
@VP	reducing cavitation	2705
@VP	enhancing tissue integrity	2729
@VP	to provide trophic support for damaged neurons	2997
@VP	provide trophic support for damaged neurons	3000
@VP	to transform the inhibitory milieu of the lesion site	3048
@VP	transform the inhibitory milieu of the lesion site	3051
@VP	to grow through the otherwise impenetrable glial scar or cystic cavity	3121
@VP	grow through the otherwise impenetrable glial scar or cystic cavity	3124
@VP	have the potential to facilitate repair after injury	3391
@VP	to facilitate repair after injury	3410
@VP	facilitate repair after injury	3413
@VP	to enhance	3465
@VP	enhance	3468
@VP	has been extensively tested in experimental SCI models -LSB- 7-14 -RSB-	3490
@VP	been extensively tested in experimental SCI models -LSB- 7-14 -RSB-	3494
@VP	extensively tested in experimental SCI models -LSB- 7-14 -RSB-	3499
@VP	to compare the outcomes achieved using OEG in sub-acute spinal cord injury model	3715
@VP	compare the outcomes achieved using OEG in sub-acute spinal cord injury model	3718
@VP	achieved using OEG in sub-acute spinal cord injury model	3739
@VP	using OEG in sub-acute spinal cord injury model	3748
@VP	isolating adult rat and human SCs	3818
@VP	vary considerably , as do the experimental results	4023
@VP	do the experimental results	4045
@VP	OEG display considerable morphological plasticity in vitro	4074
@VP	display considerable morphological plasticity in vitro	4078
@VP	-LSB- 23-26 -RSB-	4202
@VP	propriaderived OEG are less consistent -LSB- 28-30 -RSB-	4397
@VP	are less consistent -LSB- 28-30 -RSB-	4416
@VP	To initially identify transplanted OEG and SCs	4445
@VP	identify transplanted OEG and SCs	4458
@VP	transplanted OEG and SCs	4467
@VP	using an antibody to low affinity nerve growth factor receptor -LRB- p75 -RRB-	4514
@VP	was used	4583
@VP	used	4587
@VP	can be cleaved in vivo and in vitro by endogenous proteases -LSB- 34,35 -RSB-	4893
@VP	be cleaved in vivo and in vitro by endogenous proteases -LSB- 34,35 -RSB-	4897
@VP	cleaved in vivo and in vitro by endogenous proteases -LSB- 34,35 -RSB-	4900
@VP	was also used in this study	5049
@VP	used in this study	5058
@VP	to promote axonal sparing / regeneration -LSB- 4,37 -RSB-	5392
@VP	promote axonal sparing / regeneration -LSB- 4,37 -RSB-	5395
@VP	sparing / regeneration -LSB- 4,37 -RSB-	5410
@VP	improve anatomical and functional outcomes following a spinal cord contusion	5498
@VP	was chosen because	5721
@VP	chosen because	5725
@VP	deliver this type of cellular therapy in a clinical trial	5783
@VP	may be more beneficial for cell survival , integration	6156
@VP	be more beneficial for cell survival , integration	6160
@VP	reduced immune mediated rejection -LSB- 8,14,20,38-41 -RSB-	6214
@VP	may inhibit cell integration	6327
@VP	inhibit cell integration	6331
@VP	been used in relation to the analysis of axonal growth within this manuscript	6599
@VP	used in relation to the analysis of axonal growth within this manuscript	6604
@VP	described previously in a contusion model study -LSB- 8	6697
@VP	using fluorogold	6749
@VP	can not truly distinguish between spared and regenerated axons	6770
@VP	distinguish between spared and regenerated axons	6783
@VP	would have been introduced	7751
@VP	have been introduced	7757
@VP	been introduced	7762
@VP	introduced	7767
@VP	used n = 74	7790
@VP	receiving a transplant	7810
@VP	medium were perfused at 2 weeks or 4 months after transplantation	7840
@VP	were perfused at 2 weeks or 4 months after transplantation	7847
@VP	perfused at 2 weeks or 4 months after transplantation	7852
@VP	were final numbers analyzed	7930
@VP	analyzed	7949
@VP	died and in the short term groups 6 rats	7993
@VP	died	7993
@VP	in the short term groups 6 rats	8002
@VP	were extirpated	8211
@VP	extirpated	8216
@VP	dissected	8257
@VP	supplemented with bovine pituitary extract -LRB- 20 μg/mL Gibco -RRB-	8645
@VP	then plated on poly	8733
@VP	were isolated from adult female Fischer 344 rats -LSB- 19,33 -RSB-	8914
@VP	isolated from adult female Fischer 344 rats -LSB- 19,33 -RSB-	8919
@VP	dissected	9005
@VP	consisting of DMEM -LRB- Sigma St Louis , MO -RRB- with 10 % fetal calf serum	9078
@VP	cut into 1-2 mm3 pieces	9190
@VP	leaving behind fibroblasts that had migrated out of the explants	9281
@VP	had migrated out of the explants	9313
@VP	migrated out of the explants	9317
@VP	encoding the gene for DSRED-2	9645
@VP	were made according to methods described by -LSB- 104 -RSB-	9675
@VP	made according to methods described by -LSB- 104 -RSB-	9680
@VP	described by -LSB- 104 -RSB-	9706
@VP	labeled by adding the vector	9751
@VP	adding the vector	9762
@VP	using a multiplicity of infection of 100 -LSB- 12	9781
@VP	followed by 2 washes in culture medium and fresh media for growth	9863
@VP	was induced with 5 % -LRB- v/v -RRB- halothane -LRB- in 60:40 O2 : N2O -RRB-	9984
@VP	induced with 5 % -LRB- v/v -RRB- halothane -LRB- in 60:40 O2 : N2O -RRB-	9988
@VP	maintained at 2-3 %	10043
@VP	were cut rostro-caudally to expose the vertebral column	10090
@VP	cut rostro-caudally to expose the vertebral column	10095
@VP	to expose the vertebral column	10115
@VP	expose the vertebral column	10118
@VP	dropping a 10 g weight from a 12.5 mm height -LSB- 99,105 -RSB- Gel-Foam	10271
@VP	was used to stop bleeding in some animals	10370
@VP	used to stop bleeding in some animals	10374
@VP	to stop bleeding in some animals	10379
@VP	stop bleeding in some animals	10382
@VP	bleeding in some animals	10387
@VP	to circumvent diaphragm-induced dorso-ventral movement of the spinal column	10500
@VP	circumvent diaphragm-induced dorso-ventral movement of the spinal column	10503
@VP	sutured in layers with Vicryl -LRB- Johnson & Johnson , New Brunswick , NJ -RRB-	10662
@VP	to assist with maintenance of body temperature	11092
@VP	assist with maintenance of body temperature	11095
@VP	had recovered bladder tone	11351
@VP	recovered bladder tone	11355
@VP	were transplanted after no more than 2 weeks in vitro -LSB- 8 -RSB-	11406
@VP	transplanted after no more than 2 weeks in vitro -LSB- 8 -RSB-	11411
@VP	were anesthetized and the spinal cord exposed as described above	11513
@VP	exposed as described above	11551
@VP	described above	11562
@VP	mounted in a stereotaxic frame	11812
@VP	withdrawn 3 minutes later to encourage cell integration into the injection site	11859
@VP	to encourage cell integration into the injection site	11885
@VP	encourage cell integration into the injection site	11888
@VP	were sutured	11947
@VP	sutured	11952
@VP	was administered as described above	11984
@VP	administered as described above	11988
@VP	described above	12004
@VP	were carried out by observers blinded to the treatments	12079
@VP	carried out by observers blinded to the treatments	12084
@VP	blinded to the treatments	12109
@VP	to confirm the successful lesion -LRB- a score of 0 -RRB-	12214
@VP	confirm the successful lesion -LRB- a score of 0 -RRB-	12217
@VP	were consistently scoring BBB results of 10 -- 11	12411
@VP	scoring BBB results of 10 -- 11	12429
@VP	rung walking test modified from -LSB- 106 -RSB-	12468
@VP	walking test modified from -LSB- 106 -RSB-	12473
@VP	modified from -LSB- 106 -RSB-	12486
@VP	was introduced 1 week after injury and measured every week for 4 months	12506
@VP	introduced 1 week after injury and measured every week for 4 months	12510
@VP	introduced 1 week after injury	12510
@VP	measured every week for 4 months	12545
@VP	rung walking test	12590
@VP	walking test	12595
@VP	were separated	12732
@VP	separated	12737
@VP	was 1.5 m in length	12793
@VP	consisted of two clear Perspex sidewalls and a floor with removable metal rungs	12817
@VP	spaced 1 cm apart	12897
@VP	were trained to walk along the ladder to reach their home cage	12939
@VP	trained to walk along the ladder to reach their home cage	12944
@VP	to walk along the ladder to reach their home cage	12952
@VP	walk along the ladder to reach their home cage	12955
@VP	to reach their home cage	12977
@VP	reach their home cage	12980
@VP	were performed weekly and video recorded	13036
@VP	performed weekly and video recorded	13041
@VP	recorded	13068
@VP	had 3 runs per day when tested	13090
@VP	tested	13114
@VP	allowing analysis of approximately 8 steps of each hind limb	13231
@VP	was later scored -LRB- Table	13327
@VP	later scored -LRB- Table	13331
@VP	were averaged to give a single value , per rat , per trial	13365
@VP	averaged to give a single value , per rat , per trial	13370
@VP	to give a single value , per rat , per trial	13379
@VP	give a single value , per rat , per trial	13382
@VP	were anesthetized as above and subjected to a T12 laminectomy	13565
@VP	subjected to a T12 laminectomy	13596
@VP	held in a stereotaxic frame	13634
@VP	had previously been injected with OEG , SCs or control cells	13969
@VP	been injected with OEG , SCs or control cells	13984
@VP	injected with OEG , SCs or control cells	13989
@VP	were sutured in layers and the skin	14038
@VP	sutured in layers and the skin	14043
@VP	closed with Michel	14074
@VP	were treated with the post-operative care regime detailed above	14170
@VP	treated with the post-operative care regime detailed above	14175
@VP	detailed above	14219
@VP	buffered paraformaldehyde solution	14650
@VP	was replaced with 0.1 M phosphate buffer	14835
@VP	replaced with 0.1 M phosphate buffer	14839
@VP	buffered paraformaldehyde for 2 hours	15120
@VP	placed into buffered sucrose solution overnight	15162
@VP	placed into phosphate buffer containing 0.05 %	15308
@VP	containing 0.05 %	15337
@VP	based on	15448
@VP	to appropriately assess statistical differences	15576
@VP	appropriately assess statistical differences	15579
@VP	traced	15729
@VP	allocated to the groups without the knowledge of the surgeon or behaviorist	15800
@VP	taken from the naïve cages and re-housed into post-surgery cages and numbered	15890
@VP	taken from the naïve cages	15890
@VP	re-housed into post-surgery cages	15921
@VP	numbered	15959
@VP	was then combined by an independent person to identify the treatment	15981
@VP	then combined by an independent person to identify the treatment	15985
@VP	to identify the treatment	16024
@VP	identify the treatment	16027
@VP	was blinded to the treatment	16077
@VP	blinded to the treatment	16081
@VP	were performed on the same day for all groups with the same fixative batch	16122
@VP	performed on the same day for all groups with the same fixative batch	16127
@VP	reducing differences in staining between days and groups	16271
@VP	was performed by a trained viewer who was blinded to the groups	16342
@VP	performed by a trained viewer who was blinded to the groups	16346
@VP	was blinded to the groups	16380
@VP	blinded to the groups	16384
@VP	estimation One in six sections from each spinal cord	16421
@VP	mounted onto gelatin-coated microscope slides	16478
@VP	followed by cresyl violet for Nissl substance -LSB- 107 -RSB-	16575
@VP	were dehydrated through an ethanol/toluene series	16635
@VP	dehydrated through an ethanol/toluene series	16640
@VP	mounted in DPX -LRB- Chem Supply , Gillman , Australia -RRB-	16689
@VP	were visualized using a Leica DM RBE microscope and digitally photographed	16748
@VP	visualized using a Leica DM RBE microscope and digitally photographed	16753
@VP	visualized using a Leica DM RBE microscope	16753
@VP	using a Leica DM RBE microscope	16764
@VP	digitally photographed	16800
@VP	was measured in a similar manner to that described previously -LSB- 8,14,108	17196
@VP	measured in a similar manner to that described previously -LSB- 8,14,108	17200
@VP	described previously -LSB- 8,14,108	17237
@VP	to give a value for the total tissue remaining	17373
@VP	give a value for the total tissue remaining	17376
@VP	remaining	17410
@VP	showing signs of degeneration	17427
@VP	remaining to obtain a measure of intact tissue	17557
@VP	to obtain a measure of intact tissue	17567
@VP	obtain a measure of intact tissue	17570
@VP	used to compute the tissue remaining as a proportion of uninjured spinal cord	17837
@VP	to compute the tissue remaining as a proportion of uninjured spinal cord	17842
@VP	compute the tissue remaining as a proportion of uninjured spinal cord	17845
@VP	remaining as a proportion of uninjured spinal cord	17864
@VP	diluted in phosphate buffer containing 10 % normal goat serum	18158
@VP	containing 10 % normal goat serum	18186
@VP	used	18276
@VP	to identify proteoglycan deposition at the lesion site	18348
@VP	identify proteoglycan deposition at the lesion site	18351
@VP	to stain for OEG and Schwann cells -LRB- both transplanted and endogenous -RRB-	18476
@VP	stain for OEG and Schwann cells -LRB- both transplanted and endogenous -RRB-	18479
@VP	iii -RRB- anti medium	18550
@VP	to stain for spared and regenerated axons	18637
@VP	stain for spared and regenerated axons	18640
@VP	were used for	18709
@VP	used for	18714
@VP	washed three times with phosphate buffer	19137
@VP	diluted in the same solution as for primary antibodies	19217
@VP	were washed three times with phosphate buffer	19318
@VP	washed three times with phosphate buffer	19323
@VP	mounted onto gelatin-coated glass	19365
@VP	dried and then coverslipped in a glycerol-based mounting medium	19422
@VP	dried	19422
@VP	then coverslipped in a glycerol-based mounting medium	19432
@VP	were analyzed	19640
@VP	analyzed	19645
@VP	were taken using an IX70 Olympus microscope	19706
@VP	taken using an IX70 Olympus microscope	19711
@VP	using an IX70 Olympus microscope	19717
@VP	labeled cells in the 2 week and 4 month survival groups	20133
@VP	expressed as a percentage of those present at 2 weeks	20305
@VP	photography	20371
@VP	mounted onto gelatin-coated glass microscope slides , air-dried	20433
@VP	mounted in a glycerol-based mounting medium	20500
@VP	controlled with Image Pro	20703
@VP	Plus -LRB- 5.1 -RRB- software -LRB- Media Cybernetics -RRB-	20729
@VP	were taken in the centre of the z-axis of each section	20932
@VP	taken in the centre of the z-axis of each section	20937
@VP	were identified	21015
@VP	identified	21020
@VP	tagged and counted using Image Pro Plus	21037
@VP	tagged	21037
@VP	counted using Image Pro Plus	21048
@VP	using Image Pro Plus	21056
@VP	were analyzed	21090
@VP	analyzed	21095
@VP	To quantify sparing/regeneration of descending propriospinal neurons	21246
@VP	quantify sparing/regeneration of descending propriospinal neurons	21249
@VP	using an identical method in the spinal cord region rostral to the lesion site	21353
@VP	were analyzed	21492
@VP	analyzed	21497
@VP	were chosen that reflected the animal numbers	21564
@VP	chosen that reflected the animal numbers	21569
@VP	reflected the animal numbers	21581
@VP	used in this study	21610
@VP	supraspinal projecting nuclei in the brain	21657
@VP	were analyzed using a one way analysis of variance -LRB- ANOVA -RRB-	22062
@VP	analyzed using a one way analysis of variance -LRB- ANOVA -RRB-	22067
@VP	using a one way analysis of variance -LRB- ANOVA -RRB-	22076
@VP	were compared using the non parametric Kruskal Wallace ANOVA on ranks	22255
@VP	compared using the non parametric Kruskal Wallace ANOVA on ranks	22260
@VP	using the non parametric Kruskal Wallace ANOVA on ranks	22269
@VP	Transplanted groups Table 2 Scoring scale	22511
@VP	Table 2 Scoring scale	22532
@VP	rung walking test	22579
@VP	walking test	22584
@VP	describing the amount of total tissue remaining	22655
@VP	using Image Pro	22985
@VP	remaining 2 weeks and 4 months after cell transplantation	23020
@VP	remaining 2 weeks and 4 months after cell transplantation	23098
@VP	compared to medium controls	23272
@VP	after injury -LRB- i.e. day of cell transplantation -RRB- -LRB- D -RRB- Total	23355
@VP	tissue remaining at 2 weeks after medium injection	23413
@VP	remaining at 2 weeks after medium injection	23420
@VP	Demonstrates the spinal cord tissue 4 months after OEG transplantation	23771
@VP	compared to image -LRB- H -RRB-	23940
@VP	being injected with Schwann cells at the 14 day treatment time point	24006
@VP	injected with Schwann cells at the 14 day treatment time point	24012
@VP	see black arrow	24115
@VP	are present	24200
@VP	representing lentiviral	24259
@VP	transduced and transplanted OEG and Schwann cells	24283
@VP	transduced	24283
@VP	transplanted OEG and Schwann cells	24298
@VP	labeled with lentiviral DsRed2	24350
@VP	in vitro labeled with lentiviral DsRed2	24399
@VP	appear to have survived in greater numbers than the OEG	24608
@VP	to have survived in greater numbers than the OEG	24615
@VP	have survived in greater numbers than the OEG	24618
@VP	survived in greater numbers than the OEG	24623
@VP	remain in a dense aggregate	24748
@VP	indicated by GFAP and CSPG immunoreactivity	24852
@VP	is greater for OEG than for Schwann cells	25110
@VP	surrounded by strong GFAP immunoreactivity	25214
@VP	measured by mean pixels	25459
@VP	compared to Schwann cells	25628
@VP	see *	25655
@VP	compared to medium	25734
@VP	injected controls -LRB- see # -RRB-	25753
@VP	see #	25772
@VP	treated spinal cords at 4 months	25819
@VP	see arrow in D depicting DsRed-2 OEG	26171
@VP	depicting DsRed-2 OEG	26186
@VP	to be co-localized on the surface of the OEG cells -LRB- see arrows in G -RRB-	26249
@VP	be co-localized on the surface of the OEG cells -LRB- see arrows in G -RRB-	26252
@VP	co-localized on the surface of the OEG cells -LRB- see arrows in G -RRB-	26255
@VP	see arrows in G	26301
@VP	is also found surrounding Schwann cell transplants -LRB- see H -RRB-	26327
@VP	found surrounding Schwann cell transplants -LRB- see H -RRB-	26335
@VP	see H	26379
@VP	depicts the central core of the transplant	26393
@VP	see I-J	26496
@VP	has reduced intensity of staining	26553
@VP	reduced intensity of staining	26557
@VP	surrounding any surviving OEG	26675
@VP	see L	26706
@VP	labeled cells -LRB- see arrows in O -RRB-	26717
@VP	see arrows in O	26732
@VP	are not colabeled with collagen IV	26749
@VP	colabeled with collagen IV	26757
@VP	show intense staining surrounding	26854
@VP	surrounding	26876
@VP	see arrow	26931
@VP	is mostly co-localized	26972
@VP	see above dashed line	26996
@VP	are not	27034
@VP	bar in A also serves C , D , H , L and P.	27069
@VP	serves C , D , H , L and P.	27083
@VP	bar in B also serves E , F , I , J , M , N , Q and R.	27114
@VP	serves E , F , I , J , M , N , Q and R.	27128
@VP	are observed within the lesion site in all groups	27408
@VP	observed within the lesion site in all groups	27412
@VP	varied	27486
@VP	were arranged in fascicular bundles	27521
@VP	arranged in fascicular bundles	27526
@VP	constitute the ventral white matter	27646
@VP	See -LRB- C -RRB- for higher power image of -LRB- B -RRB- .	27683
@VP	see D	27772
@VP	showed a close association with DsRed-2 positive cells	27792
@VP	followed a non linear path	27851
@VP	labeled Schwann cells deep within the transplants	27908
@VP	close to microcysts -LRB- * -RRB-	27961
@VP	bar in D also serves A and B scale bar in E also serves C.	28012
@VP	serves A and B scale bar in E also serves C.	28026
@VP	serves C.	28061
@VP	comingled with host p75 positive Schwann cells	28501
@VP	see arrows	28631
@VP	are tightly clustered unlike the dispersed OEG	28726
@VP	see C-D	28774
@VP	bar in C -LRB- 100 μm -RRB- also serves A and B.	28790
@VP	serves A and B.	28813
@VP	retrogradely labeled with Fluorogold	28883
@VP	injected 8 mm caudal to the thoracic spinal cord lesion site	28920
@VP	contused spinal cord 14 days after injury	29011
@VP	were retrogradely labeled with Fluorogold	29756
@VP	labeled with Fluorogold	29774
@VP	injected caudal -LRB- 8 mm -RRB- to the lesion site -LRB- A -RRB-	29798
@VP	plotted against contusion injury only	30135
@VP	depicts the transplant day	30194
@VP	compared to contusion only	30313
@VP	to contusion only	30322
@VP	contusion only	30325
@VP	compared to control injury only -LRB- * , p < 0.05 -RRB-	30426
@VP	to control injury only -LRB- * , p < 0.05 -RRB-	30435
@VP	control injury only -LRB- * , p < 0.05 -RRB-	30438
@VP	walking behavioral testing	30489
@VP	traversing the horizontal ladder	30550
@VP	were	30765
@VP	observed on the horizontal ladder test	30809
@VP	is associated with improved retention of tissue at the lesion site	30871
@VP	associated with improved retention of tissue at the lesion site	30874
@VP	involved measuring the total amount of residual tissue	31080
@VP	measuring the total amount of residual tissue	31089
@VP	could not be classified as white or grey matter	31240
@VP	be classified as white or grey matter	31250
@VP	classified as white or grey matter	31253
@VP	grafted cells	31413
@VP	allows distinction between intact and non-intact tissue containing macrophages	31512
@VP	containing macrophages	31568
@VP	allows the area of intact spinal cord versus the cyst areas to be defined	31694
@VP	to be defined	31754
@VP	be defined	31757
@VP	defined	31760
@VP	remaining	31861
@VP	was 55.4 ± 12.8 % -LRB- mean ± s.e.m -RRB-	31952
@VP	was found to be significantly greater than controls -LRB- p = 0.028 -RRB-	32643
@VP	found to be significantly greater than controls -LRB- p = 0.028 -RRB-	32647
@VP	to be significantly greater than controls -LRB- p = 0.028 -RRB-	32653
@VP	be significantly greater than controls -LRB- p = 0.028 -RRB-	32656
@VP	visualized with Nissl staining	33251
@VP	showed good preservation of spinal tissue	33282
@VP	were present	33336
@VP	were frequently small -LRB- see Figure 1D , E and F -RRB- and very few in number	33349
@VP	were frequently small	33349
@VP	see Figure 1D , E and F	33372
@VP	very few in number	33399
@VP	mentioned above	33422
@VP	was noted in any of the control or transplanted groups -LRB- OEG or SCs -RRB-	33472
@VP	noted in any of the control or transplanted groups -LRB- OEG or SCs -RRB-	33476
@VP	see Figure 1H , I and J	33718
@VP	treated rats , and were present in 2	33817
@VP	treated rats	33817
@VP	were present in 2	33835
@VP	injected	33933
@VP	showed these cysts	33948
@VP	were labeled in vitro -LRB- as a total of all Hoechst 33342 labeled cells -RRB-	34096
@VP	labeled in vitro -LRB- as a total of all Hoechst 33342 labeled cells -RRB-	34101
@VP	labeled cells	34151
@VP	were not previously transduced with self inactivating lentiviral-DSRED-2 vectors	34196
@VP	previously transduced with self inactivating lentiviral-DSRED-2 vectors	34205
@VP	inactivating lentiviral-DSRED-2 vectors	34237
@VP	was found to be non-toxic -LRB- data not shown -RRB-	34290
@VP	found to be non-toxic -LRB- data not shown -RRB-	34294
@VP	to be non-toxic -LRB- data not shown -RRB-	34300
@VP	be non-toxic -LRB- data not shown -RRB-	34303
@VP	not shown	34322
@VP	to be as efficient as seen previously with GFP -LSB- 12,26,36,42 -RSB-	34522
@VP	be as efficient as seen previously with GFP -LSB- 12,26,36,42 -RSB-	34525
@VP	seen previously with GFP -LSB- 12,26,36,42 -RSB-	34544
@VP	labeled	34592
@VP	may occur with LacZ	34693
@VP	occur with LacZ	34697
@VP	-LSB- 44 -RSB-	34758
@VP	grafts 2 weeks following cell transplantation	34848
@VP	labeled OEG	34914
@VP	labeled SCs	34996
@VP	was detected in all animals	35008
@VP	detected in all animals	35012
@VP	surviving transplanted OEG	35139
@VP	was 83 ± 34 for OEG and 79 ± 32 for SCs	35406
@VP	analyzed	35478
@VP	had in some cases	35516
@VP	measured	35616
@VP	dispersing no more than 0.6 mm from the injection site	35721
@VP	were dispersed throughout the lesion site and adjacent spinal cord tissue	35827
@VP	dispersed throughout the lesion site and adjacent spinal cord tissue	35832
@VP	were aligned along the rostrocaudal axis of the spinal cord	35906
@VP	aligned along the rostrocaudal axis of the spinal cord	35911
@VP	was highly regular within the graft area	36015
@VP	did not disperse into the intact host CNS tissue surrounding the lesion site	36060
@VP	disperse into the intact host CNS tissue surrounding the lesion site	36068
@VP	surrounding the lesion site	36109
@VP	were detected in 11 out of 11 animals -LRB- 100 % -RRB-	36270
@VP	detected in 11 out of 11 animals -LRB- 100 % -RRB-	36275
@VP	were 21 ± 9 for OEG and 29 ± 12 for SCs	36477
@VP	found to be 19 ± 8 for OEG at the caudal part of the lesion and 28 ± 12 for SCs	36545
@VP	to be 19 ± 8 for OEG at the caudal part of the lesion and 28 ± 12 for SCs	36551
@VP	be 19 ± 8 for OEG at the caudal part of the lesion and 28 ± 12 for SCs	36554
@VP	estimated from the DSRED-2 fluorescence	36625
@VP	seen at 2 weeks post transplantation	36812
@VP	reduced from 2 weeks and 4 months	36909
@VP	see Additional file 1 : Table S1	37024
@VP	was assessed in transplanted OEG	37154
@VP	assessed in transplanted OEG	37158
@VP	was assessed across the lesion site in a rostro-caudal direction	37371
@VP	assessed across the lesion site in a rostro-caudal direction	37375
@VP	treated spinal cords -LRB- n = 6 -LRB- Figure 3A , C -RRB-	37564
@VP	was noted at the caudal aspect of the transplant zone -LRB- Figure 3B , D -RRB-	37625
@VP	noted at the caudal aspect of the transplant zone -LRB- Figure 3B , D -RRB-	37629
@VP	analyzed by pixel intensity	37782
@VP	compared to the SCs transplanted group and a 23 % reduction	37983
@VP	was not statistically significant -LRB- p < 0.05 -RRB-	38138
@VP	seen in the medium injected controls	38833
@VP	injected controls	38852
@VP	bordering the lesion site	38977
@VP	were highlighted by laminin-1 staining -LRB- Figure 4A,B,D-K -RRB-	39056
@VP	highlighted by laminin-1 staining -LRB- Figure 4A,B,D-K -RRB-	39061
@VP	was strongly immunoreactive for laminin-1 in all analyzed spinal cords	39129
@VP	analyzed spinal cords	39178
@VP	contained laminin-1	39308
@VP	injected control group	39352
@VP	appeared more extensive in both the OEG and SCs transplanted groups	39403
@VP	were not statistically significant -LRB- p = 0.15 -RRB-	39494
@VP	transplanted group -LRB- see Figure 4I , J , K vs.	39688
@VP	-LRB- see Figure 4I , J , K vs.	39707
@VP	associated with the location of surviving DSRED-2 positive transplanted cells	39834
@VP	were observed	40095
@VP	observed	40100
@VP	was similar to that observed for laminin-1	40178
@VP	observed for laminin-1	40198
@VP	resembling blood vessels	40233
@VP	transplanted group	40388
@VP	using pixel	40520
@VP	to be statistically similar -LRB- p = 0.10 -RRB-	40601
@VP	be statistically similar -LRB- p = 0.10 -RRB-	40604
@VP	could be seen in high quantities in regions of the SCs grafts	40695
@VP	be seen in high quantities in regions of the SCs grafts	40701
@VP	seen in high quantities in regions of the SCs grafts	40704
@VP	appeared to originate from DSRED-2 negative cells in the vicinity of the DSRED-2	40824
@VP	to originate from DSRED-2 negative cells in the vicinity of the DSRED-2	40833
@VP	originate from DSRED-2 negative cells in the vicinity of the DSRED-2	40836
@VP	invading from the periphery or host endothelial cells	40977
@VP	be seen at the ventral edges of each section -LRB- Figure 5A , B , and D -RRB-	41393
@VP	seen at the ventral edges of each section -LRB- Figure 5A , B , and D -RRB-	41396
@VP	were in an improved state of preservation after OEG and SCs transplants	41487
@VP	being co-extensive with DSRED-2 OEG and SCs	41673
@VP	entering SCs graft areas or putative graft areas	41736
@VP	observed to lose rostral-caudal directionality	41800
@VP	to lose rostral-caudal directionality	41809
@VP	lose rostral-caudal directionality	41812
@VP	was not seen in the OEG transplanted spinal cords -LRB- Figure 5C -RRB-	41972
@VP	seen in the OEG transplanted spinal cords -LRB- Figure 5C -RRB-	41980
@VP	contained numerous fascicles of cells with glial-like spindle-shaped morphology	42177
@VP	were positive for p75 but negative for DSRED-2	42270
@VP	may have been donor cells that were not expressing the DSRED-2 transgene	42549
@VP	have been donor cells that were not expressing the DSRED-2 transgene	42553
@VP	been donor cells that were not expressing the DSRED-2 transgene	42558
@VP	were not expressing the DSRED-2 transgene	42580
@VP	expressing the DSRED-2 transgene	42589
@VP	using lentiviral vectors encoding transgene such as GFP	42804
@VP	encoding transgene such as GFP	42829
@VP	have previously been shown to display long term expression -LSB- 12	42860
@VP	been shown to display long term expression -LSB- 12	42876
@VP	shown to display long term expression -LSB- 12	42881
@VP	to display long term expression -LSB- 12	42887
@VP	display long term expression -LSB- 12	42890
@VP	were also detected in the medium-injected groups	42953
@VP	detected in the medium-injected groups	42963
@VP	increased by glial transplantation Retrograde labeling with Fluorogold	43052
@VP	labeling with Fluorogold	43098
@VP	reaching 8 mm beyond the most caudal edge of the contusion site	43205
@VP	are presented	43341
@VP	presented	43345
@VP	compared to the control injury only group -LRB- 1204 ± 331 -RRB-	43538
@VP	projecting distally through the injury zone	43673
@VP	projecting neurons -LRB- 562 ± 43 -RRB- compared to controls	43798
@VP	did not show significant differences when compared to control injuries only	43935
@VP	show significant differences when compared to control injuries only	43943
@VP	compared to control injuries only	43977
@VP	to control injuries only	43986
@VP	control injuries only	43989
@VP	grafted groups	44062
@VP	labeled neurons in the hypothalamus	44240
@VP	compared to controls -LRB- 60 ± 15 -RRB-	44371
@VP	grafted animals -LRB- Table 1 and Figure 7 -RRB-	44566
@VP	labeled in the vestibular system	44913
@VP	compared to control injury only rats -LRB- 117 ± 27 -RRB-	45050
@VP	to control injury only rats -LRB- 117 ± 27 -RRB-	45059
@VP	control injury only rats -LRB- 117 ± 27 -RRB-	45062
@VP	counted from spinal cord segments rostral to the lesion/transplantation site	45227
@VP	see schematic in Figure 8A	45305
@VP	had reached the caudal injected Fluorogold	45361
@VP	reached the caudal injected Fluorogold	45365
@VP	injected Fluorogold	45384
@VP	see Figure 8B	45581
@VP	seen in Figure 8	45600
@VP	injected	45671
@VP	injected group -LRB- p < 0.03 -RRB-	45832
@VP	had regained bladder function	46124
@VP	regained bladder function	46128
@VP	did not increase above control scores , with all groups scoring 10 -- 11	46388
@VP	increase above control scores , with all groups scoring 10 -- 11	46396
@VP	scored a mean of 11	46532
@VP	injected	46560
@VP	scored 10	46569
@VP	scored 12	46584
@VP	scored 11 -LRB- Figure 9 -RRB-	46602
@VP	injected rats were 13	46694
@VP	were 13	46708
@VP	scored 12	46721
@VP	injected	46739
@VP	scored 10	46748
@VP	scored 11	46774
@VP	scored a mean of 14	46880
@VP	scored 13	46905
@VP	injected	46923
@VP	scored 11 and 10	46932
@VP	scored 11 and 11 respectively -LRB- see Figure 9 -RRB-	46966
@VP	scored 11 and 11 respectively	46966
@VP	see Figure 9	46997
@VP	score the rats were introduced to the ladder walk -LRB- see Figure 10A -RRB-	47049
@VP	were introduced to the ladder walk -LRB- see Figure 10A -RRB-	47064
@VP	introduced to the ladder walk -LRB- see Figure 10A -RRB-	47069
@VP	see Figure 10A	47100
@VP	walking	47242
@VP	observed between groups	47303
@VP	have shown the capacity of purified	47343
@VP	shown the capacity of purified	47348
@VP	purified	47370
@VP	to promote behavioral recovery , increase numbers of supraspinal axons	47400
@VP	promote behavioral recovery , increase numbers of supraspinal axons	47403
@VP	transplanted two weeks after a moderate spinal cord contusion injury	47504
@VP	was used to transduce OEG and SCs	47611
@VP	used to transduce OEG and SCs	47615
@VP	to transduce OEG and SCs	47620
@VP	transduce OEG and SCs	47623
@VP	to label both cell types up to 4 months in vivo following transplantation	47714
@VP	label both cell types up to 4 months in vivo following transplantation	47717
@VP	4 months in vivo following transplantation	47745
@VP	were found in similar numbers at 2 weeks	47821
@VP	found in similar numbers at 2 weeks	47826
@VP	were less than the number of SCs remaining	47898
@VP	remaining	47931
@VP	protected in the transplant groups	48138
@VP	labeled glia in the spinal cords	48246
@VP	showed a migration/dispersal difference between the two cell types	48279
@VP	were more evenly distributed in a rostro-caudal direction	48351
@VP	evenly distributed in a rostro-caudal direction	48361
@VP	compared to the tight interwoven grafts in the SCs transplanted rats	48479
@VP	compared to the SCs group	48685
@VP	was similar between OEG and SCs groups	48730
@VP	showed a closer co-existence of these matrix molecules to SCs than to OEG	48817
@VP	using neurofilament antibodies	48908
@VP	showed tighter bundles of axons within the SCs transplant zone than in OEG zones	48939
@VP	were consistently higher in the OEG group compared to control injury	49186
@VP	compared to control injury	49228
@VP	to control injury	49237
@VP	control injury	49240
@VP	injected rats	49271
@VP	using the ladder walk however	49316
@VP	did not show any significant differences between experimental and control groups	49347
@VP	show any significant differences between experimental and control groups	49355
@VP	tracing 8 mm distal to the injury/transplantation site	49451
@VP	revealed significant differences between control groups and OEG and SCs	49506
@VP	projecting axon populations	49613
@VP	are increased	49833
@VP	increased	49837
@VP	differ in their interaction with host spinal cord cells and matrix production	49860
@VP	was observed 4 months after transplantation	50010
@VP	observed 4 months after transplantation	50014
@VP	was still occurring	50100
@VP	occurring	50110
@VP	combined with tissue-rebuilding or new cell birth	50394
@VP	are potentially acting together to improve anatomical functional outcomes	50450
@VP	acting together to improve anatomical functional outcomes	50466
@VP	to improve anatomical functional outcomes	50482
@VP	improve anatomical functional outcomes	50485
@VP	employed in this study	50591
@VP	would result in all daughter cells also being labeled	50614
@VP	result in all daughter cells also being labeled	50620
@VP	being labeled	50654
@VP	labeled	50660
@VP	were fewer than when counted at 2 weeks	50728
@VP	counted at 2 weeks	50749
@VP	dispersing only up to a distance of 1.5 mm	51228
@VP	inserted into the adult CNS -LSB- 55,56 -RSB-	51349
@VP	exerted by glia during development -LSB- 59	51669
@VP	result in increased infiltration of various cells into the lesion site	51714
@VP	found on microglia and dendritic cells -LSB- 60,61 -RSB-	51955
@VP	affects the amount of tissue preservation/removal	52006
@VP	be more susceptible to death and subsequent phagocytosis by macrophages than SCs	52077
@VP	are known to secrete different factors	52163
@VP	known to secrete different factors	52167
@VP	to secrete different factors	52173
@VP	secrete different factors	52176
@VP	mentioned above which make them more susceptible to immune attack -LSB- 62 -RSB-	52257
@VP	make them more susceptible to immune attack -LSB- 62 -RSB-	52279
@VP	have the capacity to myelinate	52753
@VP	differ in their effectiveness and mechanisms involved -LSB- 75 , Plant et al. ,	52788
@VP	involved -LSB- 75 , Plant et al. ,	52833
@VP	-RSB-	52886
@VP	does occur in SCI -LSB- 45 -RSB-	52927
@VP	occur in SCI -LSB- 45 -RSB-	52932
@VP	stimulated by factors such as epidermal growth factor	53019
@VP	fibroblast growth factor-2 -LSB- 68-70 -RSB-	53080
@VP	are known to produce similar levels of FGF-2 -LSB- 71 -RSB-	53181
@VP	known to produce similar levels of FGF-2 -LSB- 71 -RSB-	53185
@VP	to produce similar levels of FGF-2 -LSB- 71 -RSB-	53191
@VP	produce similar levels of FGF-2 -LSB- 71 -RSB-	53194
@VP	have indicated new cells play a role in SCI	53252
@VP	indicated new cells play a role in SCI	53257
@VP	play a role in SCI	53277
@VP	migrate to sites of injury	53448
@VP	providing a reparative outcome	53579
@VP	are resident in the meninges react to SCI and populate the injury site	53711
@VP	react to SCI and populate the injury site	53740
@VP	react to SCI	53740
@VP	populate the injury site	53757
@VP	providing a target for glial cell differentiation or activation	53788
@VP	were ongoing	53984
@VP	is one route	54128
@VP	seen within our lesion cysts -LSB- 45,75,76 -RSB-	54347
@VP	has previously been observed in the rat -LSB- 14,45,55,77,78	54564
@VP	been observed in the rat -LSB- 14,45,55,77,78	54579
@VP	observed in the rat -LSB- 14,45,55,77,78	54584
@VP	released by Schwann cells promote the reactivity of astrocytes	54782
@VP	promote the reactivity of astrocytes	54808
@VP	Transplanted SCs stimulate astrocytes to be highly GFAP positive	54846
@VP	stimulate astrocytes to be highly GFAP positive	54863
@VP	to be highly GFAP positive	54884
@VP	be highly GFAP positive	54887
@VP	surrounded by CS56 staining	54915
@VP	forms a dense glial scar around the lesion and prevents the entry of axons	54949
@VP	forms a dense glial scar around the lesion	54949
@VP	prevents the entry of axons	54996
@VP	other host non-neuronal cells -LSB- 57 -RSB-	55032
@VP	demonstrate in sub-acute 14 day glial transplants	55085
@VP	are proficient in interacting with astrocytes in vitro -LSB- 49,80 -RSB-	55296
@VP	interacting with astrocytes in vitro -LSB- 49,80 -RSB-	55314
@VP	account for the observed axonal infiltration into the glial scar -LSB- 81 -RSB-	55473
@VP	to bind TIMP-3	55588
@VP	bind TIMP-3	55591
@VP	may also play a part in the different interaction with host glia -LSB- 26 -RSB-	55603
@VP	play a part in the different interaction with host glia -LSB- 26 -RSB-	55612
@VP	isolated from the olfactory bulb	55678
@VP	show high levels of this protein when compared to SCs -LSB- 26 -RSB-	55711
@VP	differed	56076
@VP	labeled SCs and OEG	56167
@VP	to produce basement membrane	56201
@VP	produce basement membrane	56204
@VP	producing these molecules	56256
@VP	seen in SCs grafted animals	56306
@VP	grafted animals	56318
@VP	to produce extracellular matrix such as astrocytes or endothelial cells	56377
@VP	produce extracellular matrix such as astrocytes or endothelial cells	56380
@VP	to grow through and out to innervate areas of the olfactory bulb	56632
@VP	grow through and out to innervate areas of the olfactory bulb	56635
@VP	to innervate areas of the olfactory bulb	56656
@VP	innervate areas of the olfactory bulb	56659
@VP	-LSB- 83,84 -RSB-	56697
@VP	`` crosstalking '' with fibroblasts/meningeal cells	56774
@VP	-LSB- see 48,81 -RSB- and ability to interact with these cells -LSB- 9,85 -RSB-	56822
@VP	see 48,81 -RSB- and ability to interact with these cells -LSB- 9,85 -RSB-	56823
@VP	to interact with these cells -LSB- 9,85 -RSB-	56846
@VP	interact with these cells -LSB- 9,85 -RSB-	56849
@VP	do SCs in the peripheral nerve	56964
@VP	seems very different	57011
@VP	at 2 weeks after contusion facilitated significant axonal sparing	57479
@VP	seen in transplants carried out 7 days after a contusion injury -LSB- 33 -RSB-	57579
@VP	carried out 7 days after a contusion injury -LSB- 33 -RSB-	57599
@VP	were also present in both graft groups	57707
@VP	treated animals	57766
@VP	were significantly higher than after OEG transplantation	57782
@VP	indicates a more potent , local secretion of factors by SCs compared to OEG	57845
@VP	has extensively analyzed these differences	57941
@VP	analyzed these differences	57957
@VP	was associated with an increased amount of intact tissue at the lesion site	58059
@VP	associated with an increased amount of intact tissue at the lesion site	58063
@VP	showed strongly immunoreactive profiles at the lesion site for both OEG and SCs	58190
@VP	were less linearly organized than those seen in the OEG group	58377
@VP	linearly organized than those seen in the OEG group	58387
@VP	seen in the OEG group	58417
@VP	tracing using Fluorogold	58620
@VP	using Fluorogold	58628
@VP	were seen to respond similarly in both transplant groups	58828
@VP	seen to respond similarly in both transplant groups	58833
@VP	to respond similarly in both transplant groups	58838
@VP	respond similarly in both transplant groups	58841
@VP	can not be discounted	59094
@VP	be discounted	59101
@VP	discounted	59104
@VP	responded in a far more robust fashion in the OEG group	59164
@VP	to secrete BDNF after ATP activation through the P2X4 receptor -LSB- 92 -RSB-	59355
@VP	secrete BDNF after ATP activation through the P2X4 receptor -LSB- 92 -RSB-	59358
@VP	differ to SCs in their levels of fractalkine secretion	59428
@VP	can activate microglia to become more active	59493
@VP	activate microglia to become more active	59497
@VP	to become more active	59516
@VP	become more active	59519
@VP	initiated by SCs that do not secrete this protein at the same level	59590
@VP	do not secrete this protein at the same level	59612
@VP	secrete this protein at the same level	59619
@VP	is difficult to assess at the time of cell delivery	59692
@VP	to assess at the time of cell delivery	59705
@VP	assess at the time of cell delivery	59708
@VP	may not myelinate at all -LSB- 33 -RSB-	60111
@VP	myelinate at all -LSB- 33 -RSB-	60119
@VP	were observed between the control injury	60256
@VP	observed between the control injury	60261
@VP	grafted groups	60344
@VP	are normally observed in studies similar to that undertaken here	60380
@VP	observed in studies similar to that undertaken here	60393
@VP	undertaken here	60429
@VP	occurring within reflex-based segmental cord systems -LSB- 96 -RSB-	60483
@VP	has elicited improved hindlimb function -LSB- 9,10,97 -RSB- as seen here	60603
@VP	elicited improved hindlimb function -LSB- 9,10,97 -RSB- as seen here	60607
@VP	seen here	60656
@VP	could increase locomotion	60688
@VP	increase locomotion	60694
@VP	apposing the motor associated cholinergic neurons -LSB- 98 -RSB-	60771
@VP	associated cholinergic neurons -LSB- 98 -RSB-	60790
@VP	treated rats	60831
@VP	projecting axons reaching at least 8 mm distal from the injury site	60880
@VP	reaching at least 8 mm distal from the injury site	60897
@VP	could stimulate such a behavioral response	60958
@VP	stimulate such a behavioral response	60964
@VP	grafted rats which may use an alternate but effective pathway of locomotion	61040
@VP	may use an alternate but effective pathway of locomotion	61059
@VP	use an alternate but effective pathway of locomotion	61063
@VP	seen in our results here	61261
@VP	facilitate compensatory return of function via segmental circuits -LSB- 99 -RSB-	61345
@VP	may not be delivered at the same level via the transplantation of OEG	61571
@VP	be delivered at the same level via the transplantation of OEG	61579
@VP	delivered at the same level via the transplantation of OEG	61582
@VP	transplanted at 14 days post injury	61666
@VP	than seen in earlier transplant studies	61854
@VP	is present and highly inhibitory -LSB- 100,101	61958
@VP	was not supported by immunohistochemistry for 5-HT	62241
@VP	supported by immunohistochemistry for 5-HT	62249
@VP	labels serotonergic axons innervating the spinal cord	62304
@VP	innervating the spinal cord	62330
@VP	delayed glial transplant model -LSB- 102,103 -RSB-	62592
@VP	improve tissue and behavioral outcomes	62777
@VP	modify the lesion site	62817
@VP	improve sparing/regeneration of axonal populations as shown here	62844
@VP	shown here	62898
@VP	is feasible and beneficial both anatomically	62994
@VP	are different	63145
@VP	using multiple behavioral and anatomical analysis	63216
@VP	results can only give an indication of efficacy	63271
@VP	can only give an indication of efficacy	63279
@VP	give an indication of efficacy	63288
@VP	using these glial cells at 14 days post injury time point	63389
@VP	Counts in OEG Transplanted and SC Transplanted groups	63620
@VP	Transplanted groups	63654
@VP	derived neurotrophic factor	63922
@VP	modified eagle 's medium	64060
@VP	declare that they have no competing interests	64143
@VP	have no competing interests	64161
@VP	contributed to the acquisition of data , analysis and interpretation	64216
@VP	drafting of manuscript and revising for intellectual content	64326
@VP	drafting of manuscript	64326
@VP	revising for intellectual content	64353
@VP	drafting of manuscript and intellectual content	64429
@VP	conceived of the study and design , acquisition of data , analysis	64482
@VP	drafted the manuscript	64551
@VP	have read and approved the manuscript	64587
@VP	read and approved the manuscript	64592
@VP	wish to express thanks to Seok Voon Lee for technical contributions	64646
@VP	to express thanks to Seok Voon Lee for technical contributions	64651
@VP	express thanks to Seok Voon Lee for technical contributions	64654
